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Abstract
A small group of patients with Parkinson’s disease (PD) compulsively use dopaminergic 
medications despite the frequent emergence o f harmful physical, psychiatric and social effects. This 
behavioural syndrome has been termed the dopamine dysregulation syndrome (DDS) and although 
closely related, should be distinguished from impulse control disorders. The phenomenology, risk 
factors and neurobiology of DDS have been explored in a series of observational, neuropsychological 
and pharmacological clinical studies.
Dopaminergic drug-responsive complex repetitive stereotypical behaviours (punding) were 
identified and characterised in PD outpatients selected on the basis of their dopaminergic dmg intake. 
In animal models o f Parkinson’s disease, stereotypies are known to index the neuroadaptive changes 
of sensitisation. Punding was found to be associated with DDS, dyskinesia severity and harmful 
neuropsychiatrie disturbances raising the possibility that the biological mechanisms underlying drug- 
reward and these behaviours may overlap.
Psychostimulant drugs have powerful effects on dopamine release and re-uptake in the presynaptic 
dopamine system and are capable o f inducing neuroplastic changes in the basal gangha particularly 
after their intermittent administration. Psychostimulant drugs have dopaminergic effects but have 
only been demonstrated to have weak anti-Parkinsonian effects. The acute effects of L-dopa and 
methylphenidate were examined (which has effects similar to psychostimulant drugs) in 15 untreated 
PD patients, before and again after a mean 18 months of sustained dopaminergic drug therapy. After 
sustained dopaminergic therapy, the motor effects of L-dopa and the euphoriant effects of 
methylphenidate were augmented. This provided clinical support in humans for the first time that 
sustained dopaminergic drug therapy may result in psychomotor sensitisation.
In an effort to facilitate early identification of DDS and for planning prompt therapeutic 
interventions personality traits were examined in PD patients with DDS and compared to those 
without DDS and healthy controls. DDS patients were found to differ fi'om control PD patients and 
age-matched healthy controls in personality dimensions linked with substance dependence i.e. high 
impulsive sensation seeking traits, low harm avoidance, reward dependence, self-directedness and 
cooperativeness. Impulsive sensation seeking traits in particular, in addition to premorbid addictive
behaviour were also found to predict the emergence of DDS suggesting a common neurobiological 
vulnerability.
DDS patients complain of an aversive drug withdrawal state akin to the withdrawal state seen in 
other forms of addiction. Many patients attribute avoidance of aversive “offs” as the reason behind 
their compulsive drive to self-medicate. This aversive “o ff’-state was examined in 20 DDS patients 
and PD controls and found to be associated with behaviours that may lead to sensitisation of brain 
reward systems.
Most authorities believe that compulsive drug-taking and associated behavioural disorders are 
mediated through the mesolimbic dopaminergic projections and the nucleus accumbens. DDS was 
investigated using a two-scan ‘‘C-Raclopride protocol. Drug-induced sensitisation of ventral striatal- 
circuitry appeared to mediate compulsive drug “wanting” -  providing the first evidence of such in 
humans.
Greater understanding of compulsive dopaminergic drug use in PD should not only inform the 
management o f PD but may provide insight into the mechanisms underlying impulse control 
disorders.
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Chapter 1 
INTRODUCTION
Summary
Parkinson’s disease is a common neurodegenerative disease characterised by bradykinesia, rigidity 
and rest tremor. Symptomatic treatment with drugs acting on brain dopaminergic systems has proved 
veiy effective in reducing motor disability. However, abnormal involuntary movements may mar the 
long term therapeutic response to chronic treatment in some patients.
A few individuals appear to compulsively use dopaminergic medications well in excess of a dose 
that might be expected to achieve good motor control and despite the emergence of harmfiil drug- 
responsive behaviours. This study aimed to define the range of behaviours that result from 
dopaminergic drugs and explore individual variables that may predispose to their genesis. The 
findings may provide ways o f detecting vulnerable patients at an early stage and thereby prevent the 
inevitable catastrophic behavioural and social sequelae of dopamine dysregulation and have broader 
implications for the better understanding of the mechanisms underlying addictive behaviour.
1.1 Clinical aspects of Parkinson’s disease
PD was first hilly described in 1817 by the Shoreditch apothecary James Parkinson (Parkinson, 
1817; Arnett et al. 1997). Two centuries later the cause o f the “Shaking Palsy” remains largely 
elusive, its diagnosis dependent on clinical acumen, and its management problematic. It is a slowly 
progressive, degenerative, neurological disorder that destroys selected brain regions and depletes 
nigrostriatal dopamine. In the UK around one in 500 people, or 120,000 individuals, have PD. 
Increasing age is the greatest risk factor for PD. However, up to 5% of patients who receive the 
diagnosis are under the age o f 40 years. Men are slightly more prone to developing PD than women 
(Lang and Lozano, 1998a). Diagnosis of a Parkinsonian syndrome depends on the presence of 
bradykinesia with at least one o f the following; muscular rigidity, 4-6 Hz rest tremor and postural 
instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction (Hughes 
etal. 1992).
Patients with PD may also have distressing autonomic and neuropsychiatrie symptoms which
sometimes precede the primary disturbances of movement.
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Depression (Schuurman et al. 2002), constipation (Abbott et al. 2001 ) and anosmia (Henderson et 
al. 2003) have all been reported to antedate the motor symptoms of PD by many years in some cases.
1.2 Neuropathology of Parkinson’s disease
PD is a multisystem disorder that involves nerve cells in specific regions of the human nervous 
system. The formation of intraneuronal inclusions—pale bodies and Lewy bodies in cell somata, as 
well as Lewy neurites in the cellular processes of a few vulnerable nerve cell types are considered by 
most neurologists to be an essential prerequisite for the pathological confirmation of the clinical 
diagnosis. Misfolded and aggregated alpha-synuclein is present in Lewy bodies (Golbe, 1999). Braak 
and colleagues have recently proposed a challenging and controversial hypothesis that the 
pathological process of PD starts in the enteric nervous system, the anterior olfactory structures and 
the dorsal motor nucleus of the vagus and then progresses rostrally to finally involve the neocortex 
(Figure 1-1) (Braak et al. 2004).
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Figure 1-1: Diagram showing the ascending pathological process of Parkinson’s disease (white 
arrows) -  adapted from Braak et al. 2004.
Worsening motor symptoms during the course of PD are thought to reflect degeneration particularly 
within the dopaminergic pathways. There are three main dopaminergic cell groups in the midbrain, 
the A8 group in the lateral reticular formation, the A9 group in the substantia nigra and the AlO group 
in the medial and dorsal tegmentum. The nigrostriatal system, which originates in the zona compacta 
of the substantia nigra, is identified most strongly with motor function. Fibres from this subdivision 
project primarily to the caudate-putamen (dorsal striatum). More medial are the mesolimbic and 
mesocortical dopamine systems, which are more important for motivational function and arise from 
the dopamine cells that are associated with the ventral tegmentum. Cell loss from the substantia nigra 
occurs in a region-specific manner. 1 he most severe loss of dopaminergic neurons occurs in the
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ventrolateral part of the substantia nigra pars compacta (Feamley and Lees, 1991) and follows a 
stereotyped temporospatial progression with a global caudal-to-rostral, lateral-to-medial and ventral- 
to-dorsal direction of progression (Damier et al. 1999). The loss of midbrain dopamine neurons is 
most severe and occurs earliest in ventral cell groups that project to the putamen (motor striatum) 
compared to dorsal cell groups that innervate the caudate nucleus (Gibb and Lees, 1991). The 
resulting selective loss of putaminal dopamine is thought to be responsible for the appearance of 
motor symptoms once the striatal dopamine loss exceeds the threshold value of 60% (Homykiewicz 
and Kish, 1986).
There are smaller numbers of dopaminergic neurons in the AS and AlO regions compared to the 
A9. Post-mortem studies of neuronal loss within the extranigral cell groups are difficult to interpret 
because of difference in anatomical methods and subject selection. The AS cell group has been 
reported by some to be preserved in PD (McRitchie et al. 1997; Mouatt-Prigent et al. 1994) whereas 
others have found significant reductions in dopaminergic cells in this region (Damier et al. 1999; 
German et al. 19S9; Hirsch et al. 19SS). Studies of the AlO area in PD have more consistently shown 
reductions in both dopaminergic (between S-S5%) and nondopaminergic neuron numbers (around 
21%) but this cell loss is highly variable and appears unrelated to subject age or disease duration 
(Damier et al. 1999; German et al. 19S9; Hirsch et al. 19SS; McRitchie et al. 1997; Uhl et al.
19S5). For instance, the dopamine cell depletion appears to particularly affect the parabrachial 
pigmented and parapeduncular nuclei. Moreover there is a reduction in tyrosine hydroxylase- 
immunoreactive positive cells in some AlO cell clusters (caudal linear nucleus and paranigral nucleus) 
without evidence of neurodegeneration (McRitchie et al. 1997). Therefore, other factors such as 
ageing or medication effects may be important in the aetiology of dopamine neuron loss within the 
extranigral regions. As a consequence of ventral tegmentum dopamine cell loss in PD, the 
concentrations of dopamine and its major metabolite, homovanillic acid, in the nucleus accumbens are 
reduced by 50-60% (Homykiewicz, 199S) at death. Cortical dopamine is also reduced (Homykiewicz 
and Kish, 19S6; Scatton et al. 19S3). However, in life, PD patients with advanced disease have been 
reported to show a normal capacity to release endogenous dopamine from prefrontal regions after a 
pharmacological challenge (Piccini et al. 2003).
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1.2.1 The pathological substrate for dementia in Parkinson’s disease
In the late stages, the degenerative process involves higher order centers o f the limbic loop in 
particular. The amygdala is pivotal within the limbic system and undergoes severe pathological 
changes in the course of PD. The amygdala receives a broad range of afférents, allowing integration 
of exteroceptive information with interoceptive data. It generates major projections to the isocortex 
(the prefrontal cortex in particular), limbic system (hippocampus and entorhinal region) and centers 
which regulate endocrine and autonomic functions. Lewy degeneration occurs in a specific manner 
throughout the amygdalar nuclear complex and the lesional pattern displays only minor 
interindividual variation. The most prominent changes occur in the accessory cortical and central 
nuclei. In primates, the central nuclei give projections to the nucleus basal nucleus of Meynert, ventral 
tegmental area, raphe and locus coerulus and subsequently mediate ascending influences on arousal. 
The cortical, accessory basal and granular nuclei show less severe alterations, while the basal and 
lateral nuclei, as well as the intercalated cell masses, generally remain uninvolved (Braak et al. 1994). 
Additionally, all of the limbic and autonomic centers bidirectionally connected with the amygdala 
display intense PD related changes. These structures include the periacqueductal grey, the 
parabrachial region, the gigantocellular nucleus of the reticular formation, the intermediate reticular 
/one, and the dorsal vagal area, together with the centres for regulation of the digestive tract, 
respiratory organs, and the cardiovascular system (Braak and Braak, 2000). Lewy bodies and Lewy 
neurites are also frequently seen in the hippocampal formation and are greatest in the CA2-3 fields 
(Churchyard and Lees, 1997). In the human thalamus, a specific and highly stereotypical distribution 
pattern of Lewy bodies and neurites evolves. The components of human thalamus which form part of 
the limbic loop bear the brunt of the PD-related pathology compared to the striatal, cerebellar and 
primary sensory nuclei o f the thalamus which show at best a mildly developed pathology (Rub et al. 
2002). Cortical Lewy bodies are frequently found in other limbic sites such as the entorhinal cortex, 
agranular insular cortex (layer VI), cingulate gyrus and frontotemporal neocortex (Braak and Braak, 
2000) but spare pre- and post- central gyri, the parietal and occipital cortices.
Lewy degeneration within limbic regions appears to correlate moderately well with dementia. The 
presence of dementia in PD predicts more severe neuronal loss within AlO nuclei compared to 
nondemented PD subjects, higher Lewy body density in the limbic cortex (Zweig et al. 1993), 
hippocampal CA2 region (Churchyard and Lees, 1997) and neocortex (Apaydin et al. 2002). Lewy 
degeneration of limbic and related structures may inhibit the flow of data between the neocortex and 
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the higher order centers of the limbic system, as well as hampering their influence on the prefrontal 
cortex and contribute to the cognitive decline, bradyphrenia, mood disturbance, autonomic and reward 
dysfunction of PD. In some individuals, however, cognitive decline can develop in the presence of 
mild PD related cortical pathology and, conversely, widespread cortical lesions do not necessarily 
lead to cognitive decline (Colosimo et al. 2003). On the other hand, Alzheimer type pathology is 
frequently (10-60%) found in PD patients (Mahler and Cummings, 1990) and also significantly 
correlates with the presence of dementia (Braak et al. 1996; Jellinger et al. 2002; Mattila et al.
2000). Alzheimer change is more frequently found as the density of Lewy body change increases 
(Apaydin et al. 2002). Co-existent Alzheimer change may further contribute to development of 
dementia or represent a marker o f pathological severity. Moreover, the APOE epsilon4 allele may also 
influence the prevalence of dementia in PD (Huang et al. 2006).
The role of other neurotransmitter systems in the neuropsychiatrie and motoric manifestations of 
PD is poorly understood. Neuronal loss also occurs within the cholinergic nucleus basalis of Meynert, 
the noradrenergic locus coemleus, and the serotonergic raphe nuclei. There is evidence that 
cholinergic deficits due to degeneration of the ascending cholinergic pathways contribute to cognitive 
impairment and dementia in patients with PD. A decrease in cholinergic innervation of the cerebral 
cortex and severe cellular loss in the basal nucleus of Meynert is found in patients with PD (Dubois et 
al. 1983); this deficit and cellular loss correlates with the level of cognitive impairment and presence 
of dementia (Perry et al. 1985; Hilker et al. 2005). Cognitive impairment appears to be most closely 
associated with cholinergic, but not monoaminergic, deficits in temporal and archicortical areas (Perry 
et al. 1991). Conversely, anticholinergics cause memory impairment in non-demented patients with 
PD but not in healthy control individuals (Dubois et al. 1987) and have been linked to acceleration of 
amyloidosis and senile plaque formation in the aging brain in subjects with PD (Perry et al. 2003). A 
recent study of a cholinesterase inhibitor for PD dementia found statistically significant improvements 
in measures of cognitive performance and several behavioural measures relative to placebo (Emre et 
al. 2004). Over a 6 month period, clinically meaningful (moderate or marked) improvement occurred 
in 5.3% more patients on rivastigmine, and meaningful worsening occurred in 10.1% more patients on 
placebo (Maidment et al. 2006). Noradrenaline depletion has been linked to depression (Remy et al. 
2005) and serotonergic dysfunction to tremor (Doder et al. 2003).
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1.3 Aetiology of Parkinson’s disease
In recent years, the discovery o f a number of genes and several more loci has provided important 
insight into the molecular aetiology. Some genes may cause PD through promoting protein 
aggregation. However, the presence o f Lewy bodies in carriers of mutations in some genes and their 
absence in carriers of others, still point towards a complex pathogenic network, with PD as a common 
clinical end point. Despite knowledge o f genetics in familial PD, knowledge o f the common, late- 
onset form of PD remains limited. In non-familial PD, genes and environment probably interact to 
give rise to the disease.
1.3.1 Genetic factors
There is increasing evidence that genetic factors have an important role in PD. Epidemiological 
studies with varying designs have consistently suggested a higher prevalence of PD among first- 
degree relatives of index patients compared to the general population (e.g. (Sveinbjomsdottir et al. 
2000)). Since 1997, six “PARK” genes have been identified using genetic linkage methods in families 
segregating autosomal dominant (Alpha-synuclein, UCHLl, LRRK2) and autosomal recessive 
(Parkin, PINKl and DJl) forms of PD (Table 1-1). Then, the discovery of PD-causing, dominantly- 
acting-synuclein mutations (PARK 1 (Polymeropoulos et al. 1997)) and its association between a 
polymorphic marker in the promoter region of alpha-synuclein gave insight into PD in its common, 
“sporadic” form (Fairer et al. 2001). Upon the identification of the mutations in its encoding gene, it 
was identified to be a principal component of Lewy bodies (Spillantini et al. 1997). The physiological 
role of alpha-synuclein is still somewhat obscure, but its abundant localisation at presynaptic 
terminals and some functional studies indicate a possible role in synaptic plasticity and vesicular 
transport. The mutant protein results in increased apoptotic responses, enhanced susceptibility to 
oxidative stress, and facilitates fibril formation giving rise to Lewy bodies (Alves da Costa, 2003). 
Most recently, leucine-rich repeat kinase 2 (LRRK2) was identified as an important causative gene in 
families linked to the autosomal dominantly inherited PARKS locus on chromosome 12pl 1.2-ql3.1. 
The predicted product of the LRRK2 gene is a large protein with 2527 amino acids; sequence 
comparison suggests that it may function as a protein kinase (Paisan-Ruiz et al. 2004). It is implicated 
in up to 10% of autosomal dominant PD cases (Di Fonzo et al. 2006) and is associated with a variety 
of histopathological findings (Galpem and Lang, 2006). A mutation in the gene encoding ubiquitin 
carboxyterminal hydrolase 1 (UCHLl) has been described in a single small German kindred with
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autosomal dominantly inherited PD (PARKS (Leroy et al. 1998)) and the S18Y polymorphism in the 
UCHLl gene may be associated with decreased risk for PD (Maraganore et al. 2004a).
Table 1-1: Loci and genes linked and associated with PD (adapted from Mata etaL  2004)
PD locus Chromoso
me
Gene Mode of 
inheritance*
Clinical
features
Reference
PARKl 4q21.3 a-synuclein AD Early onset (Polymeropoulos et al. 1997)
PARK2 6q25.2-27 Parkin AR Early onset (Kitada gf a/. 1998)
PARK3 2pl3 - AD Late onset (Gasser gf a/. 1998)
PARKS 4pl4 UCHL-1 AD Late onset (Leroy e/ a/. 1998)
PARK6 lp35-36 PlNKl AR Early onset (Valente er a/. 2004)
PARK? lp36 DJl AR Early onset (Bonifati et al. 2003)
PARKS 12ql2-ql3.1 LRRK2 AD Late onset (Paisan-Ruiz et al. 2004; Z imp rich et 
al. 2004)
PARK9 lp36 ATP13A2 AR Early onset (Ramirez et al. 2006)
PARKIO lp32 - Complex Late onset (Hicks et al. 2002)
PARK l 1 2q36-37 - Complex (Pankratz et al. 2002)
- 2q24.1 Nurrl Complex Late onset (Le et al. 2003)
*AR=autosomal recessive, AD=autosomal dominant inheritance
Parkin mutations are the most common cause of autosomal recessive PD. It is typically young-onset 
without Lewy degeneration. Parkin localises to the Lewy bodies of PD in those patients who do not 
carry Parkin mutations (Hague et al. 2005). In addition, polymorphisms in the Parkin gene may be 
associated with idiopathic PD (West et al. 2002). Both parkin and UCHLl are involved in the 
ubiquitin dependent degradation of intracellular misfolded, unassembled, or damaged proteins by the 
proteasome, a multicatalytic complex. Autosomal recessive mutations in the DJ-1 gene (PARK7) are 
thought to be a rare cause of PD with prominent behavioural disturbances early in the course of the 
disease. DJ-1 mutations are associated with impaired oxidative stress defense, lead to reduced DJ-1 
protein stability, and the mutant protein is rapidly degraded through the ubiquitin-proteasome system
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(Miller et al. 2003). DJ-1 polymorphisms may also confer increased susceptibility to sporadic PD 
(Maraganore et al. 2004b). Autosomal recessively inherited mutations in the PTEN induced kinase 1 
on chromosome lp36 (PARK6) are also implicated in PD. Cell culture studies suggest that PINKl is 
mitochondrially located and may exert a protective effect on the cell that is abrogated by the 
mutations, resulting in increased susceptibility to cellular stress (Valente et al. 2004). Although 
abnormal protein inclusions characterise many genetic forms of PD, there is incomplete understanding 
of the nature of these protein interactions, the triggers for inclusion formation, and their role in disease 
pathogenesis.
1.3.2 Environmental factors
One factor consistently associated with a reduced risk of PD is smoking. Three recent meta­
analyses of case-control and cohort studies have examined the association between smoking and PD 
(Allam et al. 2004; Heman et al. 2002; Sugita et al. 2001). Compared to never-smokers, the pooled 
relative risk of PD for ever-smokers was 0.51-0.59, for past smokers 0.66-0.80, and for current 
smokers 0.35 0.39. PD risk also decreases with cumulative exposure to smoking: the relative risk per 
10 additional pack-years was between 0.78-0.84. This relationship has been claimed to exist even 
after adjusting for possible genetic influences on addictive behaviours (Heman et al. 2002). Caffeine 
intake also appears to be protective against PD independently of smoking (Heman et al. 2002). A 
meta-analysis showed a pooled relative risk of PD of 0.69 (95% Cl 0.59-0.80) for coffee drinkers 
compared to non-coffee drinkers (Heman et al. 2002). An independent predictive relationship 
between alcohol intake and PD is less clear (Heman et al. 2003) and transient Parkinsonism has even 
been described after alcohol withdrawal and excess (Femandez and Lees, 1992). A possible 
explanation is that the central actions of caffeine and nicotine may improve the health of brain 
dopamine systems (Allam et al. 2004) and protect against PD (Quik, 2004).
However, it is possible that these findings are epiphenomena rather than being causally linked. 
Certain personality characteristics of individuals destined to develop PD may make them less prone to 
start smoking (and/or more likely to stop) (Menza et al. 1994; Evans et al. 2006a). A distinctive 
ananacastic behavioural profile has been anecdotally associated with PD. As a group they tend to be 
industrious, anhedonic, obsessive, cautious, inflexible and disinclined to take risks (Hubble and 
Ko Her, 1995; Menza et al. 1993; Paulson and Dadmehr, 1991 ; Todes and Lees, 1985). These 
personality variants may antedate the motor changes in PD by decades (Poewe et al. 1990). Novelty
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seeking and related personality variants have been characterised by reduced novelty seeking scores 
and are proposed to be related to variations in dopaminergic function in the mesolimbic system. They 
strongly predict the uptake and maintenance of drug-taking behaviours (Cloninger, 1987a;
Zuckerman, 1994). Certain genes such as polymorphisms in genes involved in dopamine catabolism 
(Checkoway et al. 1998) might also modify behaviours such as smoking, caffeine and alcohol intake.
A number of causative factors have been found to induce Parkinsonism similar to that of idiopathic 
PD, including vascular insults to the brain, repeated head trauma, neuroleptic drugs, and manganese 
toxicity (Adler, 1999). The toxicant 1 -methyl-4-phenyl-l ,2,3,6-tetrahydropyridine caused acute 
Parkinsonism similar to the idiopathic disease in a small group of drug addicts (Langston et al. 1983) 
and spawned an interest in the possible role of exogenous toxicants in the development of PD.
A rural environment has generally, although not always, been found to be associated with an 
elevated risk of PD. There is varying support for a relation with such factors as the use of herbicides 
or pesticides and consumption of well water (Priyadarshi et al. 2001 ), farming, and rural living. 
However, epidemiology and toxicology studies are limited by méthodologie weaknesses and fail to 
account for gene-environment interactions. Even if one accepts the role of pesticide use, the 
proportion of patients with such exposure, and therefore the importance of this risk to the public 
health, is limited to approximately 10 percent of the population with PD (Semchuk et al. 1992). Also 
most of these chemicals have only been used for the last 40 years (Rajput et al. 1987).
1.4 Motor features of Parkinson’s disease
The most frequent presentation for PD is an asymmetrical resting tremor in a limb, most commonly 
one hand that disappears with voluntary movement. It frequently emerges in a hand while the person 
is walking. Rest tremor is virtually pathognomonic of PD and may involve the tongue, head, trunk and 
chin (Nutt and Wooten, 2005). The bradykinesia of PD begins asymmetrically in about 75 percent of 
patients (Gelb et al. 1999). It is often described by the patient as a weakness of a hand or leg, but 
strength testing reveals no abnormalities. However, assessment of dexterity by finger tapping and toe 
tapping shows slowing, reduced amplitude of movement, and irregular cadence that become more 
apparent as the patient continues the movement. F ine movements are affected more than large 
movements, so that the patient first notices difficulty using small tools and fastening buttons.
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Repetitive movements also suffer; for example, brushing the teeth may be difficult. Bradykinesia also 
manifests as micrographia, hypomimia, reduced blink rate, and hypophonia.
The rigidity of PD may be experienced as stiffness associated with vague aching and discomfort of 
a limb suggesting musculoskeletal syndromes, particularly bursitis and tendinitis. In the arm, this 
rigidity may progress to a frozen shoulder. Early PD may cause slowing of gait, dragging of the foot, 
and decreased arm swing on the affected side. Patients may notice difficulty getting out of cars, rising 
from deep chairs, and rolling over in bed. Shuffling gait, freezing, and falls develop in the course of 
the disease. Disease progression leads to the bilateral spread of symptoms, but asymmetry is 
maintained in the degree of symptoms experienced with the onset side generally remaining the most 
affected throughout the disease.
1.5 Symptomatic therapy of Parkinson’s disease
1.5.1 Early medical treatment
None of the currently available treatments for PD are capable of replacing or restoring the 
degenerating neurons. The perceived selective nature of the presynaptic nigrostriatal degeneration 
constituted the biochemical rationale for the first use of dopaminergic drug therapies in targeting 
disease symptoms (Homykiewicz and Kish, 1986). Dmgs are warranted when the patient is 
sufficiently bothered by symptoms to desire treatment or when the disease is producing disability; 
patients’ preferences are critical to making this decision. If the patient needs treatment for motor 
symptoms, efficacious agents for initial therapy include L-dopa, dopamine agonists, anticholinergics 
agents, amantadine, and selective monoamine oxidase B (MAO-B) inhibitors. Dopaminergic agents 
are more potent than the anticholinergic agents, amantadine, and selective MAO-B inhibitors in 
attenuating the motor symptoms. L-Dopa, a dopamine precursor, is considered the most effective anti­
parkinsonian agent. In randomised trials comparing L-dopa and a dopamine agonist, activities of daily 
living and motor features of PD improved with L-dopa by about 40 to 50 percent (as compared with 
approximately 30 percent with dopamine agonists) (Nutt and Wooten, 2005). Although dopamine 
agonists are slightly less effective than L-dopa, they are alternative first-line agents for PD. The 
various dopamine agonists have similar efficacy. One potential advantage of these agents is that, as 
compared with L-dopa, their use is associated with a lower risk by a factor of two or three of 
dyskinesia and motor fluctuations in the first four to five years of treatment, particularly among
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patients receiving dopamine-agonist monotherapy (Nutt and Wooten, 2005). However, it is common 
for L-dopa to be needed in addition to dopamine-agonist therapy within a few years after diagnosis to 
control advancing symptoms. In general, a slightly lower incidence of motor complications is 
achieved by initiating a dopamine agonist at the expense of significantly worse disability scores 
throughout the first years of therapy (Lees et al. 2001). Dopamine agonists are avoided in the 
treatment of patients with dementia because of the drugs’ propensity to produce hallucinations.
1.5.2 Late medical treatment
The main symptoms of PD respond inconsistently. Tremor may be more resistant to medical 
therapy than other symptoms. With disease progression patients develop persistent and progressive 
disability even in "on" periods (those characterised by greater mobility due to the beneficial actions of 
L-dopa) of motor fluctuations. Motor fluctuations occur in -50%  of patients after 5 years of L-dopa 
therapy (at this time they usually affect patients for <25% of their waking hours). The proportion of 
patients affected increases to -70%  among those treated for more than 15 years (Miyawaki et al.
1997). Motor fluctuations include predictable "o ff periods (predictable periods of immobility or 
greater severity of other Parkinsonian symptoms when medications wear “o ff’ - i.e., "wearing o ff) , 
and unpredictable “o ff’ periods (or “on”-”o ff’ fluctuations). With ongoing treatment, patients with 
motor fluctuations may notice an increase in the interval between a dose of medication and the 
patient's experience of an “on” response ("delayed on") and the absence of a response to an individual 
dose ("dose failure" or "no on"). Motor fluctuations are typically more troublesome in patients with 
young-onset PD (Jankovic, 2005).
L-Dopa-induced dyskinesias are clinically and pharmacologically heterogeneous. Dystonie 
posturing of a limb may coincide with low levels of dopaminergic stimulation, such as occurs in the 
“o ff’ periods. Early on many patients are unaware of the presence of their choreoathetotic 
movements, which usually occur when the effect of the medication is at its peak. With time, these 
dyskinesias may become a source of considerable disability and may persist throughout the response 
to an individual dose. Some patients have enhanced dyskinesia, especially involving the lower body, 
at the onset or end of the response to medication (so-called diphasic dyskinesias) (Lang and Lozano, 
1998b).
A large body of preclinical evidence and clinical data indicate that L-dopa-induced motor 
complications arise from pulsatile stimulation of striatal dopamine receptors (Kuoppamaki et al.
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2002). Pulsatile stimulation of dopamine receptors leads to gene and protein changes in striatal 
neurons with alterations in neuronal firing patterns and the consequent development of motor 
complications (Obeso et al. 2000). These changes in the postsynaptic medium spiny neurons of the 
striatum, particularly involve glutamatergic receptors, and in striatopallidal circuits. Disease severity 
and half life of the dopaminergic agent employed are important factors in the pathophysiology of 
motor fluctuations (Widnell, 2005). L-Dopa-induced dyskinesia emerge within days in l-Methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine (MPT?) monkeys where there is a 95% loss of nigral neurons, 
whereas they develop over months or years in PD patients where there is typically a 30-60% loss of 
dopamine neurons at the time symptoms first appear. Studies in MPTP lesioned monkeys also 
illustrate the importance of plasma half life in the induction of dyskinesia (Obeso et al. 2000; Pearce 
et al. 1998). Short-acting dopaminergic agents such as L-dopa provide benefit that is associated with 
dyskinesia. In contrast, long-acting dopamine agonists provide lesser benefit, but with a marked 
reduction in both the severity and frequency of dyskinesia. Indeed, dyskinesias are seen with pulsatile 
administration of a short-acting dopamine agonist, but not when the same agent is administered by 
continuous infusion (Bibbiani et al. 2005). This hypothesis is supported by the progressive 
improvement in fluctuations and dyskinesias, in the response to treatment in patients treated with 
continuous methods of dopaminergic stimulation, such as with subcutaneous apomorphine pumps 
(Katzenschlager et al. 2005).
1.5.3 Nonpharmacological therapies
L-Dopa-related motor complications are a reason why patients with PD may be referred for 
surgery. Neurosurgical approaches in advanced PD have concentrated on placing a discrete lesion or 
electrode into the subthalamic (STN) or globus pallidus pars interna (GPi) with the aim of disrupting 
basal-ganglia pathways back towards normal. These techniques were initially developed in the 1950s. 
With improvement in surgical techniques, deep brain stimulation (DBS) of the subthalamic nucleus 
(STN) is now generally regarded as the most effective form of surgical therapy for PD (Volkmann et 
al. 2004). Persistent improvement (with no evidence of tolerance to the stimulation) in L-dopa- 
responsive motor features has been demonstrated for a number of years after STN DBS in the “off- 
medication” state (i.e. reduction in “o ff’ scores; tremor, rigidity, akinesia and disabling “o ff’-period 
dystonia). Doses of dopaminergic drugs can be substantially reduced and in part because of this and in 
part because of an antidyskinetic effect of chronic stimulation, L-dopa-induced dyskinesias are
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improved. The symptoms experienced by patients in their best “on” response to L-dopa are not 
aflected (Krack et al. 2003). Whereas motor improvement has been consistently documented, 
cognitive dysfunction, mood changes, behavioural disturbances, and apathy are potential 
complications of STN DBS (Burkhard et al. 2004; Funkiewiez et al. 2004). Preoperative psychiatrie 
vulnerability, the effects of surgery, stimulation, medication changes, and psychosocial adjustment 
have been proposed as causative factors. Cautious preoperative screening and careful postoperative 
follow-up is likely to be required to optimise treatment response.
1.6 Non-motor features of Parkinson’s disease
Patients report a broad spectrum of non-motor symptoms and in some these symptoms may come to 
overshadow the motor disability. They include neurobehavioural disturbances, psychosis, cognitive 
impairment, autonomic disturbances involving cardiovascular regulation, swallowing, bladder and 
bowel function, sensory symptoms such as pain and REM sleep behaviour disorder and deficits of 
olfaction.
The ineidence of dementia has been estimated to be four times greater than in eontrols. Several 
features are consistently reported to be associated with prevalent dementia. Risk factors for dementia 
include age at onset, age at the time of study, duration of the disease, predominant akinetic-rigid 
features, depression, and atypical neurological features (such as early occurrence of autonomic failure, 
symmetrical disease presentation, and moderate response to dopaminergic treatment). Dementia is a 
major risk factor for nursing home placement and the risk of death in patients with PD is substantially 
higher for those with dementia (Emre, 2003).
Some patients develop a paranoid psychosis with a prominent pathological jealousy which 
improves following reduction of anti-Parkinsonian therapy. Vesperal visual hallucinations, usually of 
people, and animals, are common as are extracamp ine and passage hallucinations and may be 
associated with delirium and daytime somnolence. Misidentification syndromes are also frequently 
reported by family members (Adler, 2005). Antipsychotic medications are often used to treat 
neuropsychiatrie complications (such as hallucinations) of PD (Emre et al. 2004) but these are not 
always effeetive and recently cholinomimeties have been proposed as an alternative for the 
hallucinations (Ondo et al. 2002; Emre et al. 2004; Ondo et al. 2005). Clozapine to date remains the 
only atypical antipsychotic drug with proven efficacy in 2 small short-term placebo-controlled
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randomised controlled trials in PD patients with drug-induced psychosis (The Parkinson Study Group, 
1999; Poliak et al. 2004). Adverse effects include sedation, subjective worsening of Parkinsonism, 
postural hypotension, neutropenia and sialorrhea. All of the atypical antipsychotics are associated with 
an adverse metabolic syndrome (Newcomer, 2005) and carry an increased risk o f death (Schneider et 
al. 2005).
I here seems to be a reciprocal relationship between PD and depression; depression is frequently 
associated with PD (figures ranging between 2.7% and 70% (Bum, 2002a)) and developing 
depression in mid-adult life is an independent risk factor for the subsequent development of PD 
(Schuurman et al. 2002). Significant anxiety is also frequently associated with depression in PD. 
Depressive symptoms may increase the risk of subsequent dementia and are closely related to quality 
of life, sleep disturbance and sexual dysfunction in the PD patient. They are also an important and 
consistent contributor to caregiver distress (Bum, 2002a).
1.6.1 Non-motor fluctuations *
The majority o f L-dopa treated patients with PD experience non-motor fluctuations in the course of 
their illness (Gunal et al. 2002; Witjas et al. 2002). They typically occur after the appearance of 
motor fluctuations and are often equally or even more disabling (Witjas et al. 2002). Non-motor 
symptoms have also been linked to increased disability due to motor complications but this correlation 
is not invariable (Witjas et al. 2002). About two-thirds of patients describe mood fluctuations 
(Nissenbaum et al. 1987; Witjas et al. 2002) characterised by withdrawal, anxiety, fatigue, 
irritability, lassitude, sadness, transient suicidal feelings and panic (Gunal et al. 2002; Hillen and 
Sage, 1996; Witjas et al. 2002): described under the rubric “dysphoria” (Maricle et al. 1998). More 
distressing “o ff’ symptoms include hallucinosis, guilt, aggression, moaning and screaming (Riley and 
Lang, 1993; Gunal et al. 2002; Hillen and Sage, 1996; Steiger e/ a/. 1991; Witjas et al. 2002). In 
contrast, euphoria, hypomania, aggression and hyperactivity are occasionally associated with the 
“on”-state (Lawrence et al. 2003; Gunal et al. 2002; Witjas et al. 2002). Recognition that these 
capricious mood changes are coupled with striking motor fluctuations has led to a view that these 
mood fluctuations might represent a psychological reaction to worsening motor disability (Menza et 
al. 1990) or be the independent result of changing brain dopamine levels (Nissenbaum et al. 1987;
1 lardie et al. 1984; Friedenberg and Cummings, 1989; Cantello et al. 1986). Mood changes may not, 
however, be inextricably linked with motor “offs” . Several reports have highlighted cases where
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severe diurnal mood fluctuations dominate the clinical picture (Riley and Lang, 1993). In one study 
using L-dopa infusions, the resultant mood changes preceded motor benefit by several minutes 
(Maricle et al. 1998). Another study using patient diaries failed to find consistent temporal 
relationships between mood and motor state (Richard et al. 2001). A comparison of the mood 
response to L-dopa challenge versus stimulation of the subthalamic nucleus has shown that L-dopa 
clearly has a more potent psychotropic effect despite equivalent motor benefits (Funkiewiez et al.
2003).
Cognitive performance may become part of the fluctuating cycles but it does not appear to be 
strongly influenced by affect-arousal states (Gotham et al. 1988). Dopaminergic medication improves 
or impairs cognitive performance depending on the nature of the task (Cools et al. 2003).
The precise origin of pain and other sensory symptoms in PD is unknown although the thalamus 
and corpus striatum have been implicated. Pain and sensory symptoms usually but not invariably 
develop ipsilateral to the body area with worse motor function and may precede the diagnosis of PD 
(Roller, 1984). As the illness progresses, many patients report fluctuating pain that occurs with 
akinesia that may overshadow all motor symptoms (Goetz et al. 1986b) but others may relate the pain 
to “on”-periods or dyskinesias (Quinn et al. 1986). The pain is often diffuse but can be difficult to 
discriminate from radicular or neuropathic causes (Quinn et al. 1986). Cryptogenic painful oral and 
genital syndromes poorly responsive to therapy have also been described (Ford et al. 1996). Patients 
with pain that is unresponsive to dopatherapy have been found to have lower pain tolerance levels and 
lower cerebrospinal fluid levels of monoamine metabolites (5-hydroxy-indole acetic acid) suggesting 
that other n euro transmitter systems may also be involved (Urakami et al. 1990). Akathisia (Lang and 
Johnson, 1987), paraesthesia, dysaesthesia, tight feelings, numbness (Gunal et al. 2002; Witjas et al. 
2002) and a clinically unapparent internal tremor (Shulman et al. 1996) are other common sensory 
phenomena. Sensory symptoms frequently fluctuate with medication dosing and often cause 
considerable nocturnal distress.
Fluctuating patients may demonstrate autonomic signs that include sweating, pallor, hyperpyrexia, 
and tachycardia at the inception o f their “o ff’ states (Barbeau, 1972). Patients on chronic therapy have 
been shown to have higher resting pulse rate, greater orthostatic fall in blood pressure, and increased 
sweating responses to a heat stimulus in the “o ff’ state (Goetz et al. 1986a). Subjective breathlessness 
typically occurs in the “o ff’-state (Witjas et al. 2002; Raudino, 2001) but occasionally accompanies
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dyskinesia (Jankovic and Nour, 1986). Urinary symptoms cause significant nocturnal morbidity. They 
arc primarily irritative (frequency, urgency, urge incontinence) and correlate with the urodynamic 
finding of involuntary detrusor contractions at early stages of bladder filling (detrusor hyperreflexia) 
(Singer, 1998). In fact, L-dopa has been shown to aggravate detrusor hyperreflexia despite improving 
voiding symptoms (Uchiyama et al. 2003). The presence of early urinary symptoms has been linked 
to greater reductions in striatal ['^^l]-2p-carbomethoxy-3p-(4-iodophenyl)-N-(3-fluoropropyl)- 
nortropane ([123IJ-FP-CIT) uptake (Sakakibara et al. 2001 ). Off period urinary hesitancy or even 
retention may occur. Abdominal discomfort, aerophagy, and flatulence, bloating and feelings of 
constipation can cause significant “o ff’ period distress. Unpredictable visual blurring, drooling, oral 
dryness, distal cold sensations and facial flushing are common. Chest pain, paroxysmal hunger, fever, 
“o ff’ nausea, belching and coughing are less common symptoms (Witjas et al. 2002).
Some non-motor symptoms have been previously linked to disease-related parameters such as 
motor scores (Gunal et al. 2002; Nissenbaum et al. 1987), disease duration, dementia, psychosis or 
fixed depression (Racette et al. 2002). In contrast, other symptoms appear to be associated with the 
duration or dose of dopatherapy (Witjas et al. 2002). Questionnaire and interviewed based studies of 
non-motor symptoms in PD highlight the burden and range of symptomatology reported in the “o ff’ 
state (Gunal et al. 2002; Nissenbaum et al. 1987; Racette et al. 2002; Witjas et al. 2002; Hillen and 
Sage, 1996).
1.7 Compulsive use of dopaminergic drugs in Parkinson’s disease -  Dopamine 
Dysregulation Syndrome”
1.7.1 Essential features of patients who compulsively use dopaminergic drugs
A small subgroup of PD patients starts to take increasing quantities of medication well beyond the 
dose required to treat their motor disabilities in the early years of their disease. These patients request 
higher and higher medication doses, complain of medication ineffectiveness and tend to increase their 
drugs contrary to medical advice. Later on in the course of the illness, they take large quantities of 
drugs (over 1.5 grams of L-dopa a day) and in spite of this continue to request more dopaminergic 
drug therapy in the face of disabling dyskinesias and distressing behavioural disturbances 
(Giovannoni et al. 2000; Merims et al. 2000; Spigset and von Scheele, 1997). Many self medicate 
using somatic cues to take their next dose of medication and any attempt by the physician to reduce
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the medications is met with strong resistance. Hoarding of medication and secret pill-popping are 
characteristic. These patients typically identify avoidance of the distressing negative off period 
alTective state as the reason why they need frequent dosing schedules (Beam et al. 2004) and some 
acknowledge a subjective “kick”, “msh”, “high” or mood benefit after taking short acting 
dopaminergic dmgs (Giovannoni el al. 2000). They become preoccupied with the timing and dosing 
of their medication.
1.7.2 Medication tolerance
Tolerance to dopamine replacement therapy and withdrawal has proved difficult to demonstrate 
clinically because of the efficacy of dopaminergic medication in relieving symptoms although dose 
requirements generally increase somewhat over time. The development of tolerance to L-dopa is also 
complicated by pharmacokinetic changes related to progressive dopaminergic denervation and loss of 
presynaptic dopamine storage mechanisms. The duration of benefit from a single dose of L-dopa tends 
to reduce slightly over time but motor fluctuations are more related to an increase in baseline 
disability with an increased amplitude of motor response (Colosimo et al. 1996). Clinical 
pharmacological studies with intravenous dopa have demonstrated tolerance within days of initiating 
therapy and resensitisation to its effect occurs within a similar time period (Gancher et al. 1996; Nutt 
et al. 1994). These findings were part of the basis for the former recommendation of “drug-holidays” 
by some physicians.
1.7.3 Medication withdrawal
PD patients often describe feeling “o ff’ despite the absence of significant worsening in the motor 
signs of Parkinsonism (non-motor off) and may only perceive themselves as being “on” when they 
have developed severe peak-dose dyskinesias. Typical “withdrawal” reactions from dopaminergic 
drug therapy may be masked by the severe motor impairment but motor and behaviour changes 
frequently occur during “on” or “off” states. These very distressing psychic fluctuations seem to 
parallel the motor state in many patients but in others “off” period anxiety and dysphoria can precede 
the motor “off” by some time. The mood during Parkinsonian “off” periods is identical to the negative 
affective state of withdrawal from psychostimulants in dependent individuals and is characterised by 
depression and anxiety which is quickly alleviated by a further drug dose (Menza et al. 1990).
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1.7.4 Medication intoxication
Like many drugs which act on the dopaminergic system, intoxication with dopaminergic therapy 
leads to an organic psychosis (toxic confusional state) usually manifest as delirium and hallucinations 
and this can resolve on dose reduction. An acute paranoid psychosis associated with pathological 
jealousy similar to that seen with amphetamine and cocaine use may also occur. Thinking becomes 
disorganised and they display poor judgement. Rapid mood shifts are common and aggressive 
behaviour occurs in some patients (Giovannoni et al. 2000). Patients become very demanding, with 
irritability, and low frustration tolerance. Mania may promptly resolve after reductions in anti- 
Parkinson medications (Courty et al. 1997; Tack et al. 1988) but is often replaced by a negative 
affective state with varying degrees o f dysphoria, depression, irritability and anxiety. A few patients 
overuse their medication deliberately to induce hypomania and euphoria (O'Brien et al. 1971 ; 
Przedborski c /ûf/. 1992).
1.7.5 Is this syndrome a substance dependence disorder or an addiction?
Tolerance, withdrawal, and hypomanie mood swings are insufficient to diagnose a Diagnostic and 
Statistical Manual, 4th edition (DSM-IV) “substance dependence disorder” (American Psychiatric 
Association, 1994) in a patient with a progressive incurable neurological disease. Under DSM-IV 
criteria (American Psychiatric Association, 1994), substance dependence involves a maladaptive 
pattern of substance use. The correct use of dopaminergic drugs in PD is to treat the motor symptoms 
of the disease. In a study of patients from a London clinic, structured psychiatric interviews were used 
in an attempt to distinguish between a “physiological” adaptive dependence with PD and a 
“pathological” or maladaptive dependence. In 10 patients thought to be misusing drug therapy and a 
group of age-matched patients with PD fi-om the same clinic who were not thought to be misusing 
drug therapy, a significantly larger proportion of misusers reported anxiety and depression when 
unmedicated (Beam et al. 2004). Avoiding being unmedicated was the reason given by most misusers 
for taking more medications. In addition, a significant number of misusers reported that their 
medications had a negative impact on their quality of life. A past history o f alcohol use was greater in 
the misusing group, and previous illicit drug use was reported in a small number o f patients. The use 
of dopaminergic therapy therefore appears maladaptive in some PD patients, and thus they appear to 
meet DSM-IV criteria for dependence.
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The International Classification of Disease and related health problems, 10th revision (lCD-10) 
criteria for “addiction” (World Health Organization, 1990) differ from DSM-IV criteria for 
“dependence”, but present similar difficulties when applied to PD. Nevertheless, it is clear that the 
individuals in the above study (Beam et al. 2004) would meet lCD-10 criteria; they show difficulties 
in controlling their substance-taking behaviour, have a strong compulsion to take the substance, and 
continue to use the substance despite clear evidence of harmful consequences.
The terms dependence and addiction, however, may be unnecessarily stigmatising and inappropriate 
given an inexorably progressive neurodegenerative disorder. The label DDS reflects the disorder’s 
salient features, and indicates compulsive and dysregulated drug use beyond that needed to achieve 
relief of motor symptoms, resulting in harmful consequences.
1.7.6 Clinical profiles of compulsive dopaminergic drug therapy use
DDS is a pattern of pathological dopamimetic medication use characterised as compulsive and 
beyond that needed to control the motor symptoms. This use then results in further physical, 
emotional, social and financial difficulty independent of the disability related to Parkinsonism. 
Proposed criteria for identifying the syndrome are given in (Table 1-2). Compulsive use can continue 
despite unsuccessful efforts by the physician, carer or patient to cut down the total daily medication 
dose.
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Table 1-2: Current working diagnostic criteria for compulsive dopaminergic drug use (adapted 
from Giovannoni et al. 2000)
Paikinson's disease with documented L-dopa responsivaiess 
Need for increased doses of dopaminergic drugs in excess of those normally required to relieve 
Parkinsonian syn^toms and signs
Pattern of pathological use: «[pressed need increased dopaminergic drug therapy in the presence
of excessive and significant dyskinesias débite being **on'% drug hoarding or drug-seeking behaviour, 
unwillingness to reduce dmgs 
Inq)airment of social or occiq>ational funcficWng due to die presence of disabling drug-induced 
psychomotor disorders 
Developmmt of hypomanie, manic, or cyclodiymic affective syndrome in relation to dopaminergic 
drags 
Development of a withdrawal state characterised by dysphoria, depression, irritability, and anxiety 
with reduction of dopaminagic drugs 
Duration of disturbance is of at least 6 months
A review of published case reports reveals that the majority of affected patients is male and have 
younger onset PD with an estimated mean age of disease onset around 48 years (Table 1 -3). Past 
heavy alcohol intake or past experimental dmg use may predispose to developing DDS (Beam et al. 
2004; Soyka and Huppert, 1992). Dopamine neural networks are specifically implicated in the 
syndrome. Dysregulation in these patients seems specific to dopaminergic dmgs as these patients do 
not ovemse anticholinergic medications which are abused by other patient groups (Dose and Tempel, 
2000). Compulsive use is most frequently reported with L-dopa but may occur with both ergot and non­
ergot derived dopamine agonists (Table 1 -3). Many case reports highlight the use of acute “rescue” dmgs, 
such as dispersible oral formulations of L-dopa and subcutaneous apomorphine. The addition of 
intermittent apomorphine injections to the therapeutic regimen can unmask or trigger medication ovemse
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(Giovannoni et al. 2000). Although there are no reports of its compulsive use, treatment with the 
dopaminergic, monoamine oxidase-B inhibitor selegiline can induce hypomania, compulsive spending, and 
transvestic fetishism (Kurlan and Dimitsopulos, 1992; Menza and Golbe, 1988; Riley, 2002). Interestingly, 
there are also rare reports of compulsive use of implanted subthalamic nucleus deep brain stimulators with 
constant demands for increases in stimulation parameters (Houeto etal. 2002).
The overall incidence o f dopaminergic dysregulation in PD is unknown. At one centre, the 
incidence was estimated at 4% (Giovannoni et al. 2000). At another centre, the incidence was similar 
at 3.5% (Pezzella et al. 2005) but the incidence in patients with PD is likely to be considerably lower 
than this because of difficulties in case identification and referral bias. Management is difficult. A 
concerted attempt to slowly reduce the total daily dose of dopaminergic therapy under regular medical 
supervision is mandatory. If an impulse control disorder or disabling punding has been identified, 
patients who are able to discontinue or significantly decrease dopamine agonist treatment can be 
expected to achieve full remission or a clinically significant reduction in symptomatology without 
deterioration in motor control (Mamikonyan et al. 2008; Kimber et al. 2008). Attempts to achieve 
concordance with the patient and enforcement of dose reduction by the family are important if 
clandestine self-medication is to be avoided.
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Table 1-3: Case reports of compulsive dopaminergic drug use in PD
Author Pts
Age
PD
onset
Age
DDS
onset
Premorbid 
psychiatric 
history/ drug 
history
Daily
LEU*
W ithdrawal
Relapse
after
attempted
reduction
Hoarding,
seeking,
craving
meds Punding Dyskinesias Behaviour
Euphoria/
hypomania Aggression
Psychosis,
delusions,
paranoia
Social or 
relationship 
breakdown
(Sollaeta/. 2006) IM 58 62 No 700+-*- . . . Yes . . . — Yes S No Yes
(Witjas e/a/. 2005) 2M 39
(30-48)
45
(38-53)
1 alcohol 2.3g No Yes . . . No Yes 2S Yes (2) Yes Y es(l) Yes
(Niroibffg and 
Waters, 2005)
2M 47
(45-50)
— 1 nicotine 600mg No Yes — — — 2G,E IS No — Y es(l)
(Borek and 
Friedman, 2005)
2M 51
(36-66)
62
(49-75)
No 5g Y es(l) Yes — — Y es(l) 28 1 Y es(l) Y es(l) No
(Avanzieto/. 2004) 2M 50
(48-52)
57
(53-61)
No 800mg No No — ~ — 2 0 Y es(l) No No Yes
(Muller e/a/. 2002) IM 27 35 Nicotine 1.4 Yes No Yes ---- Yes E,H ---- Yes Yes Yes
(Seiiano-Duenas,
2002)
3M,
IF
56
(49-62)
66
(59-71)
— 2.6g
(2.4-2.9K)
Yes (2) — . . . Yes Yes (3) 4G, IE — — — Yes (4)
(Houeto et o/. 2002) 2M 45 59
(58-61)
Alcohol, 
illegal drugs, 
bipolar
<1.4g Y es(l) Y es(l) Y es(l) Yes (2) 28, 2G Y es(l) Yes (2) No Yes (2)
(Gschwandtner et al. 
2001)
IM — 62 No l.Og . . . No — — Yes G Yes No No Yes
(Merims et al. 2000) IM 60 78 — 22g Yes — Yes — Yes No Yes — Yes No
(Giovannoni et al. 
2000)
4M,
IF
39
(36-42)
— 1 alcohol, 3 
depression
3.2g
(2.0-5.5g)
Yes (3) Y es(l) — — Yes (4) 38 Yes (2) — Yes (3) Yes
(Courty et a/. 1997) 4M 50
(46-57)
59
(50-65)
1 alcoholism, 
1 depression
1.3 g 
(0.9-1.7K)
Yes (2) Yes (2) . . . — — 48 — Yes (4) Yes (2) Yes (4)
(Spigset and von 
Scheele, 1997)
2M 54
(51-58)
59
(52-66)
— 1.7g
(1.5-2.0g)
No Y cs(l) . . . — Yes (2) — Yes (2) No Y es(l) Yes
(Weinman and 
Ruskin, 1995)
IM 53 63 — 3.5g+ — Yes . . . — Yes 18 Yes Yes — Yes
(Soyka and Huppert, 
1992)
IM — — Alcoholism — Yes — — — Yes — —
(U tti etal. 1989) IM 37 64 No Ig ---- No . . . — — 18 Yes ----- Yes Yes
(Tack et a/. 1988) IF 18 25 Slow
psychomotor
development
Up to 
2.5g
Yes Yes Yes 1 Theft Yes Yes Yes
(Nausieda, 1985) 5M 50
(41-55)
54.4
(46-60)
— 1.9g
(1.5-2.5g)
Yes (3) Yes (4) — Yes (5) 1H,2 8 Yes (4) Yes (2) Yes (2) Yes (5)
(Pridre, 1984) IF 60 49 — 5g 
(no DCI)
. . . — . . . Yes — Yes No — Yes
(Vogel and Schiffter, 
1983)
IM 46 48 — Up to 
2.0g/day
— — — Yes 18 — Yes Yes Yes
(Quinn et a/. 1983) IM 44 47 premorbid 
increased 
sexual interest
Up to4g No Yes Yes Yes 18 No Yes
* Values given are mean (range), LEU -  L-dopa equivalent unit as per Evans et al. 2004, DCI -  dopa decarboxylase inhibitor, S -  hypersexuality, G -  gambling, E -  eating, H -  buying
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Lack of adherence to recommended therapy is commonplace and is related to various factors such 
as the type of treatment, patient beliefs, physician or factors such as cost and availability of 
medications (Balkrishnan, 1998). Fear of perceived adverse events is an increasingly common 
explanation for non-adherence with proposed treatment schedules. Less commonly, however, 
excessive use of prescribed medications can occur with agents such as analgesics, anticholinergic 
agents, corticosteroids, tranquilisers and psychostimulants (American Psychiatric Association, 1994) 
and may relate to the medications’ benefits on mood and psychological state. The primary therapeutic 
aims in PD are the relief of symptoms without the introduction of adverse events, and improved 
quality of life. There are many reasons why a regular dosing of dopaminergic replacement therapy 
may not always achieve the therapeutic aims. For instance, medications may not be effectively 
absorbed or be timed effectively for a patient’s needs. This short duration response leads to cycles of 
gratifying mobility alternating with dips in motor performance associated with a return of motor 
impairment, dysphoria and depression which patients find extremely unpleasant. The majority of 
patients can effectively self-regulate medication dosing in partnership with the treating physician to 
achieve adequate symptom control without spiraling drug increases. However, a few take it upon 
themselves to take higher than recommended doses to avoid at all costs any “o ff’ periods. There is an 
increasing compulsion to take dopaminergic therapy, and a loss of control in limiting its intake. These 
patients repeatedly ask their doctors for larger doses of dopaminergic therapy. Excessive chronic 
dopaminergic stimulation when combined with the pathological substrate of PD can involve 
alterations in neuroanatomic circuitry that regulate reward, incentive motivation behavioural 
constraint and addictive behaviour and result in DDS. This may be triggered by the emergence of a 
short duration response to medication with disagreeable motor and mental “o ff’ periods.
As anti-Parkinsonian treatment is available on prescription for a well defined medical condition, 
there is no need for patients to devote time to illicitly procuring them. However, they often devote 
large amounts of time to complex dosing schedules and hoard extra medication, which they then 
surreptitiously use to supplement their prescribed medication. Prescriptions are sometimes acquired 
from different health providers. Drug hoarding may become apparent when attempts are made to 
restrict the supply of medication during hospitalisation. The family and carers may be forced to store 
medication in locations where the patient is not able access them and resort to strict dosing schedules 
to limit dose escalation. Patients with DDS request additional tablets despite being dyskinetic and
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may retain them for future use. Similarly, they often insist on frequent rescue “boosters” . Dishonesty, 
manipulation and addictive denial systems are usually coupled with complete lack of insight.
1.7.7 Common disabling phenomenology in dopamine dysregulation syndrome
DDS is characterised by impulsivity, compulsivity, and an overwhelming pre-occupation with a 
particular behaviour pattern or mood state. The significant additional impact on social and 
occupational functioning that often brings the dopaminergic drug misuse to the attention of others can 
lead to divorce, breakdowns in close interpersonal relationships, financial difficulties related to 
compulsive spending, and legal difficulties due to inappropriate sexual advances and aggressive 
behaviour (Giovannoni et al. 2000). The disabihty due to PD is usually sufficient in itself to affect 
social and occupational function but in those with DDS the behavioural changes have a significant 
distressing impact on their families and friends. Demands for medication, inappropriate sexual 
behaviour, financial difficulties related to compulsive spending, and aggressive behaviour frequently 
lead to divorce increasing isolation and even criminal proceedings.
1.7.7.1 Craving
Patients sometimes adopt devious manipulative strategies (e.g. simulation o f akinetic (Vogel and 
Schiffter, 1983) tremor states, bizarre distressing dystonie postures or even bribery (Muller et al. 
2002)) or aggressive outbursts to access additional medication. I am aware of an incident resulting in 
a life-threatening injury in which one patient assaulted another for the purpose of procuring extra L- 
dopa. Craving can often occur in the absence of withdrawal or “o ff’ states (Courty et al. 1997). An 
impatient, intense desire for further dopatherapy may be induced by its actual administration; 
particularly if the first dose is perceived as suboptimal. Patients sometimes develop idiosyncratic 
perseverative patterns of self-administration as well as stereotyped patterns of behaviour around 
dosing times. Compulsive foraging for dopatherapy is also occasionally observed (Tack et al. 1988)
-  one patient has been known to scrounge through sharps disposal containers for apomorphine 
residues (unpublished observation).
1.7.7.2 Euphoria and hypomania
Feelings of euphoria, perceived omnipotence, invulnerabihty and inappropriate joy can occur 
during the peak medication effects with racing thoughts and grandiose ideation (Serrano-Duenas, 
2002). Paradoxically, the patient may complain of depression and threaten suicide (Muller et al.
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2002) despite their euphoric appearance (Courty et al. 1997). Pathological jealousy (Othello 
Syndrome), disorganisation or pressure of speech and thought processes, an increasing inability to 
distinguish reality from fantasy, insomnia and psychomotor agitation may bring the disorder to the 
physician’s attention. The indiscriminate enthusiasm for interpersonal interaction seen classically in 
mania, however, is absent. Furthermore these feelings are usually cyclical or short-lived (hours or 
days), and punctuated by episodic blunting of emotional response, social withdrawal, and apathy.
1.7.7.3 Dysphoria and non-motor offs
Withdrawal of dopaminergic drugs is characterised by feelings of sadness, exaggerated 
psychomotor slowing, dysphoria, fatigue, anhedonia (Funkiewiez et al. 2003) and apathy (Czemecki 
et al. 2002). Somatic complaints also include cryptogenic abdominal discomfort, painful limb and 
trunk sensations and autonomic disturbances such as profuse sweating (Witjas et al. 2002). In DDS, 
marked anxiety, irritabihty, exaggerated rebound depressive, dysphoric, anergic and somatic 
symptoms are described which may occur in the absence of “off period motor disabihty” (Giovannoni 
et al. 2000; Serrano-Duenas, 2002). “ofF’-period panic attacks also occur.
1.7.7.4 Appetitive behaviours
Various disorders of impulse control characterise DDS. Hypersexuahty is a common disabling feature 
with both an increase in libido and in males, recurrent penile erections. This can lead to great marital 
disharmony (Berger et al. 2003; Lawrence et al. 2003) as a result o f compulsive, disinhibited 
masturbation, persistent and forceful and occasionally aggressive sexual demands on partners, use of 
sex phone lines, internet sites, pornographic literature and prostitutes (Giovannoni et al. 2000). 
Paraphilias including exhibitionism, pederasty (Berger et al. 2003), sadomasochism, zoophilia 
(Jimenez-Jimenez et al. 2002), and fetishism (Quinn et al. 1983) may occur in individuals with a 
history o f similar, possibly “repressed” proclivities. A few cases of serious sexual assault on strangers 
have also occurred.
Pathological gambling occurs particularly in individuals with a premorbid history of an interest in 
betting. Alterations in function of dopaminergic reward systems as well as dysfunctional impulse 
control are implicated in pathological gambling (Potenza et al. 2003; Yoon, 2004). Family fortunes 
can be squandered, and huge debts run up causing terrible family distress (Kurlan, 2004). The 
gambling behaviour has been noted to be medication responsive (Gschwandtner et al. 2001 ; Molina
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et al. 2000). In particular, switching or reducing dopamine agonists may lead to resolution of the 
problem (Driver-Dunckley et al. 2003; Dodd et al. 2005).
Compulsive shopping, eating disorders (Giovannoni et al. 2000; Muller et al. 2002) and binge 
eating (Lawrence et al. 2003; Nirenberg and Waters, 2005) may also be features of hypomanie 
phases. Some patients develop severe and uncontrollable food cravings.
1.7.7.5 Aggression
The dopamine system is imphcated in the processing of signals of aggression (Lawrence et al. 
2002). Heightened aggression is common in DDS and includes irritability, low tolerance of 
frustration, angry outbursts, use o f insulting language or gestures, jealousy, threats of homicide and 
occasional violence. Patients report brief exaggerated feelings of power and dominance.
1.7.7.6 Psychosis
Depression, mood swings, paranoia, panic attacks and psychosis are common complications of 
habitual cocaine use (Harris and Batki, 2000). Psychosis in methamphetamine and cocaine addicts has 
been linked to dopaminergic neuroadaptations within mesocortical systems (Sekine et al. 2003). In 
DDS, unchecked dopaminergic dmg use leads to intoxication and a dose-dependent reversible organic 
psychosis. Delirium, paranoid ideation, fears of persecution, panic, and auditory, visual or tactile 
hallucinations may all be present. Severe dyskinesias, sleep disturbance, and extreme motor agitation 
are common accompaniments.
1.7.7.7 Compulsive behaviours (stereotypies)
Punding is an intense fascination with repetitive tasks such as collecting, arranging, or dismantling 
objects and it may cause isolation from or conflict with other people. These complex repetitive 
behaviours develop from prepotent habits, which are idiosyncratic, and depend on an individual’s 
occupation, interests and pastimes. Punding was first described in amphetamine addicts (Rylander, 
1966; Schiorring, 1977) but has been more recently been recognised in PD (Friedman, 1994). Long 
term dopatherapy-use (Kurlan, 2004) or frequent dopatherapy-dosing are also risk factors and it may 
resolve or improve with reductions in dopaminergic dmg therapy (Femandez and Friedman, 1999). 
Men tend to repetitively tinker with technical equipment such as radio sets, clocks, watches and car 
engines; the parts of which may be analysed, arranged, sorted, and catalogued but rarely put back 
together. Women, by contrast, incessantly sort through their handbags, tidy continuously, bmsh their 
46
hair, or polish their nails. Office workers and clerks may shuffle papers or fiddle purposelessly with 
computers. A seamstress may collect and arrange buttons. A dissociation between knowledge and 
behaviour develops as individuals become unable to control automatic stimulus-response selection 
mechanisms i.e. patients know they are disruptive and unproductive, but continue to perform them.
1.7.7.8 Dyskinesias
DDS patients commonly identify restriction of social activities due to embarrassment about 
dyskinesia as their most disabling problem. Physical and psychological problems reported by patients 
include repeated injury because o f dyskinesias (Beam et al. 2004). Also during the “on ” or high 
phase of medications, these patients will often become restless and develop akathisia with an urge to 
walk. They can walk great distances without purpose and lose track of time.
1.8 Basal ganglia circuits in health and disease
The organisation of corticostriatal systems has been considered in terms of segregated parallel circuits 
which connect limbic, prefrontal, oculomotor, and motor cortical areas through subregions of the 
basal ganglia and the ventral thalamic nuclei to analogous cortical areas. The basal ganglia are 
thought to modulate the release or inhibition of movements by way of direct and indirect pathways 
that act as a push-pull system o f cortico-basal ganglia circuits. Functional integration within these 
pathways is retained by means of neuromodulation occurring through striatal dopaminergic receptors 
(Figure 1-2). In PD, this modulation is lost due to dorsal striatal dopamine depletion: resultant 
increased activity in the output nuclei then leads to increased inhibition of the glutamatergic 
excitation of the motor cortex and a subsequent reduction in voluntary movement. This simple brake- 
accelerator view of basal ganglia pathways has been refined by the realisation that it is not simply the 
total neural activity but the pattern of neural activity that determines the operation of these pathways. 
The leading surgical therapies for PD are now modelled on this direct-indirect pathway concept: i.e. 
to improve movement, a lesion o f the motor part of the globus pallidus pars interna (GPi) is made in 
the ventrolateral pallidotomy procedure and in therapies based on deep-brain stimulation, inactivation 
of the subthalamic nucleus is brought about by a chronically implanted stimulator device.
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Figure 1-2; Schematic representation of basal ganglia function in health and Parkinson’s 
disease
1. the ventrolateral thalamic nuclei (VL) excite the motor cortex, causing motor 
activity; VL is normally inhibited by the globus pallidus pars interna (GPi)
2. dopaminergic neuronal loss in PD leads to greater activity of the GPi (and linked 
subthalamic nucleus), causing less net motor activity (akinetic, rigid syndrome)
3. subthalamic nucleus lesion (hemiballismus) or putaminal dopaminergic neuronal loss 
lessens GPi activity, causing excessive, spontaneous motor activity
Norm al Parkinson's disease
CORTEX CORTEX
A
Putam en Putamen
D2 D l D2 D l
SNc
GPeGPe
VL VL
STN k >  ' STN
GPi
V
BrainstemB rainstem
spinal cord spinal cord • in h ib ito ry
SNc; Substantia  n igra pars com pacta , G P i; G lobus pallidus pars interna, G Pe; G lobus pallidus pars ex terna, S T N ;
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1.9 Dopamine functions in motivation and learning
Another theme of basal gangha research mainly based on experimental laboratory work is that the 
basal ganglia have important fimctions in relation to learning and memory. Electrophysiological 
studies of the activity of single neurons in behaving animals highlight a role for dopamine beyond 
simple reward function. After presentation of reward, short, phasic activation of dopamine neurons 
are common (70-80% of neurons) in the medial tegmental regions that project to the nucleus 
accumbens and frontal cortex but are also found in intermediate and lateral sectors that project to the 
caudate and putamen (Schultz, 2000). While these neurons are phasically excited by the receipt of an 
unanticipated reward, this response habituates as the reward becomes predictable and the cells fire 
instead in response to reliable predictors -  such as a programmed light flash or an apparatus noise -  
of the reward. The same neuron may show inhibition of normal firing when an expected reward fails 
to arrive at the normal time. On the other hand, only a few dopamine neurons show phasic activation 
in response to punishers (Mirenowicz and Schultz, 1996) or neuronal activity may be depressed rather 
than activated by the omission of a reward (Hollerman and Schultz, 1998). The midbrain 
dopaminergic signal reports the degree to which a reward cannot be predicted. It is indicated by the 
discrepancy between the reward obtained for a given behavioural action and the reward that was 
predicted to occur as a result o f that action (the reward prediction error) (Hollerman and Schultz, 
1998) and is reflected in the final midbrain dopaminergic signal.
An alternative explanation is that the dopamine signal facilitates the reallocation o f limited 
behavioural and cognitive processing capacity towards any unexpected event of behavioural 
significance, including reward. This hinges on the notion that the dopamine signal has a more general 
role in associative learning (Redgrave et al. 1999). Indeed, a selective increase in dopamine release 
in the nucleus accumbens occurs when an association is formed between two stimuli neither of which 
induce dopamine release prior to the formation of the association (Young et al. 1998). This suggests 
a role for mesolimbic dopamine in the modulation of associative learning in general, not only that 
involving reinforcement.
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Figure 1-3: Areas implicated in reward
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VTA -  ventral tegmental area, SNc -  substantia nigra pars compacta, VP -  ventral pallidum, STN -  subthalamic nucleus, 
GPe -  external globus pallidum, GPi -  internal globus pallidum, S N r -  substantia nigra pars reticulatum.
Dopaminergic mediated learning and memory invokes molecular and cellular adaptations and 
dopamine has been proposed to have a role in the modulation of long-term potentiation within the 
ventral tegmental area (VTA). In this model, once a contingency is learned, the same conditioned 
stimulus will activate output neurons, with no need for ongoing activity of dopaminergic neurons. As
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a contingency is learned, there is habituation of mesolimbic dopamine transmission. At the same time, 
the responsiveness of mesocortical outputs amplify as the contingency extends to become a 
conditioned stimulus (Di Chiari, 1998). If the contingency reverses, the synapses from the neurons 
representing the previous conditioned stimulus are no longer active when the output neuron is active, 
and the synapses become weaker by a process of heterosynaptic long-term depression (Rolls, 2000; 
Thomas et al. 2000; Thomas et al. 2001). The late phase of this so-called process of “long-term 
potentiation” involves structural changes in synaptic connection and changes in synaptic density 
(Berke and Hyman, 2000) and occurs through related alterations in the cellular transcription (Bibb et 
al. 2001). Reorganisation of the cerebral cortex can be directly related to ventral tegmental 
dopamine-mediated activity (Bao et al. 2001) and dopamine-enabled reorganisation of higher-level 
cortical areas has an important role in sensory integration, association of emotion with sensory 
stimuli, learning and operant conditioning.
Neurons in the striatum (Apicella et al. 1991), subthalamic nucleus (Matsumura et al. 1992), pars
reticulata of the substantia nigra (Schultz, 1986), anterior cingulate (Niki and Watanabe, 1976), and
lateral hypothalamus (Burton et al. 1976) also respond to conditioned reward stimuli but encode
different aspects of rewarding stimuli. Whereas, the responses of dopamine neurons display rather
homogenous population responses to reward, predominantly influenced by event unpredictability,
other reward responsive neurons in the basal ganglia and frontal cortex respond at varying times to
other components of reward related tasks. The orbitofrontal cortex receives trans-synaptic inputs from
the striatum, which displays prominent reward-dependent activity, the amygdala and rostral and
medical temporal lobe (Carmichael and Price, 1996). Neurons in the orbitofrontal cortex distinguish
between rewards and punishers (Thorpe et al. 1983), between rewards and conditioned rein forcers,
and also discriminate between different liquid or food rewards. Many of these behaviours reflect the
incentive motivational value relative to the available alternative reward, as inferred from the animals’
preference in overt choice behaviour (Tremblay and Schultz, 1999). In contrast, many neurons of the
ventrolateral prefrontal cortex appear to primarily process the visual features of environmental objects
(Kubota and Niki, 1971) and derive inputs from posterior parietal and inferotemporal cortex (Pandya
and Yeterian, 1996). Striatal neurons display a large spectrum of reward-dependent responses. The
nature of striatal responses indicate that the expectation of reward strongly influences striatal
activities and relate to the behaviour producing these rewards. So, the striatal neurons are seen to
respond to reward-dependent movement preparatory instructions, to reward-dependent movement 
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preparatory instructions, to reward-dependent movement triggers, during reward expectation and to 
primary reward (Apicella et al. 1991; Apicella et al. 1992; Schultz et al. 1992). Other neurons 
display activations which are related to the magnitude o f rewards (amygdala (Pratt and Mizumori, 
1998)). Neurons of other brain structures, such as the striatum, orbitofrontal cortex, and amygdala, 
appear to code the quality, quantity, and preference of rewards and possibly even reflect 
representations of goals. Activations in these brain structures may serve to provide selective teaching 
signals for certain groups of neurons whereas the homogeneous reward response of dopamine neurons 
might be characterised as broadcasting a global reinforcing signal along divergent projections to large 
numbers of neurons in the striatum and frontal cortex (Schultz, 2001).
1.10 Do models of psychostimulant addiction help to understand compulsive 
dopaminergic drug use in PD?
Current theories of addiction incorporate the idea that drugs activate and, via neuroadaptive 
processes, change dopaminergic neurotransmission in the nucleus accumbens and related circuitry, 
altering important reward-related processes (although different theories posit different processes) 
(Robinson and Berridge, 2003).
1.10.1 Do the dopaminergic drugs used to treat PD activate brain “reward’’ pathways?
There are some data on the activation of accumbens-related reward pathways by dopaminergic dmgs 
used to treat PD. Conditioned place-preference is used as one index of reward. In the learning phase of 
this procedure, animals receive a stimulus in one compartment of the place-conditioning chamber, and 
receive a control stimulus in another. In the test phase, animals do not receive a stimulus and are free to 
go to either compartment. Rewards such as food, sexual stimuli, and psychostimulant drugs cause 
conditioned place preferences to occur; animals spend more time in the compartment previously paired 
with reward (Bardo and Bevins, 2000).
In rats, L-dopa combined with the catechol-O-methyltransferase inhibitor entacapone induces a 
conditioned place preference similar to that induced by psychostimulants such as amphetamine 
(Katajamaki et al. 1998). This effect is also produced by the dopamine agonists apomorphine (Papp,
1988; van der Kooy et al. 1983) and bromocriptine (Hoffinan et al. 1988), suggesting they are 
“rewarding”. Such conditioned place preference is accompanied by increased dopamine turnover in the 
accumbens, and lesions to the accumbens disrupt apomorphine-induced place preference (van der Kooy
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et al. 1983) and self-administration (Zito et al. 1985). Pramipexole increases activity in accumbens- 
related circuitry (Black et al. 2002). In normal humans, dopamine agonist therapy seems to have 
relatively minor effects on mood. However, occasionally when used in the treatment of prolactinoma, 
a reversible psychosis (Boyd, 1995), mania (Kemperman and Zwanikken, 1987), hypersexuahty and 
pathological gambling (Press Association, 2001 ; Evans and Butzkueven, 2007) may occur. The abuse 
potential of these drugs has also been described in healthy humans (Manoharan et al. 2002; Steiner and 
Wirguin, 2003) and in patients with nonneurodegenerative illnesses (Ross and Ward, 1992; Steiner and 
Wirguin, 2003). Dopaminergic drug therapy used to treat PD seems to share at least some of the 
properties of potentially addictive drugs.
1.10.2 Theories of compulsive psychostimulant use
1.10.2.1 Pleasure models
The oldest explanation for addictions is that they are driven by feelings of pleasure (Aristotle, 
1976). Contemporary variants of pleasure theories— such as Wise’s hedonia theory (Wise, 1985)— 
assume that drugs act as rewards because they induce some kind of pleasure, and that this is what 
compulsive drug users seek. Ethological theories of reward are commonly apphed to comparative 
studies of drug seeking: any stimulus that elicits locomotor approach behaviour will serve as a reward 
or “positive reinforcer” (Vaccarino et al. 1989). Wise (Wise, 1985) equated the approach responses 
induced by rewards—as seen in conditioned place preference—with the experience of pleasure: “It is 
the approach response and the motivational arousal caused by rewards which I believe to be most 
clearly associated with pleasure”. In PD patients, an acute L-dopa dose can lead to small increases in 
“happiness” and “positive mood”, which may increase with escalating doses and over time (Brown et 
al. 1984; Maricle et al. 1998). Although a few DDS patients report peak-dose feelings of euphoria 
and joy, there is little evidence that they experience greater L-dopa-induced euphoria than individuals 
who do not develop it. In fact, large doses of L-dopa often lead to unpleasant feelings (Table 1-3) and 
increases in “positive mood” are not reported early on in the course of treatment of PD (Maricle et al. 
1998).
There are general problems for pleasure theories of addiction (Berridge and Robinson, 1998; 
Robinson and Berridge, 2000; Robinson and Berridge, 2003). People will work for small doses of 
drugs (e.g., cocaine) that lack discernible pleasurable effects (Comer and Collins, 2002; Lamb et al.
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1991 ) (i.e., the motivation to take drugs can be dissociated from drug-induced pleasure) (Berridge and 
Robinson, 1998; Robinson and Berridge, 1993; Robinson and Berridge, 2003). Attempts to rescue the 
pleasure theory of addiction suggest that the pleasurable effects of drugs may only be open to verbal 
report if they exceed a given threshold (Panksepp et al. 2002; Shizgal, 1999). Most psychologists 
accept that a lack of verbally reported pleasure does not mean a lack of pleasure experience. Although 
pleasure is often defined as a conscious feeling, it can exist without conscious awareness—which is 
the product of a constructive process—rather than being a direct “readout” of the underlying affective 
state (Frijda, 2001).
There are further problems for the hedonia model. If all compulsively used drugs activate 
accumbens dopamine systems, and if the use of these drugs is motivated by pleasure, then destmction 
of dopamine neurons should abolish pleasure (Wise, 1985). Berridge and colleagues (Berridge and 
Robinson, 1998) have studied the role of dopamine in the mediation o f pleasure—by use o f the taste- 
reactivity paradigm—based on stereotyped reactions emitted by rats to tastes, which are thought to be 
homologous to human reactions to highly palatable food (Steiner et a l  2001). Contrary to the 
hedonia hypothesis, near total dopamine depletion induced by n euro toxins does not diminish facial 
expressions of pleasure to sweet tastes, even though it abohshes motivation to eat (Berridge and 
Robinson, 1998). So, even if the “pleasure” experienced by addicts is unconscious, it is not the same 
as the sensory pleasure experienced when eating, for example, sweet foods (Berridge and Robinson,
1998). In human beings, dopaminergic blockade diminishes self-reported drug “Wanting” but not 
drug “liking” (Berridge and Robinson, 1998).
It may still be possible to argue for a pleasure theory of addiction, if it is accepted that there may be 
different kinds of pleasure, and that not all pleasures are sensory pleasures (Nuttin, 1973 ; Frijda,
2001; Rozin, 1999). Frijda (Frijda, 2001) distinguishes sensory, aesthetic, achievement/mastery, 
activity, rehef, and social pleasures; Rozin (Rozin, 1999) distinguishes sensory, aesthetic, and 
mastery pleasures. Although dopamine does not mediate sensory pleasure, it could mediate other 
forms of pleasure that could be causally related to drug euphoria and to compulsive drug use (Drevets 
et al. 2001; VoLkow e/a/. 2002a). Panksepp and colleagues (Panksepp e/a/. 2002) have proposed a 
similar approach. They argue that ultrasonic vocalisations are expressions of particular emotional 
states in rats. Rats emit vocalisations of about 50 kHz in several reward-related situations (e.g., during 
playful interactions, before sexual intercourse, and while anticipating food) (Panksepp etal. 2002).
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50 kHz ultrasonic vocalisations are also emitted in places associated with previous psychostimulant 
administration and can be elicited by injection of dopamine agonists into the accumbens (Panksepp et 
al. 2002). Panksepp suggests that these responses are homologous to states of euphoria, excitement, 
or joytul anticipation in human beings.
1.10.2.2 Hedonic homeostatic dysregulation
Several models of addiction suggest that addicts are motivated to take drugs not only for pleasure, 
but also -  and perhaps eventually primarily -  by the desire to avoid unpleasant withdrawal symptoms. 
Opponent process theory (Solomon and Corbit, 1974) proposes that pleasant doses of a drug activate 
a dose-dependent “a” process in brain reward circuits, which in turn triggers activation of an 
unpleasant opposite “b” process, and which serves to restore homoeostasis (Solomon and Corbit, 
1974). The subjective state of the individual is created from summation of the “a” and “b” processes. 
The “a” process causes euphoria. The “b” process initially manifests as a decay of euphoria after 
initial peak (Solomon and Corbit, 1974). With repeated drug use, the “b” process becomes 
strengthened and manifests as tolerance to euphoria. Unpleasant withdrawal is caused when the drug 
effects wear “o ff’, since the “b” process is assumed to last longer than the “a” state. It is only the “b” 
process that is assumed to grow in magnitude and duration with repeated drug use: even a small dose 
will reinstate it and trigger withdrawal (Solomon and Corbit, 1974). Abstinence from the drug decays 
the “b” process, and once it returns to normal, the individual is no longer addicted (Solomon and 
Corbit, 1974).
The hedonic homoeostatic dysregulation (HHD) model of Koob and Le Moal (Koob and Le Moal, 
1997; Koob and Le Moal, 2001 ) is a variant of opponent process theory based on allostatic, rather 
than homoeostatic, adaptation. Allostasis is the maintenance of stabihty outside the normal 
homoeostatic range in response to chronic demands. In HHD, before addiction, the anticipation and 
experience of drug-induced pleasure motivates the individual. However, HHD defines addiction as 
the presence of an unpleasant emotional state of dysphoria, irritabihty, and anxiety during abstinence 
(Koob and Le Moal, 2001). With repeated drug intake, the “b” process does not return to normal 
homoeostatic baseline, resulting in an allostatic state. This unpleasant state (allodynia or anhedonia 
[loss of pleasure]) reflects a decrease in baseline pleasure levels -  associated with reduced dopamine 
function (Barr et al. 2002) -  and an increase in drug intake is needed to compensate for the shift in 
baseline reward. There is evidence that some patients with PD show reduced reward-related brain
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activity (Kunig et al. 2000), which, according to HHD, would confer increased vulnerability to 
dopaminergic drug addiction (Koob and Le Moal, 1997; Koob and Le Moal, 2001). A history of 
depression with associated anhedonia may be a predisposing factor in some cases (Table 1-3).
Robinson and Berridge (Robinson and Berridge, 1993; Robinson and Berridge, 2003) criticise the 
use of the term “hedonic” in HHD. They argue that low dopamine concentrations are not associated 
with anhedonia. The notion o f multiple types of pleasure (Frijda, 2001 ; Rozin, 1999), however, could 
be used to counter this criticism. Another problem with HHD is that the acute and chronic neural 
adaptations to drug use can take anywhere from minutes to weeks to return to their normal sensitivity 
but do not appear to be sufficiently long-lasting to be involved in the tendency of addicted individuals 
to relapse. Furthermore, dopamine innervation of the ventral striatum may not exclusively subserve 
reward. Stimuli with aversive qualities (e.g. footshock, restraint stress and anxiogenic drugs) can, like 
reinforcing stimuli, increase nucleus accumbens dopamine transmission (Imperato et al. 1992; 
Horger et al. 1995; Kalivas and Duffy, 1995; McCullough and Salamone, 1992). In addition, 
conditioned punishment, which is another learning paradigm, as well as conditioned reinforcement, is 
also potentiated by systemic administration of amphetamine (Killcross et al. 1997).
In their initial account of compulsive dopaminergic drug use in PD, Giovannoni and colleagues 
(Giovannoni et al. 2000) labelled it as a form of HHD. Prominent unpleasant symptoms can be a 
feature of the withdrawal state and these form part of current working diagnostic criteria (Giovannoni 
et al. 2000). Patients also report feeling “relief’ when given dopaminergic drugs. Beam and 
colleagues (Beam et al. 2004) emphasise that the avoidance of being unmedicated was the primary 
reason given for increasing dmg intake. However, although the withdrawal syndrome may explain 
many of the features of addiction, definitions of substance dependence emphasise a pattem of 
compulsive substance use which may lead to reductions in social, occupational, or recreational 
activities (American Psychiatric Association, 1994). The neural substrate underlying these features is 
likely to involve wider neural networks than solely the dopaminergic mesolimbic system. There are 
also cases of long-term compulsive dopaminergic use that show no subjectively unpleasant 
withdrawal signs (Table 1-3). A further problem for withdrawal based explanations of compulsive 
dopaminergic dmg use is that dmg craving is often elicited by dmg administration itself—in 
association with euphoria— at the moment when withdrawal symptoms should be at their weakest 
(Giovannoni et al. 2000). Moreover, at least one report suggests that pharmacological relief of
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unpleasant withdrawal symptoms does not reduce compulsive dopaminergic drug use (Courty et al. 
1997).
Withdrawal may have a role in compulsive drug use for reasons other than simply the desire to 
avoid unpleasant feelings. An alternative to avoidance theory views withdrawal states as equivalent to 
natural motivational states such as hunger (Berridge and Robinson, 1998; Hutcheson et al. 2001). 
Incentive motivational accounts of addiction assume that the withdrawal-state induced by depriving 
an addict o f drugs increases the incentive value of the drug to such an extent that drug seeking 
becomes the dominant behaviour (Hutcheson et al. 2001 ).
According to incentive motivational accounts, patients with PD undergoing withdrawal are 
experiencing drug “hunger”, rather than just a desire to overcome an unpleasant feeling. Indeed, some 
of the reports of compulsive users describe severe feelings of urgency on withdrawal, “driving” them 
to take more (Nausieda, 1985).
1.10.2.3 Habit theory
Habit theory is a recent approach to addiction that downplays the part of emotions, and places 
greater emphasis on learning mechanisms (Everitt and Wolf, 2002). A habit is an automatic action in 
a given situation, without direct reference to the goal of that action. The premise of habit models is 
that, despite beginning as a goal-directed action, in which individuals seek drugs based on the 
knowledge and desire of the pleasure they produce, there is an eventual progression to a form of 
automatic behaviour in which voluntary control over drug use is lost (Hogarth et al. 2003). In 
addition, stimuh consistently present in the environment gain motivational power through their 
predictive association with drugs, and thereby elicit and support drug-seeking and cause relapse via 
associative-leaming mechanisms (Everitt et al. 2001; Everitt and Wolf, 2002).
This approach has gained attention partly owing to the finding that dopamine neurons signal errors 
in reward prediction that are critical for associative learning (Waelti et al. 2001). Repeated exposure 
to psychostimulants facilitates such learning and triggers neuroadaptations in dopamine systems and 
intracellular signalling-pathways similar to those seen during learning (Berke and Hyman, 2000). 
Striatal dopamine is also clearly involved in the development and reinforcement of automatic 
stimulus-response habits (Everitt et al. 2001 ; Everitt and Wolf, 2002; Ito et al. 2004).
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Habit theory provides a good explanation for the stereotypical behaviour seen in punding —a 
common feature of compulsive dopaminergic drug use in PD. These stereotyped behaviours include 
prepotent, habitual routines (e.g., grooming), which are homologous to the complex stereotyped 
responses seen in rats during hyperdopaminergic states (Berridge and Aldridge, 2000a; Young and 
Thiessen, 1991). Strong stimulus-response habits form the basis of such routine activities. Stereotypy 
represents the culmination o f a continuous process of psychomotor stimulation and behavioural 
competition (Robbins et al. 1990; Toates, 1998). Smaller doses of psychostimulant drugs potentiate 
the approach responses to rewards, which are mediated by accumbens dopamine (Ikemoto and 
Panksepp, 1999; Robbins et al. 1990). With increased doses, prepotent stimulus-response habits— 
mediated by the dorsal striatal structures—are potentiated and gain control over behaviour (Robbins 
et al. 1990; Whishaw et al. 1992). Stereotypies develop from prepotent habits (Toates, 1998), which 
are idiosyncratic, depending on individual life histories (e.g., office workers stereo typically shuffle 
papers, a seamstress will stereotypically collect and arrange buttons). Individuals become unable to 
control automatic stimulus response selection mechanisms (i.e., stereotypies are purposeless, and 
there is a dissociation between knowledge and behaviour) (Robbins et al. 1990; Toates, 1998). 
Patients realise that these behaviours are irrational, but are unable to stop them.
Habit theory explains other features of compulsive dopaminergic drug use in PD less well. This 
theory may mistake automatic, habitual action for motivational compulsion: no matter how habitual 
drug-taking becomes, automatic stimulus -response processes cannot in themselves confer compulsive 
qualities to drug seeking and intake (Robinson and Berridge, 2003). In defense of habit theory, it has 
been argued (Wise, 2002) that the effects of vast doses of dopa drugs are far in excess of any normal 
physiological range, and thus habits may have supranormal qualities. Habit models cannot easily 
explain the apparently flexible goal directed actions that patients with PD use to obtain dopa drugs 
(e.g., feigned akinetic states).
The habit model does not explain why most patients with PD are not addicted to dopaminergic 
drugs. Drug use should become habitual in all patients, but the incidence o f compulsive dopaminergic 
drug use in PD is very low. Habit theorists must posit extra pathology in susceptible individuals. For 
example, frontal cortical pathology could cause additional loss of regulation of habitual behaviours 
(Jentsch and Taylor, 1999). Rats with lesions to the frontal cortex show persistent responses to 
cocaine that are no longer under the control of contingent presentation of cocaine-associated cues
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(Weissenborn et al. 1997). The ability to modulate habits and conditioned responses can be impaired 
in some patients with PD, and such deficits are exacerbated by L-dopa (Cools et al. 2001; Cools et 
al. 2003). Furthermore, the stereotyped collecting behaviour seen in compulsive dopaminergic drug 
users resembles that seen in patients with frontal-lobe damage who have “forced collection ism”
(Voile et al. 2002). However, even with this additional pathology, the criticism that habitual response 
and motivational compulsion are not equivalent seems valid.
1.10.2.4 Incentive Sensitisation Theory
According to Robinson and Berridge's incentive sensitisation theory (1ST) (Robinson and Berridge, 
2000; Robinson and Berridge, 2003), compulsive drug use results from progressive and persistent 
neuroadaptations induced in dopamine projections to the accumbens-related circuitry (Robinson and 
Berridge, 2000; Robinson and Berridge, 2003). These neuroadaptations can include: long-lasting 
changes in dopaminergic and GABAergic neurotransmission, changes in intracellular signalling 
pathways activated by these neurotransmitters, and even persistent changes in the physical structure 
of neurons themselves (Berke and Hyman, 2000; Robinson and Berridge, 2000; Robinson and 
Berridge, 2003).
The critical neuroadaptations for compulsive drug use make these neural systems hypersensitive, or 
sensitised, where sensitisation is a progressive increase in drug effect with repeated administration, to 
the incentive motivational or rewarding effects of drugs (Robinson and Berridge, 2000; Robinson and 
Berridge, 2003). The systems sensitised, according to this theory, mediate a subcomponent of reward 
termed incentive salience (Berridge and Robinson, 1998; Robinson and Berridge, 2000; Robinson and 
Berridge, 2003). Incentive salience is neither a hunger, nor a withdrawal state. Rather, it is one component 
of normal appetite which, if attributed to stimuli, causes them to become attractive and “Wanted”, 
which triggers approach and pursuit (Robinson and Berridge, 2000; Robinson and Berridge, 2003). 
This “Wanting” is quite separate from “liking”(sensory pleasure) (Berridge and Robinson, 1998).
The process of neural sensitisation in the accumbens circuitry eventually leads to excessive 
incentive salience attribution to the drugs and dmg-related stimuh that activate this circuitry, making 
them highly attractive and pathologically “Wanted” or craved (Berridge and Robinson, 1998; 
Robinson and Berridge, 2000; Robinson and Berridge, 2003). According to incentive sensitisation 
theory, the system that causes incentive sahence attribution can produce dmg seeking not only in the 
absence of subjective pleasure (mediated by the “liking” system), but also in the absence of conscious 
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awareness of “Wanting” itself (i.e., it can act as an unconscious motivational process) (Robinson and 
Berridge, 2000; Robinson and Berridge, 2003). Incentive salience is not the same as incentive learning, 
although 1ST suggests a role for associative learning in the expression of sensitisation (Robinson and 
Berridge, 2000; Robinson and Berridge, 2003). For example, increased incentive salience following 
chronic amphetamine treatment in rats can increase the salience of appetitive stimuli in the 
environment which the animal has had no opportunity to consume and learn the reward value of these 
stimuli (Nocjar and Panksepp, 2002). Incentive sensitisation theory can be contrasted with theories that 
emphasise incentive learning mechanisms (Di Chiara, 1999; Hutcheson et al. 2001).
Psychomotor sensitisation is used as a marker of neural sensitisation, because it is assumed that the 
neural substrate that mediates the psychomotor-activating effects of dmgs is either the same as, or at least 
overlaps with, the neural substrate for reward effects (Robinson and Berridge, 2000; Robinson and 
Berridge, 2003; Wise and Bozarth, 1987). L-Dopa-induced dyskinesia is generally thought to be a 
sensitisation phenomenon (Graybiel et a l 2000; Olanow et al. 2000). The development of dyskinesia in 
animal models of PD requires the same dmg schedule as that necessary to induce psychomotor 
sensitisation by psychostimulants (Graybiel et al 2000). Stimulant-induced locomotor sensitisation is 
only seen when dmgs are given intermittently, and the most robust sensitisation occurs when injections are 
widely spaced over time (Robinson and Berridge, 2003). Sensitisation is strongest when high or rapidly 
escalating doses are given (Robinson and Berridge, 2003). Sensitised locomotor responses in rats are 
sensitive to stress (Robinson and Berridge, 2000; Robinson and Berridge, 2003), as are dyskinesias in PD 
(Durif et al. 1999). “On” dyskinesias -  including dystonie, choreic, or stereotyped movements -  are 
commonly seen in individuals who compulsively use dopaminergic dmg therapy (Table 1 -3). 
Additionally, sensitised synaptic dopamine responses in the dorsal striatum also correlate with dyskinesia 
severity (Pavese et al. 2006). The stereotypical actions seen in punding may also result from psychomotor 
sensitisation processes (Graybiel et a l 2000).
The neuroadaptations that cause dyskinesias and punding are similar to those seen after psychomotor 
sensitisation by, for example, amphetamine (Beike and Hyman, 2000; Graybiel et al. 2000; Robinson and 
Berridge, 2003). They occur, however, in the dorsolateral striatum, rather than the accumbens-related 
circuitry (Graybiel et a l 2000). Although there is evidence of a role for “motor” stmctures such as the 
dorsolateral striatum in reward processing (Ito et al. 2004; Salamone et a l 2003; Volkow et a l 2002b), 
and that both motor and incentive phenomena share key characteristics, there are clear dissociations
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between them. Locomotor sensitisation that follows chronic amphetamine administration in rats does not 
necessarily predict incentive sensitisation (Nocjar and Panksepp, 2002). Furthermore, even though 
compulsive dopaminergic drug use in PD is associated with dyskinesias, few dyskinetic patients are 
compulsive dmg users.
Changes at the neuronal level induced by chronic L-dopa may be region specific and involve primarily 
the dorsolateral striatum (Mura et al. 2002). However, data for unilaterally 6-hydroxydopamine-lesioned 
rats -  the rodent analogue of PD (Cenci et al. 2002) -  shows that repeated administration of L-dopa 
triggers dopamine D3 receptor overexpression in the accumbens (Guilin et al. 2001), which is a 
neuroadaptation involved in compulsive dmg use (Berke and Hyman, 2000; Guilin et al. 2001).
Many of the symptoms seen in DDS patients are consistent with the dmgs having increased incentive 
salience. Craving -  in the absence of either heightened pleasure or unpleasant withdrawal symptoms -  can 
be seen. Patients will go to extreme lengths to obtain medication, despite the risk of harmful consequences 
(Giovannoni et al. 2000), and will also report being “driven” to take more dmgs (Nausieda, 1985). 
Hoarding -  itself an accumbens dopamine dqiendent process (Kelley and Stinus, 1985) -  of dmgs has been 
described, consistent with the dmg’s increased “attractiveness” (Giovannoni et al. 2000).
According to 1ST, the abihty of sensitisation to enhance responsiveness to rewards is not confined to 
dmg rewards: it also apphes to other appetitive behaviours (Robinson and Berridge, 2000; Robinson and 
Berridge, 2003). For exanple, an animafs willingness to work for various rewards can be increased by 
repeated exposure to psychostimulants (Robinson and Berridge, 2000; Robinson and Berridge, 2003). In 
one study (Nocjar and Panksepp, 2002), chronic amphetamine treatment in rats increased both 
amphetamine-induced place preference and appetitive behaviour for food and sexual rewards. Animals 
that developed the strongest amphetamine-induced place preference, however, were not necessarily the 
same animals that developed magnified food and sex-seeking behaviours. Such individual differences may 
be due to pre-existing temperament factors (Nocjar and Panksepp, 2002).
A global sensitisation of appetitive behaviours readily accounts for symptoms of hypersexuality and 
compulsive eating m PD. Furthermore, both money (Knutson et al. 2001 ; Koepp et al. 1998) and 
consumer goods (Erk et al. 2002) activate the accumbens circuitry, which means that symptoms of 
compulsive shopping and gambling could also be explained by 1ST. These findings are relevant to the 
debate as to whether or not behavioural and chemical addictions share the same substrates (Holden, 2001).
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Similarly, certain forms of aggression can be considered as appetitive behaviours and are mediated by 
accumbens dopamine release (Lawrence et al. 2002).
Excessive “Wanting” of dcpaminergic drugs can override more stable life goals and priorities, leading to 
impaired decision making. The abihty of sahent incentives to momentarily override the influence of current 
goals on behaviour can lead to the exploitation of novel opportunities and, therefore, can be beneficial. 
When this behaviour becomes excessive, potentially minous drug pursuit and the control of behaviour by 
salient stimuh rather than long-term goals can result (Driver-Dunckley et al. 2003 ; WyveU and Berridge, 
2001). There are also data to suggest that chronic long-term administration of large doses of 
psychostimulants can lead to impairment in regions of the prefrontal cortex that are important for 
regulation of behaviour by long-term goals. A synergistic increase of incentive saisitisation and impaired 
goal-directed behaviour could lead to the DDS in PD.
In contrast to pleasure theories, 1ST supposes that accumbens dopamine also has a role in threat-related 
motivation, and it has been suggested that heightened sahence of threatening stimuh can explain 
symptoms of anxiety, panic, and psychosis seen after very high dmg intake.
Individual variabihty is an important feature of sensitisation in both its development and its expression 
(Robinson and Berridge, 2000; Robinson and Berridge, 2003). Pharmacological, genetic, sex-related, age- 
related, temperamental, activity-level dependent, social, and experiential factors are all important (Abarca 
et al. 2002; Laviola et al. 2001 ; Marinelli and Piazza, 2002; Robinson and Berridge, 2000; Robinson and 
Berridge, 2003). Experiential factors include cross-sensitisation between stress and psychostimulants, and 
cross-sensitisation between different dmgs (Robinson and Berridge, 2000; Robinson and Berridge, 2003). 
Individual differences like these may eventuahy help to explain the profile of patients with PD Wio are 
vulnerable to developing DDS: young-onset male cases, with a past history of heavy alcohol or illegal-dmg 
use, and poor social circumstances (Giovannoni et al. 2000).
Another feature of sensitisation is that it is not an inevitable consequence of repeated dmg exposure 
(Robinson and Berridge, 2000; Robinson and Berridge, 2003). Rather, the ability of dmgs to induce 
sensitisation -  and the expression of such sensitisation -  is modulated by learning and contextual factors 
(Robinson and Berridge, 2000; Robinson and Berridge, 2003). The abihty of dmgs to induce sensitisation 
is greater in new than in famihar environments; whereas the expression of incentive sensitisation 
appears greatest in contexts distinctly related to dmg-taking in the past, and is also influenced by the 
diurnal state of the animal (Abarca et al. 2002; Robinson and Berridge, 2000; Robinson and Berridge, 
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2003). Notably, the effects of L-dopa on locomotor processes in rats are modulated by learning and 
contextual factors (Carey, 1992).
1.10.2.5 Individual differences in vulnerability to addiction
Another group of addiction theories focus on why particular individuals are more susceptible to 
addiction than others. Genetic variation may partially underlie a substantial proportion of 
vulnerability to addictive diseases -  as well as complex personality and physiological traits -  such as 
impulsivity, risk taking and stress responsivity. For instance, in animal models, there are marked 
strain differences in acquisition o f drug seeking that are potentially influenced by behavioural 
temperament (Dellu et al. 1996) and this susceptibility appears to be polygenic (Crabbe et al. 1999). 
The behavioural traits that increase an animal’s susceptibility to drug reinforcement resemble some of 
the features of high-sensation seeking in humans. Conversely, norepinephrine transporter (NET), 
vesicular monoamine transporter gene (Wang et al. 1997), metabotrobic glutamate receptors 
(Chiamulera et al. 2001), 5HT IB gene (Castanon et al. 2000) and nicotinic acetylcholine receptor 
influence an animal’s susceptibility to psychostimulants (Xu et al. 2000). NET is implicated in 
dopamine uptake in brain regions with low level of dopamine transporter (Moron et al. 2002) such as 
the frontal cortex and noradrenergic inputs to the bed nucleus of the stria terminalis from the caudal 
medulla are critically involved in the aversion of opiate withdrawal (Delfs et al. 2000).
In humans, novelty seeking (Cloninger, 1987b) and sensation seeking (Zuckerman, 1994) 
personality traits, are useful constructs to predict human risk-taking behaviours (such as risky and 
stressful activities and unsafe sexual practices that are avoided by others). These personahty traits, 
called Impulsive Sensation Seeking (ISS), might have distinct neurochemical and genetic substrates 
mediated by genetic variability in the transmission of dopamine as well as other neurotransmitters 
(Kreeke^a/. 2005).
Furthermore, personality and physiological traits themselves differentially affect the various stages 
of addiction, defined chronologically as initiation of drug use (Cloninger et al. 1988), regular drug 
use, addiction/dependence (Hawkins et al. 1992; Cloninger et al. 1988; Nathan, 1988) and 
potentially relapse. The predictive relationship between ISS traits and addiction vulnerability 
purportedly reflects some rewarding aspect of experiencing novelty and suggests that novelty-elicited 
exploration and drug stimuli may interact in biologically and behaviourally meaningful ways.
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Phenotypic differences in sensitivity to addictive drugs can also be responsive to environmental 
factors and stress. Stress, corticosterone, and mesencephalic dopaminergic neurons seem to be 
organised in a pathophysiological chain determining a vulnerability to addiction. The mesolimbic 
dopaminergic system has been shown to have a stimulatory action upon the hypothalamic-pituitary- 
adrenal (HPA) axis and visa versa (Piazza and Le Moal, 1998). Thus, corticosterone itself is readily 
self-administered by animals and stimulates dopamine release (Piazza et al. 1993). Moreover, these 
effects are mediated by individual differences in responses to novelty (Dellu et a l  1996).
Childhood and adolescence are periods of brain plasticity during which maturation continues 
through neuroanatomical, neurochemical, and neurophysiological changes which correspond to 
significant shifts in cognitive, psychological and social development. During maturation, ISS traits 
are important adaptive components to exploration behaviour, sociability and sexual and 
consummatory behaviour. Consistent with this, adult behavioural phenotypes are modified by early 
childhood and adolescent experiences. For example, early deleterious rearing influences the 
development of brain monoaminergic systems that result in undercontrolled and immature behaviours 
in adulthood which may be associated with excess alcohol use (Higley et al. 1996). Early drug 
exposure in childhood confers individual susceptibility to recurrent drug use via enhancing the 
affective response to a new drug or inducing long-lasting neurochemical changes within mesolimbic 
structures that may predispose to heightened reinforcing effects. In animals, even a single exposure to 
morphine can induce long-lasting behavioural and neurochemical changes in the brain e.g. 
(Vanderschuren et al. 2001). Along similar lines, one study in humans found that current alcohol use, 
prior recreational use of stimulants, and baseline level of se lf reported arousal appeared to influence 
subjective response to the common drug caffeine (Chait, 1992).
1.10.2.6 Role for dopamine in the behavioural functions o f the prefi’ontal corticostriatal system -  
dysfunctional inhibition?
Another phenomenon seen with addiction may contribute to a reduced capacity for cognitive 
control, leading to impairment in regulating behaviour. Regions of the frontal cortex involved in 
inhibitory response control may be directly affected by long-term exposure to drugs of abuse. The 
deseending influences on striatal mechanisms from the prefrontal cortex may have a role in the 
progressive loss of control over drug-seeking in addiction as separate to its consolidation as habitual 
drug-seeking (Everitt et al. 2001). As discussed, forebrain dopaminergic transmission results in an
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increased propensity to emit conditioned responses to stimuli with appetitive or aversive value. This 
net change in behaviour is likely subserved by a potentiation of stimulus-reward learning (by 
dopamine actions in the amygdala) and an augmentation in conditioned reinforcement (by dopamine 
actions in the striatum). Dopamine also has an important role in mediating many cognitive functions 
of the frontal cortex (Cohen et al. 2002). Chronic exposure to dmgs of abuse has been shown to be 
neurotoxic to monoaminergic neurons, causes reductions in brain monoamine neurotransmitter 
concentrations (Ridley et al. 1982), and long-term impairments in frontal cortical function (Jentsch 
and Taylor, 1999). Subsequently, the cortical deficits in fonction associated to long-term exposure to 
dmgs of addiction may lead to a decrement in the inhibitory modulation of conditioned responses (by 
dopamine actions in the frontal cortex) and underlie the persistent and strong propensity for relapse, 
especially in the presence of dmg-associated stimuli in the addict’s environment.
Lesions of the frontal cortex in humans produce deficits such as impulsivity, perseveration, deficits 
in working memory, impairments of inhibitory control, impairments of cognitive set shifting, 
impairments of reversal o f stimulus-reward contingencies and deficits in behavioural modulations in 
the face of changing motivational valences of stimuh (Baylis and Gaffan, 1991 ; Collins et al. 1998; 
Dias e/a/. 1997; Robbins e/a/. 1990; Robbins, 1996; Tucker er a/. 1995). The mesocorticolimbic 
dopamine system plays an important role in cognitive processes related to the prefrontal cortex 
including working memory (Brozoski et al. 1979; Castner et al. 2000) and reward based learning 
(Hollerman and Schultz, 1998). Stimulation or depletion of mesocorticohmbic dopamine has adverse 
effects on mesocorticolimbic function; e.g., excessive, as well as insufficient stimulation of dopamine 
DI receptors in the prefrontal cortex impairs working memory (Zahrt et al. 1997).
Drug abusers also show behavioural traits reminiscent of impaired prefrontal cortex function such 
as a reduced concern for the consequences of their actions, difficulties with decision making, and a 
lack of judgement. On detailed cognitive testing, chronic drug users show evidence of cognitive 
impairments relating to cortico striatal circuitry dysfunction such as impaired reversal learning and 
perseveration, similar to patients who have damage to the orbitofrontal prefrontal cortex. These 
cognitive deficits relate to alterations in the motivational attributes of a stimulus and the changes in 
the balance between expectation of immediate reward and prediction of long-term losses. Other 
disorders of compulsive behaviour, such as pathological gambhng, also linked to dysfunction of the 
striato-thalamo-orbitofrontal circuit, are often seen in association with dmg addiction. These
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cognitive changes are not seen in patients with damage to other sectors of the prefrontal cortex such 
as the dorsolateral cortex (Bechara et al. 2001 ; Omstein et al. 2000; Rogers et al. 1999).
In the earliest stages of PD, a similar pattem of neuropsychological impairment has also been 
found. The frontal deficit of untreated patients with PD has been shown to extend across a variety of 
neuropsychological functions including attentional set-shifling and task set shifting (Lees and Smith, 
1983). Deficits of frontal lobe functions are differentially affected with disease stage (Owen et al. 
1992) and, in medicated Parkinson’s patients, are exaggerated by L-dopa withdrawal, suggesting an 
involvement of brain dopamine systems (Lange et al. 1992). However, dopamine modulation in PD 
can have dissociated effects on fi-ontal cognitive processes as some aspects of memory and cognition 
in PD have demonstrated impairment secondary to dopaminergic “replacement” (Cools et al. 2001; 
Cools et al. 2003). Functional imaging techniques have shed insight into the processes which 
mediate the effect of dopaminergic medication on high level cognitive functioning in Parkinson’s 
patients (Cheesman et al. 2005 ; Cools et al. 2002; Lewis et al. 2003). Analysis of reward 
processing in PD patients reveals dysfunction of dopaminergic mesolimbic pathways. The brain 
reward response, assessed with positron emission tomography (PET), shows selective failure of 
striatal activation (Kunig et al. 2000) and reduced activation of the limbic regions (Goerendt et al.
2004). However, both L-dopa medication and STN deep brain stimulation restore activation of 
ventromedial prefi-ontal cortical areas with the presentation of rewards compared to the “o ff’ state. 
Connectivity analysis indicates that the two treatments achieve this via different modulatory effects. 
Medication appears to exert its neuromodulatory influence through activation of the mesolimbic 
dopaminergic pathways while deep brain stimulation exerts its neuromodulatory influence through 
activation of basal ganglia-firontal circuitry. Furthermore, reward responsivity is enhanced with either 
STN stimulation or dopaminergic therapy (Goerendt et al. 2006).
Functional imaging techniques in addicted humans also occupy a pivotal role in mapping the 
neuropsychological impairments and investigating the persistent behavioural states characteristic of 
addiction. Drug addicted individuals show cerebral hypoperfusion in the periventricular, fi-ontal and 
other neocortical regions and these changes correlate with specific cognitive impairments. In 
protracted withdrawal, the orbitofrontal cortex of drug abusers is hypoactive in proportion to the 
levels of dopamine D2 receptors in the striatum (Volkow et al. 1993) and these changes correlate 
with behavioural measures of inhibition. Moreover, drug-induced craving specifically activates limbic
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regions in functional imaging studies (Childress et al. 1999; London et al. 2000) and has been 
shown to induce increased levels of dopamine in the nucleus accumbens (Fontana et al. 1993; Grant 
et al. 1996; London et al. 2000; Self, 1998; Sell et al. 1999).
1.11 Functional neuroimaging
PET is a non-invasive imaging technique that uses molecules that are labeled with short-lived 
radioisotopes that are injected intravenously. These molecules can then be traced in the brain and 
their kinetic properties and anatomical distribution can be determined. Quantitive relationships 
between drug binding in vivo and drug effects in patients can be compared using this technique.
An important prerequisite for drug development is that the molecule maintains its properties after 
labelling. This is the reason for the common use o f the positron-emitting radionuclide '*C; the 
substitution of naturally occurring ‘^ C with ”C does not change the biochemistry or the 
pharmacology of the molecules (Farde, 1996).
At a PET measurement, a radio labelled molecule (ligand) is injected intravenously and is 
distributed via the bloodstream to all parts of the body. The radioligand passes the blood-brain-barrier 
and binds to target receptors as well as non-target proteins and extracellular matrix. When the 
radioactive atom in the molecule decays it emits a positron that collides with an electron one to a few 
millimeters away and annihilate. The annihilation produces two 51 IkeV gamma rays (i.e. two 
photons). The photons travel at approximately 180® angle and are detected by a coincidence detector 
system outside the subject.
By using a complicated algorithm, an image of the regional radioactive decay can be calculated. In 
neuroreceptor imaging studies the regional radioactivity is corrected for decay and plotted versus time 
to yield time-activity curves (TACs). Different mathematical models are then applied on these TACs 
to calculated biological parameters describing ligand-receptor binding in vivo.
"C-labeled raclopride (RAC) is used in PET to study the function of dopaminergic synapses. RAC 
binds to dopamine D2 receptors and is a highly selective, rapidly reversible inhibitor of dopaminergic 
D2 receptor function (Farde et al. 1985).
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Chapter 2
IS DOPAMINERGIC DRUG THERAPY CAPABLE OF INDUCING 
PSYCHOMOTOR SENSITISATION IN HUMANS?
Summary
The stimulant effects of two dopaminergic drugs (L-dopa and methylphenidate) before and after 
initiating regular dopaminergic drug therapy in patients with PD were studied. The motor, 
psychomotor and reward-potentiating effects of oral L-dopa and methylphenidate (MPH) were 
assessed in 15 medieation-naiVe patients on separate occasions under double-blind (medication-naive) 
conditions after a placebo and then repeated the testing sessions in the same (medication-experienced) 
patients following a mean period of 18 months continuous dopaminergic dmg therapy. In the 
medication-naive condition active dmgs did not improve affect and only L-dopa improved motor 
function. In the medication-experienced condition, active dmgs improved positive affect compared to 
the medication-naive condition and there was a significantly enhanced effect o f L-dopa on motor 
function. Reward-responsivity was enhanced by both L-dopa and methylphenidate. In conclusion, 
sustained dopaminergic dmg therapy augments the motor effects of an acute challenge with L-dopa 
and induces euphoriant effects to L-dopa and methylphenidate challenges.
2.1 Introduction
The long term effects of repeated pulsatile dopaminergic dmg therapy in PD may induce various 
neuroadaptations. Sensitisation of striatal dopaminergic neurons may cause dyskinesias whereas dmg 
tolerance may manifest as a shortening of duration of dmg effect with the emergence of end-of-dose 
deterioration. Dopaminergic dmgs may also lead to complex repetitive stereotypies (Friedman, 1994), 
impulse control disorders (Voon et al. 2006b) and compulsive self-administration via sensitisation of 
ventral striatal dopamine systems (Lawrence et al. 2003).
The mood, psychomotor, and reward-potentiating effects of L-dopa (which was expected to
primarily enhance motor function) and methylphenidate (MPH -  expected to have a euphoriant
effect) in previously untreated PD patients were assessed. It was predicted that the motor effects of L-
dopa would be enhanced and that the euphoriant effects of methylphenidate might be sensitised by
long-term dopaminergic dmg therapy. L-dopa and MPH were administered on separate occasions 
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under double-blind conditions and then again after sustained dopaminergic therapy for a mean period 
of eighteen months.
2.2 Methods
2.2.1 Patient selection
15 patients (8 males and 7 females) who fiilfilled Queen Square Brain Bank Criteria for the 
diagnosis of PD ranging in age from 38-79 years (mean 59 years) were recruited from a specialist 
clinic prior to initiating dopaminergic drug therapy. Disease duration ranged from 2-9 years (median 
4.0 years). Three patients smoked, 4 were ex-smokers, 2 had previous binge or hazardous alcohol use 
and 2 reported prior non-medical use of cannabis. Patients gave written informed consent for 
protocols approved by the Joint Ethics Committee o f the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology. Patients scored a minimum of 25 of a possible 32 on the 
mini-mental Parkinson (Mahieux et al. 1995). Thirteen patients receiving MPH had a normal ECG 
within 2 weeks of baseline testing and 2 with a history of heart disease did not undergo any MPH 
challenges.
2.2.2 Study design
Medication-naive PD patients attended the outpatient department on consecutive days for testing. 
Patients were informed that the purpose of the testing was to examine how different drugs influence 
mood and motor symptoms and whether any observed effects changed over time. Patients were 
informed that they would “receive placebo and an active drug (L-dopa and MPH) in a random order 
on one day, and placebo and the other active drug in a random order on the next”. The same testing 
procedure would be repeated following a period of sustained anti-Parkinson drug treatment. Testing 
in the medication-experienced state was done after overnight withdrawal o f the patients’ normal anti- 
Parkinson medications (except in the case of cabergoline which was withheld for 3 days prior to 
testing). To reduce the possibility of nausea, domperidone 20mg three times per day was administered 
for 3 days prior to each of the study days. Unbeknown to the patient, each test involved 
administration of placebo (lactose) followed approximately 75 minutes later by the active drug. The 
purpose of the placebo was to minimise expectancy effects. Active drugs (L-dopa and MPH) were 
identical in appearance to the placebo and were prepared and dispensed in a predetermined random 
order controlled by a pharmacist. Patients were blinded to the order of medication administration and
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the expected medication effects. After each pair of challenges in the medication-naive and 
medication-experienced conditions, patients were asked to identify which drug in each testing session 
they thought was inactive. The rater (AE) was blinded to the identity of the active drug. Blinding was 
maintained until after the database was unlocked at the conclusion of the study.
The testing was repeated after a mean 18 months (range 2-24) of sustained dopaminergic drug 
therapy in 14 individuals using a separate predetermined randomisation code. Twelve patients had 
received a minimum of 15 months of therapy. One patient was lost to follow up and another 
retrospectively revealed to treating physicians that he had used therapy only intermittently until 2 
months prior to retesting. Another requested earlier repeat testing at 6 months. The latter 2 patients 
were included in the analysis as affective responses to L-dopa have been previously reported to occur 
as early as with the second dose (Maricle et al. 1998). At the time of the repeat testing, patients were 
taking L-dopa (n=7; mean daily dose 300mg), cabergoline (2; mean 2mg), pergolide (2; mean 2mg), 
ropinirole (2; mean 14.5mg), and bromocriptine (1; mean 30mg). L-dopa patients were older than 
agonist patients (mean 66.0 years ±SD 9.6, versus 52.8 ±9.5,/7=0.020).
2.2.3 Challenge protocol
At 9:30am patients completed baseline questionnaires. Pulse and blood pressure were monitored at 
20 minute intervals. At 10:30am, the placebo was given followed by the active medication 
approximately 75 minutes later.
2.2.4 Affect and drug ratings
Visual analogue scales (VAS) were used to quantify aspects of positive affect (PA) and anxiety 
(Bond and Lader, 1974) at baseline and then at 20 minute intervals for 60 minutes after placebo and 
100 minutes after active drug. Patients were asked to rate their feelings at each observation time. A 
summary score for PA was calculated from the mean score of ratings on a 100-mm line for each of 
the adjectives ‘stimulated’, ‘active’, ‘competitive’, ‘excited’, ‘enthusiastic’, ‘happy’, ‘self-confident’ 
with anchors of ‘not at all’ at 0mm and ‘extremely’ at 100mm. Patients were also asked to rate 
‘anxious’. Significant increases in VAS ratings of PA have consistently been reported following an 
oral dose of a psychostimulant drug compared to placebo in both drug-naive and -experienced 
humans and are thought to be indicative of a drug’s abuse liability (Foltin and Fischman, 1991).
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2.2.5 Reward responsivity
The Card Arranging Reward Responsivity Objective Test (CARROT) (Powell et al. 1996) was 
done at baseline, 60 minutes after placebo and 80 minutes after active drug. The patient is asked to 
sort cards displaying series of digits into three piles on four occasions (Taskl, Task2, Task3, and 
Task4). Taskl is the time to sort 60 cards as quickly as possible and is used for subsequent trials. The 
mean number of cards sorted in Task2 and Task4, in which the patient is asked to sort the cards as 
quickly as possible, represents the “ nonrewarded” rate. In Task3 the patient is asked to sort the cards 
as quickly as possible and is told that for every five cards sorted, he would receive a 10 pence reward, 
and the number of cards sorted represents the “ rewarded” rate. “ Reward responsivity” is computed 
as (rewarded - nonrewarded) nonrewarded x 100.
2.2.6 Motor performance
The Unified Parkinson Disease Rating Scale (UPDRS) motor scale (Fahn et al. 1987) was done at 
baseline, 60 minutes after placebo and 80 minutes after active drug.
2.2.7 Analysis
The assumptions of normality and constant variance of the model residuals were reasonably met for 
each of the analyses. Although anxiety scores after baseline were generally toward the lower end of 
the scale (range of mean scores 19.8-31.4mm) and somewhat right-skewed.
The change in PA and anxiety after placebo were examined with two-way repeated measures 
ANOVAs to examine the nature of the time-course effect across the four trials (2 trials [T1 and T2] in 
the medication-naive condition and 2 trials [T3 and T4] in the medication-experienced condition). 
TIME (0, 20,40, and 60 minutes) and TRIAL (4 levels; T l, T2, T3 and T4) served as repeated 
measures. The effects of repeated placebo administration on UPDRS and reward responsivity was 
examined using two-way repeated measures ANOVAs across the 4 trials in which the placebo was 
administered. STATE (at baseline and after placebo) and TRIAL (4 levels) served as the within- 
subject repeated measures.
The effects of L-dopa and MPH on PA, anxiety from the medication-naive to the medication- 
experienced condition were compared using three-way repeated measures ANOVAs to examine the 
nature of the time-course effect. TIME (0,20,40, 60, 80 and 100 minutes after drug), DRUG (L-dopa 
and MPH) and CONDITION (i.e. medication-naïve versus medication-experienced) served as
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repeated measures. The effects of L-dopa and MPH administration on UPDRS and reward 
responsivity were examined using three-way repeated measures ANOVAs. STATE (after placebo and 
after active drug), DRUG (L-dopa and MPH) and CONDITION (i.e. medication-naive versus 
medication-experienced) served as repeated measures. To examine whether there was a change in the 
magnitude of effect on the UPDRS with drug from the medication-naive to the medication- 
experienced condition, the change in UPDRS (i.e. UPDRS after drug -  UPDRS after placebo) was 
examined with a two way repeated measures ANOVA. DRUG (L-dopa and MPH) and CONDITION 
(i.e. medication-naive versus medication-experienced) served as repeated measures.
2.3 Results
Patients correctly guessed which drug was the placebo in 19 of the 28 trials in the medication-naive 
condition, and 21 of the 26 challenges in the medication-experienced condition. Only 4 patients 
correctly identified the placebo in every trial and, at the end of the study, when asked, none were 
aware of the intention to administer placebo first.
23.1 Change after placebo
2.3.1.1 Subjective state
Figure 2-1A illustrates patient ratings of PA at baseline and after placebo for TI-T4. There was a 
significant TRIAL x TIME interaction (F(9,99)=\ .98; p=0.049) for PA. Figure 2-1B illustrates patient 
ratings of anxiety at baseline and after placebo for T1-T4. There was a significant TRIAL x TIME 
interaction F(9,99)=3.74; p =0.001 for anxiety. These interactions suggest that the changes in PA and 
anxiety across time after administration of the placebo were not consistent across the four trials. Post- 
hoc pairwise comparisons of change in PA and anxiety comparing 0 minutes with 20,40 and 60 
minutes after placebo were of most interest and are given in Table 2-1. Moreover, preplacebo (0 
minutes) PA ratings at Trial 1 were significantly higher than Trial 4 (mean difference 15.2, SE 6.6, 
/?=0.041, Cl 0.7 -  29.6) but there was no difference between Trial 2 and 3. In TI there were no 
differences in mean PA between the time points. In T2-T4, PA ratings were lower at 0 minutes 
compared to later time point. Preplacebo (0 minutes) anxiety ratings at Trial 1 were significantly 
higher than Trial 2 (mean difference 17.2, SE 7.2,/?=0.033, Cl 1.6 -  32.8) and Trial 3 (mean 
difference 22.1, SE 8.0,/?=0.016, Cl 4.8 -  39.3). Ratings of anxiety were higher at 0 minutes
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compared to later time points in Tl and T2 only but not at T3 or T4. No differences between 20, 40 
and 60 minutes were observed for PA or anxiety (data not shown).
Figure 2-1 : Mean visual analogue scale ratings of A. positive affect and B. anxiety at baseline, 
20, 40 and 60 minutes after administration of placebo in Trial 1, 2, 3, and 4. Error bars 
represent SEM.
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Table 2-1: Post-hoc pairwise comparisons of visual analogue ratings of positive affect and 
anxiety at time points within TRlALs 1 ,2 ,3 , and 4.
POSITIVE AFFECT
Trial Time A Time B Difference St Error P-value 95% Cl
T rial 1 0 mins 20 mins Ë33 3.20 0.7 (-5.02, 7.68)
0 mins 40 mins -1.67 3.20 0.6 (-8.02,4.68)
0 mins 60 mins -1.25 3.20 0.7 (-7.60,5.10)
Trial 2 0 mins 20 mins 3.34 3.20 0.3 (-3.01,9.69)
0 mins 40 mins 9.42 3.20 0.004 (3.07,15.77)
0 mins 60 mins 8.92 3.20 0.006 (2.57,15.27)
Trial 3 0 mins 20 mins 9.08 3.20 0.006 (2.73,15.43)
0 mins 40 mins 11.50 3.20 <0.001 (5.15,17.85)
0 mins 60 mins 11.00 3.20 <0.001 (4.65, 17.35)
Trial 4 0 mins 20 mins 5.00 3.20 0.12 (-1.35, 11.35)
0 mins 40 mins 7.42 3.20 0.02 (1.07, 13.77)
0 mins 60 mins 8.67 3.20 0.008 (2.32, 15.02)
ANXIETY
Trial Time A Time B Difference St Error P-value 95% Cl i
Trial 1 0 mins 20 mins -27.92 4.73 <0.001 (-37.31,-18.53)
0 mins 40 mins -26.08 4.73 <0.001 (-35.47,-16.69)
0 mins 60 mins -30.75 4.73 <0.001 (-40.14, -21.36)
Trial 2 0 mins 20 mins -7.08 4.73 0.14 (-16.47,2.31)
0 mins 40 mins -15.66 4.73 0.001 (-25.05,-6.27)
0 mins 60 mins -9.91 4.73 0.04 (-19.30, -0.52)
Trial 3 0 mins 20 mins -2.92 4.73 0.5 (-12.31,6.47)
0 mins 40 mins -7.33 4.73 0.12 (-16.72,2.06)
0 mins 60 mins -8.17 4.73 0.09 (-17.56,1.22)
Trial 4 0 mins 20 mins -7.92 4.73 0.10 (-17.31, 1.47)
0 mins 40 mins -7.33 4.73 0.12 (-16.72,2.06)
0 mins 60 mins -5.33 4.73 0.3 (-14.72,4.06)
75
2.3.1.2 UPDRS and reward responsivity
No significant change after placebo was found on the UPDRS scores (main effect of STATE 
/'f 1,10)= 1.48, /?=0.125) or reward responsivity (STATE F( 1,10)=2.56,/?=0.141).
23.2 L-dopa and methylphenidate effects in medication-naïve and medication- 
experienced conditions
To reduce confounding effects of pre-baseline affect on drug response, active drugs were equally 
represented in the first and second trials for each condition. A one factor within-subjects ANOVA of 
predrug VAS ratings showed that participants did not differ in PA (F(3,33)=0.993;/?=0.408) or 
anxiety (E’(3,33)=0.475;/?=0.702) immediately prior to the administration of L-dopa or MPH on any 
trial (i.e. at TIME-0 or 60minutes after placebo).
2.3.2.1 Subjective effects after active drug administration
For PA, three-way interaction between CONDITION x  DRUG x TIME was not significant 
(F’(5,55)=0.261,/?=0.933) and therefore removed fi-om the model. There was a significant interaction 
between CONDITION x TIME (F’(5,55)=2.52,/7=0.040) (Figure 2-2) for PA. Post-hoc mean 
comparisons of time points within conditions showed this was due to an effect on PA by active drug 
in the experienced condition compared to the naïve condition (Table 2-1). In the naïve condition, 
there were no differences in mean PA between the 6 time points. In the experienced condition, mean 
PA was significantly lower at 0 mins and 20 mins compared to 60 mins, 80 mins and 100 mins and 
the mean PA at 40 mins, was significantly lower than at 100 mins. There were no significant 
differences between 60 mins, 80 mins and 100 mins (data not shown). The other two factor 
interaction CONDITONx  DRUG was not statistically significant F ( l,l 1) = 0.05,/?=0.83.
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Figure 2-2: Mean visual analogue ratings o f Positive Affect (±SEM): CONDITION (medication-
naive and medication-experienced) by TIME interaction.
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Table 2-2: Post-hoc pairwise comparisons for visual analogue ratings of Positive Affect scores 
between different times for both L-dopa and methylphenidate in the medication-naïve and 
medication-experienced conditions.
Medication-naïve condition
Time A Time B
Difference
(B-A) St Error P-value 95% Cl
0 mins 20 mins -0.03 2.63 > 0 .9 (-5.30,5.24)
0 mins 40 mins -0.03 2.63 > 0.9 (-5.30,5.24)
0 mins 60 mins 1.64 2.63 0.5 (-3.63,6.91)
0 mins 80 mins 0.97 2.63 0.7 (-4.30, 6.24)
0 mins 100 mins -1.40 2.63 0.6 (-6.67,3.87)
20 mins 40 mins 0.00 2.63 > 0.9 (-5.27,5.27)
20 mins 60 mins 1.67 2.63 0.5 (-3.60,6.94)
20 mins 80 mins 1.00 2.63 0.7 (-4.27, 6.27)
20 mins 100 mins -1.37 2.63 0.6 (-6.64,3.90)
40 mins 60 mins 1.67 2.63 0.5 (-3.60,6.94)
40 mins 80 mins 1.00 2.63 0.7 (-4.27, 6.27)
40 mins 100 mins -1.37 2.63 0.6 (-6.64,3.90)
Medication-experienced condition
Time A Time B Difference St Error P-value 95% Cl
0 mins 20 mins 0.75 2.63 0.8 (-4.52, 6.02)
0 mins 40 mins 2.92 2.63 0.3 (-2.35,8.19)
0 mins 60 mins 6.04 2.63 0.03 (0.77,11.31)
0 mins 80 mins 6.46 2.63 0.02 (1.19,11.73)
0 mins 100 mins 9.71 2.63 <0.001 (4.44,14.98)
20 mins 40 mins 2.17 2.63 0.4 (-3.10,7.44)
20 mins 60 mins 5.29 2.63 0.05 (0.02,10.56)
20 mins 80 mins 5.71 2.63 0.03 (0.44,10.98)
20 mins 100 mins 8.96 2.63 0.001 (3.69,14.23)
40 mins 60 mins 3.12 2.63 0.2 (-2.15,8.39)
40 mins 80 mins 3.54 2.63 0.18 (-1.73,8.81)
40 mins 100 mins 6.79 2.63 0.01 (1.52,12.06)
There was also a significant DRUG x TIME (F(5,55)=3.18,/?=0.014) for PA (Figure 2-3). Post-hoc
pairwise comparisons of time points within drugs showed no significant differences in mean PA
between the 6 time points for L-dopa. However, for MPH, mean PA was significantly lower at 0 mins
and 20 mins compared to 60 mins, 80 mins and 100 mins (Table 2-3). In addition, comparison of
conditions within time points showed the mean PA was significantly higher for MPH compared to L-
dopa at 80 minutes (mean difference 9.33, SEM 3.99,/?=0.02, 95% Cl 1.41 -  17.25). Other time
points failed to reach significance.
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Figure 2-3: Mean visual analogue ratings o f  Positive Affect (±SEM): DRUG (L-dopa versus
MPH) by TIME interaction.
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Table 2-3: Post-hoc pairwise comparisons for visuai analogue ratings of Positive Affect scores 
between different times for L-dopa and methylphenidate across the medication-naïve and 
experienced conditions.
L-dopa
Time A Time B
Difference
(B-A)
St
Error P-value 95% Cl
0 mins 20 mins -0.17 2.74 > 0.9 (-5.61,5.27)
0 mins 40 mins -2.29 2.74 0.4 (-7.73,3.15)
0 mins 60 mins 0.25 2.74 0.9 (-5.19,5.69)
0 mins 80 mins -2.79 2.74 0.3 (-8.23,2.65)
0 mins 100 mins -0.21 2.74 0.9 (-5.65,5.23)
20 mins 40 mins -2.12 2.74 0.4 (-7.56,3.32)
20 mins 60 mins 0.42 2.74 0.9 (-5.02,5.86)
20 mins 80 mins -2.62 2.74 0.3 (-8.06,2.82)
20 mins 100 mins -0.04 2.74 > 0 .9 (-5.48,5.40)
Methylphenidate
Difference St
Time A Time B (B:A) _ Error F-value 95% Cl
0 mins 20 mins 0.88 2.74 0.7 (-4.56,6.32)
0 mins 40 mins 5.17 2.74 0.06 (-0.27, 10.61)
0 mins 60 mins 7.42 2.74 0.009 (1.98,12.86)
0 mins 80 mins 10.21 2.74 <0.001 (4.77,15.65)
0 mins 100 mins 8.50 2.74 0.003 (3.06,13.94)
20 mins 40 mins 4.29 2.74 0.12 (-1.15,9.73)
20 mins 60 mins 6.54 2.74 0.02 (1.10,11.98)
20 mins 80 mins 9.33 2.74 0.001 (3.89,14.77)
20 mins 100 mins 7.62 2.74 0.007 (2.18,13.06)
No significant effects were found for anxiety; i.e. CONDITION jc DRUG x  TIME (F(5,55)=0.589, 
p=0.70S), CONDITION % TIME (F(5,55)=0.539,/?=0.746), DRUG jc CONDITION (F (l,l l)-0.220, 
/>=0.649) and DRUG x  TIME (F(5,55)=0.582,p=0.714). Anxiety scores after placebo were towards 
the lower end of the scale. Hence, the scale might have been relatively unresponsive to further 
decreases in anxiety score.
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2.3.2.2 Incentive motivational effects 
Three-way ANOVA revealed that the three factor interaction between CONDITION, DRUG and 
STATE was not statistically significant for reward responsivity (F(I,I I)=0.47,/?=0.5I); nor were any 
of the two-factor interactions. The only statistically significant effect was the main effect of STATE 
(F(I,11)=20.42,/?=0.00I) indicating that L-dopa and MPH both acted to increase reward 
responsivity. Post-hoc pairwise comparison of showed significantly higher reward responsivity across 
the medication-naïve and experienced conditions (after placebo mean -0.5%, after drug mean 4.1%, 
SE 1.0%,/7=0.001, 95%CI 2.4% -  6.9%) (see Table 2-4). The main effects of condition and drug 
were not statistically significant (F(I,I I)=0.8I,/?=0.39 andF(I,I I)=0.002,/7=0.97 respectively).
Table 2-4: Mean reward responsivity by CONDITION, DRUG and STATE.
Condition Drug State Mean
Standard
Deviation
Naïve L-DOPA After placebo 
After drug
-0.7%
3.9%
5.5%
6.2%
MPH After placebo 
After drug
-1.3%
2.6%
7.2%
5.8%
Experienced L-DOPA After placebo 
After drug
-0.3%
4.2%
4.4%
5.4%
MPH After placebo 
After drug
0.1%
5.8%
4.3%
8.0%
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Table 2-5: Posthoc pairwise comparison for UPDRS of state within condition and drug 
combination
Condition Drug STATE A STATE B
Difference
(B-A) St Error P-value 95% Cl
Naïve L-dopa Prior to drug
After
drug -5.16 1.35 0.003 (-8.13,-2.19)
MPH Prior to drug
After
drug -2.09 1.35 0.15 (-5.06,0.88)
Experienced L-dopa Prior to drug
After
drug -10.33 1.35 <0.001 (-13.30, -7.36)
MPH Prior to drug
After
drug -0.92 1.35 0.5 (-3.89,2.05)
Table 2-6: Posthoc pairwise comparison for change in UPDRS in naïve versus experienced 
condition for L-dopa versus methylphenidate
Mean change
Mean change in UPDRS Mean
in UPDRS under difference Standard
under Naïve Experienced (Experienced error of 95% Cl for mean
Drug condition condition -  Naïve) difference P-value difference
L-
DOPA
-4.80 -9.57 -4.77 1.69 0.03 (-9.28,-0.27)
MPH -1.77 -0.92 0.85 1.83 0.97 (-$.00, 5.70)
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Table 2-7: Post-hoc pairwise comparisons for visual analogue ratings of positive affect scores 
between different times for L-dopa and methyiphenidate across the medication-naïve and 
experienced conditions.
L-dopa
Time A Time B Difference
St
Error P-value 95% 01
0 mins 20 mins -0.17 2.74 >0.9 (-5.61,5.27)
0 mins 40 mins -2.29 2.74 0.4 (-7.73,3.15)
0 mins 60 mins 0.25 2.74 0.9 (-5.19,5.69)
0 mins 80 mins -2.79 2.74 0.3 (-8.23, 2.65)
0 mins 100 mins -0.21 2.74 0.9 (-5.65, 5.23)
20 mins 40 mins -2.12 2.74 0.4 (-7.56, 3.32)
20 mins 60 mins 0.42 2.74 0.9 (-5.02, 5.86)
20 mins 80 mins -2.62 2.74 0.3 (-8.06, 2.82)
20 mins 100 mins -0.04 2.74 > 0.9 (-5.48, 5.40)
M ethylphenidate
St
Time A Time B Difference Error P-value 95% Cl
0 mins 20 mins 0.88 2.74 0.7 (-4.56, 6.32)
0 mins 40 mins 5.17 2.74 0.06 (-0.27, 10.61)
0 mins 60 mins 7.42 2.74 0.009 (1.98, 12.86)
0 mins 80 mins 10.21 2.74 < 0.001 (4.77, 15.65)
0 mins 100 m bs 8.50 2.74 0.003 (3.06, 13.94)
20 mins 40 mins 4.29 2.74 0.12 (-1.15,9.73)
20 mins 60 mins 6.54 2.74 0.02 (1.10, 11.98)
20 mins 80 mins 9.33 2.74 0.001 (3.89, 14.77)
20 mins 100 mins 7.62 2.74 0.007 (2.18, 13.06)
No significant effects were found for anxiety; i.e. CONDITION x DRUG x TIME (F(5,55)=0.589, 
/7=0.708), c o n d i t i o n  % TIME (F(5,55)=0.539,;?=0.746), DRUG jc CONDITION (F (l,l 1)=0.220, 
/?=0.649) and DRUG x TIME (F(5,55)=O.582,/7=0.714). Anxiety scores after placebo were towards
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the lower end of the scale. Hence, the scale might have been relatively unresponsive to further 
decreases in anxiety score.
2.3.2.3 Incentive motivational effects
Three-way ANOVA found a significant main effect of STATE (i.e. state after placebo versus after 
drug) for reward responsivity (E’(l,ll)=20.42,/7=0.001) indicating that L-dopa and MPH both acted 
to increase reward responsivity. Post-hoc pairwise comparison showed significantly higher reward 
responsivity across the medication-naïve and experienced conditions (after placebo mean -0.5%, after 
drug mean 4.1%, SE 1.0%, p=0.001, 95%CI 2.4% -  6.9%).
2.3.2.4 Motor effects
A significant interaction was found for STATE x  DRUG x CONDITION (F(l ,11)=11.75,/?=0.006) 
(Figure 2-4). The change from after placebo to after drug was similar for MPH in the naïve and 
experienced conditions, however the change is larger for L-dopa in the experienced condition 
compared to the naïve condition (Table 2-8). Lower order interactions were as follows: CONDITION 
JC DRUG interaction: F{\,\\)=3J9,p=0.0S, CONDITION jc STATE interaction: F ( l,l  1)=2.31, 
/?=0.I6, DRUG X STATE interaction: F (l,l l)=16.57,/?=0.002, CONDITION main effect: 
F(1,11)=9.81,/7=0.01, d r u g  main effect: F(l,ll)=28.02,/7<0.001, STATE main effect: 
F(l,ll)=36.29,p<0.001.
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Figure 2-4: UPDRS part 3 after placebo versus drug (L-dopa or methylphenidate) in the 
medication-naïve and medication-experienced condition.
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Change in UPDRS induced by drug was calculated. The interaction between DRUG and 
CONDITION was statistically significant F(l,50)=5.10,/?=0.028). This means the comparison 
between the conditions should be done separately for each dmg. These are shown in Table 2-5. The 
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mean change in UPDRS differed statistically significantly between the naïve and experienced 
conditions for L-dopa (/7-value 0.03) but not for MPH (p-value -  0.96).
Table 2-8: Posthoc pairwise comparison for UPDRS of state within condition and drug 
combination
Condition Drug STATE A STATE B Difference St Error P-value 95% Cl
Naïve L-dopa Prior to drug After drug -5.16 1.35 0.003 (-8.13, -2.19)
MPH Prior to drug After drug -2.09 1.35 0.15 (-5.06, 0.88)
Experienced L-dopa Prior to drug After drug -10.33 1.35 < 0.001 (-13.30, -7.36)
MPH Prior to drug After drug -0.92 1.35 0.5 (-3.89, 2.05)
2.4 Discussion
L-Dopa is an amino acid dopamine precursor that crosses the blood brain barrier, converted rapidly 
to dopamine and taken up into vesicles by a transporter protein in dopaminergic nerve terminals, 
before being released through exocytosis of presynaptic vesicles. L-dopa accelerates learning in 
healthy controls independently of a minor effect on affect (Knecht et al. 2004). In PD, L-dopa is 
highly effective in improving motor symptoms. The precise mechanisms of action are probably not 
simply due to replenishment of striatal dopamine (Goerendt et al. 2006). Alternately, 
methylphenidate alters vesicular monoaminergic transporters and increases extracellular dopamine. 
Methylphenidate has a potential for abuse because it produces behavioural effects similar to other 
stimulants such as d-amphetamine. In healthy controls, the intensity of the pleasant affective response 
with MPH relates to the rapidity of its brain uptake (Volkow et al. 2004) and the magnitude of the 
resultant striatal dopamine response (Volkow et al. 1999).
Negative and positive affect are generally not regarded as occupying opposite ends of the same 
dimension but represent independent subjective dimensions of broader biobehavioural systems of 
approach and withdrawal corresponding to separate reaction systems in the brain (Watson et al.
1999). The purpose of placebo administration prior to active drug in this study was to reduce the 
effects of conscious expectancy on reported drug effects - thus parsing out the effects of expectancy 
from true drug effects. In PD the placebo response can result in enhanced brain dopamine release and
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many studies have reported objective improvements in motor performance (de la Fuente-Femandez et 
al. 2001). Dissociable changes in positive and negative affect were found after the administration of 
placebo that appeared to be influenced by expectancy as well as possibly the development of a 
medication-withdrawal state characterised by reduced levels of positive affect. With successive trials, 
baseline measures of anxiety and positive affect tended to decrease, the change in positive affect after 
placebo increased, and the change in anxiety decreased. There was also a dissociable response in 
aspects of positive and negative affect after methylphenidate administration in the medication- 
experienced condition.
Patients in this study received sustained therapy with L-dopa or dopamine agonists. L-Dopa and 
dopamine agonists have similar psychostimulant effects to those extensively studied in animal 
experiments of sensitisation (Henry et al. 1998; Hoffman et al. 1988), as both can induce 
dyskinesias and motor fluctuations. Both classes of drugs may also evoke compulsive self­
administration in vulnerable individuals with PD (Lawrence et al. 2003) and in non-Parkinsonian 
patients (Steiner and Wirguin, 2003) and alleviate apathy following bilateral subthalamic nucleus 
deep brain stimulation to treat refractory motor deficits in PD (Funkiewiez et al. 2004).
A variety of drug effects were found to change following chronic dopaminergic therapy. Subjective 
euphoriant effects (i.e. enhanced PA) of active drug became evident only after a period of regular 
dopaminergic therapy. These findings are in line with studies that have demonstrated the development 
of a “mood” response to L-dopa after treatment initiation in early PD. It has been shown that 
dopaminergic drugs can have “rewarding” effects in laboratory animals (Hoffman et al. 1988; 
Katajamaki et al. 1998) and can produce cross-sensitisation to other drugs (McDaid et al. 2005) or 
naturally motivated behaviours (Fiorino and Phillips, 1999). In a study by Nutt and colleagues, MPH 
appeared to have no acute effect on mood in 8 PD patients with advanced disease but they did not 
discriminate between positive and negative affect. The 8 patients had also received L-dopa therapy 
for several years and may therefore have been better able to distinguish between L-dopa, MPH and 
placebo. Nutt and colleagues also reported that both mood and motor performance were significantly 
enhanced by a combination of oral MPH with a L-dopa infusion (Nutt et al. 2004). In our study, it is 
possible that the mood response to the second dose of MPH may be due to the effects of repeated 
dosing with MPH -  i.e. sensitisation rather than cross-sensitisation. However, these findings are 
consistent with the notion that sustained dopaminergic therapy may cross-sensitise patients to the
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euphoriant, as well as the motoric effects of MPH but the effects are modified according to disease 
stage.
Brain dopamine systems are not only relevant to movement, but also mediate some of the 
rewarding effects of food, sex, as well as culturally learned rewards (e.g. money) (Knutson et al. 
2001). In this study, an acute challenge with both L-dopa and MPH enhanced responding for a small 
financial reward during the CARROT. This is consistent with clinical observations in which 
dopamine agonists have been linked to the development of a variety of impulse control disorders such 
as pathological gambling (Voon et al. 2006b), food bingeing, compulsive shopping and 
hypersexuality (Evans and Lees, 2004). Furthermore, a small sub-group of PD patients can also 
become sensitised to the rewarding effects of dopaminergic drugs and begin to compulsively and 
inappropriately self-medicate.
Dopamine has a broad role in the control of movement and it may be difficult to distinguish 
between the ability to move and the motivation to move (Wise, 2004). Patients in our study were told 
that one of two medications, given one hour and a quarter apart, might enhance movement or mood. 
Despite methylphenidate’s effect on enhancing striatal dopamine, no demonstrable effect was found 
on the motor UPDRS score. In contrast, L-dopa gave a consistent and highly significant motor 
benefit. Moreover, the motor benefit with L-dopa became significantly greater after chronic 
dopaminergic therapy compared to the medication-naive condition. In general, a greater amplitude of 
motor response with L-dopa in dopa-naive patients predicts earlier onset of motor fluctuations (a form 
of drug tolerance), a greater augmentation in L-dopa’s motor effects, and the development of 
dyskinesias (McColl et al. 2002; Nutt, 2007) (regarded as sensitisation effects that result from 
pulsatile dopaminergic drug dosing (Graybiel et al. 2000)).
The relatively small number o f study participants and the multiple statistical comparisons require 
caution with interpretation of the data. However, many of the variables measured are conceptually 
related (such as explicit measures of positive and negative affect), the primary effects of interest were 
few - the potential euphoriant effects of MPH and motoric effects of L-dopa and incentive 
motivational effects were consistently found with both drugs and are relevant to clinical observations 
in patients treated with dopaminergic drugs. Further, evaluation is not blinded with respect to the 
patient so that one or more readings for any particular patient may be biased.
In conclusion, in this study, the psychomotor effects that are believed to be enhanced by acute 
challenge with drugs acting on mesolimbic and mesostriatal monoaminergic systems were found to be 
sensitised by sustained intermittent dopaminergic drug therapy in PD and it can be concluded that 
neuroadaptive changes may mediate a number of drug-induced behavioural disturbances seen in the 
course of dopaminergic therapy for PD.
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Chapter 3 
FUNDING IN PARKINSON’S DISEASE: ITS RELATION TO THE 
DOPAMINE DYSREGULATION SYNDROME
Summary
Funding is a term that was coined originally to describe complex prolonged, purposeless and 
stereotyped behaviour m chronic amphetamine users. A structured interview of 50 patients with 
higher dopamine replacement therapy requirements (>800LEU/day) from 123 unselected patients 
with PD in a Parkinson’s clinic identified 17 (14%) patients with punding. Funding was 
acknowledged as disruptive and unproductive by the patients themselves, but forcible attempts by 
family to interrupt the behaviour led to irritability and dysphoria. Punding was associated with very 
high doses of dopamine replacement therapy often related to a pattern of chronic inappropriate 
overuse of dopaminergic medication. This is an under-reported, socially disabling phenomenon which 
is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically 
distinct from both obsessive-compulsive disorder and mania.
3.2 Introduction
Punding was first described in amphetamine addicts by Rylander in California (Rylander, 1972) 
and Schiorring in Denmark (Schiorring, 1981). Punding is a complex stereotyped behaviour 
characterised by an intense fascination with repetitive manipulations of technical equipment, the 
continual handling, exarnining and sorting common objects, grooming, hoarding, pointless driving or 
walkabouts, and the engagement in extended monologues devoid of content. It has occasionally been 
reported in association with dopaminergic therapy in PD (Fernandez and Friedman, 1999; Friedman, 
1994). Other likely examples of L-dopa-induced punding in PD can be found in the literature 
described as “obsessive-compulsive behaviour” or “hypomania” (Serrano-Duenas, 2002). Patients 
were systematically surveyed a specialist PD clinic for punding and related behavioural disorders.
3.3 Methods
Consecutive outpatients fulfilling Queen Square Brain Bank criteria for PD (Hughes et al. 1992) 
were interviewed and Mini Mental State Examination (MMSE) was administered. The Unified
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Parkinson’s Disease Rating Scale (UPDRS) part 2 was done in the “on” state. Patients were asked to 
provide a list of all current medications and their dosages. Patterns of compulsive use were looked for 
using recently proposed criteria (Giovannoni et al. 2000) and previous episodes of treated psychosis 
recorded. Treated psychosis was defined as the presence of hallucinations that required reduction in 
dopamine replacement therapy (DRT) or introduction of antipsychotic medications. Calculation of a 
daily L-dopa equivalent unit (LEU) dose for each patient was based on theoretical equivalence to L- 
dopa (similar to previous reports (Parkin et al. 2002)) as follows; L-dopa dose + L-dopa dose jc 1/3 if 
on entacapone + bromocriptine (mg) jc 10 + cabergoline or pramipexole (mg) jc 67 + ropinirole (mg) x 
20 + pergohde (mg) jc 100 + apomorphine (mg) x 8. Patients taking a daily dose greater than or equal 
to 800 LEU were then contacted and asked to undertake a standardised interview about their hobbies 
or pastimes (see Appendix A). The interview approach was developed from preliminary discussions 
with PD patients who had been identified as punders, animal models of drug related stereotypies and 
from a previous published questionnaire designed to identify punding in psychostimulant users 
(Schiorring, 1977). Punding was defined as a repetitive stereotypical behaviour that was recognised 
by the patient as disruptive (i.e. preventing sleep, eating, timing of medication doses or everyday 
social interactions) but associated with feelings of calmness / relief. Each subject was rated as having 
no, mild, moderate or severe punding independently by two investigators (Andrew Evans and Regina 
Katzenschlager). Punding was rated as severe if the patient had engaged in a single activity all night 
leading to loss of sleep in the last month and causing social disruption; moderate if there was social 
disruption and lesser degrees of sleep disturbance and mild if there was no significant or very mild 
social disruption. The patients completed an obsessive-compulsive inventory (Foa et al. 1998); the 
categories of which correspond to the content domains of the six most common primary obsessions 
and the six most common primary compulsions. Patients were also asked about the presence of 
hypomanie symptoms. Data were analysed with SPSS Version 11.0, SPSS Inc., Chicago, 111. Means 
were compared using Students t test, or Mann Whitney U test as appropriate. The chi-squared test 
was used for proportions in a two-by-two contingency table. Associations were tested with Spearman 
rank correlation.
3.4 Illustrative case
A 55-year-old woman developed PD at the age of 37. She responded well to L-dopa but increasing 
motor handicap soon forced her to stop working as a seamstress. Within seven years of disease,
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refractory motor fluctuations led to the introduction of continuous subcutaneous apomorphine 
infusion. She required very high doses of apomorphine by infusion and additional frequent rescue 
injections to prevent distressing “o ff’ periods each of which were heralded by a tight feeling in the 
jaw. She is maintained on apomorphine monotherapy (450mg apomorphine/24hours: 10-24 
intermittent apomorphine rescue injections per day on a background of a continuous subcutaneous 
infusion). Over the last few years, she had experienced cycles of virtually continuous wakefulness 
lasting 24-48 hours during which she required frequent apomorphine rescue injections. These were 
followed by periods of severe exhaustion, tension and chaotic disorganisation before she finally fell 
into an exhausted slumber. As her DRT requirements increased, she developed an intense fascination 
with buttons. She sorted through a growing collection, numbering a few thousand; arranging them by 
size, color and type but never succeeded in finishing her cataloguing and categorising despite 
continuing the activity for many hours during the day and overnight. She described the sorting as 
“incredibly soothing” and became very irritated if she was interrupted. She also spent excessive time 
unproductively tidying rooms and turning out drawers, washing clothes and dishes. The tidying was 
purposeless, did not occur in response to a fear of germs or dirt and the house became more and more 
disorganised the longer she continued. She was often frustrated by her inability to stop the activity, 
describing it “like being on a merry-go-round”. Introduction of paroxetine up to a daily dose of 40mg 
was of no benefit. Quetiapine, 25mg nocte, normahsed her sleeping pattern and “calmed” the 
behaviour but was poorly tolerated because of sedation.
3.5 Results
Clinical data were obtained from 123 of 179 consecutive outpatients with PD. The remainder either 
did not return information regarding medication dosing or did not consent. Of the respondents, 58 
patients took a daily dose of 800 or more LEU and fifty of these were able to complete the more 
detailed interview; 6 patients were lost to follow up and 2 died during the study.
None of the patients in the lower dose group were suspected by the treating clinicians (AJL, AE, 
DP, and RK) to be punders although the semi-structured interview was not systematically applied to 
this group. Complex repetitive stereotypies (punding) were identified in 17 of the 50 patients 
interviewed in the higher dose group. Punders were of comparable age, disease duration and disability 
to non-punders but took a significantly higher total daily dose of DRT and required more daily rescue 
doses of medication (Table 3-1). Punders took L-dopa (16), apomorphine via continuous infusion (9), 
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cabergoline (6), pergolide (2), amantadine (2), selegiline (1), entacapone (1) and bromocriptine (1). 
Nonpunders took L-dopa (33), entacapone (14), pergolide (10), amantadine (7), ropinirole (6), 
apomorphine (4), cabergoline (3), pramipexole (2), bromocriptine (2) and selegiline (1). Punders were 
significantly more likely to use apomorphine (%^=9.71; df=l ;p=0.002), cabergoline (j^=5.21; df=l ; 
p=0.022) and less likely to take entacapone (^=7.13; df=l;/>=0.008). Forty-five of the 50 patients 
who undertook the stmctured interview were also able to complete the obsessive-compulsive 
inventory (OCI). Five were unable to complete it beeause of concomitant medical illness (1), active 
psychosis (1), and poor understanding of the questions (3). There was a general trend to increased 
subscale and total scores for frequency and distress ratings in the punders versus non-punders (Table 
3-2). However, only the doubting distress (z=1.953;/?=0.051) and hoarding distress (z=2.317;/?=0.02) 
subscales approached significance. All patients remained under regular outpatient review. No patients 
were observed in the eourse of clinical follow up to develop euphoric or more cheerful mood, and 
none displayed evidence of an elevated, expansive or irritable behaviour, flight of ideas, inflated self­
esteem, grandiosity, or excessive self-confidenee consistent with hypomanie mood disorder. One 
patient with moderately severe dementia (MMSE 21) had simple behavioural stereotypies in isolation 
(repetitive arranging of bed linen overnight) and was not included in the punding group. The severity 
of punding was rated on the basis of time consumed and the social repercussions, by the clinician 
interviewers as mild in 7, moderate in 8 and severe in 2.
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Table 3-1: Characteristics o f  punders versus nonpunders
Punders Nonpunders
Number (female) 17(5) 33 (14) %2=0.806; /7^0.369
Age (range) 59.4 (46-76) 63.4 (47-80) /=1.618; p=0.103
Disease duration (range) 14.8 (8-25) 14 (4-27) /= -0.701;/?=0.487
MMSE (range) 28.4 (26-30) 28.1 (21-30) Z=0.042; /?=0.97
UPDRS Part 2 (range) 18.4(12-26) 17.7 (5-29) r=-0.192;p=0.83
Daily LEU dose (range) mg 1707 (800-3600) 1130 (800-1533) Z=3.681; /?<0.001
Daily rescue doses (range) 3 (0-20) 0.2 (0-2) Z=5.042;/?<0.001
Number using nocturnal rescue 
doses (%)
10/17(58%) 2/33 (6%) %2=17.125;p<0.001
Hrs sleep/night (range) 3.6 (2-6) 5.7 (3-9) Z=4.101;/?<0.001
Hours/day at primary 
hobby/pastime (range)
6.6 (2-16) 3.9 (1-7) Z=3.64; /7<0.001
Table 3-2: Means (M) and standard deviations (SD) of the Obsessive Compulsive Inventory 
(OCI) frequency and distress ratings
Punders (N=16) Non punders (N=29)
OCI Total 
Score
Frequency M (SD) 27.6 (17.4) 24.0(19.6) /= -1.281;p=0.207
Distress M (SD) 14.8 (12.6) 10.0(11.5) /= -0.594; ;?=0.541
The stereotyped behaviours reported were often influenced by the subject’s previous occupation 
(Table 3-3). Increasing clinical severity of the punding behaviour significantly correlated with higher 
total daily LEU dose (r^=0.53,/?<0.001), younger age (r^= -0.31,p=0.03), reduced sleep time 
overnight (r^= -0.64, p<0.001) and average number of daily rescue doses (r^=0.72,/?<0.001).
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Table 3-3: Description o f stereotypical behaviours
A ge/sex O ccu p a tio n B e h av io u r C o m m en ts
70M Retired
engineer
Sorts rock  collection , co llects w ood A pom orphine  in jection  prior to bed w ou ld  often  lead to 
early  w ak ing  - after tak ing a late injection, he w ould  prepare 
h is rocks by  the bedside for sorting
70M Retired
electrician
O bsessed  w ith  pho tography , d ism antled  5 cam eras, co llects m usic R equired  quetiap ine for organic  psychosis/m orb id  jea lo u sy
65M Retired
businessm an
D ism antles  radios, pens, v ideo and clock, repetitive  paper shuffling, 
purpose less  tidy ing /stra igh ten ing  up
D ay  centre for carer relief.
62M Retired
clergym an
R epetitively  w riting  poetry , fills pockets w ith  useless objects, tinkers 
w ith  com puter, d ism antled  voice am plifier
61M R etired
bio logist
D ism an tles  cars/law nm ow ers, excessive D IY  (D o-it-yourself), 
fascina tion  w ith  b irds and  fish, rem oves batteries from  electric 
goods, surrep titious food theft
M edica tions d ispensed  daily  to  restric t supply
60M R etired
m achinist
D IY , sorts stam ps overnight, dism antled  electric  drills, paces in 
backyard  overnight
R eduction  in  even ing  contro lled  re lease  m edications 
im proved  sym ptom s
59M A ccountant T inkers w ith  m odel ra ilw ay , d ism antled  fridge, v ideo reco rder and 
apom orph ine pum p, excessive D IY
Past alcohol excess, lib idousness reso lved  w ith  enforced  
D R T  reduction  (carer) and addition o f  cyproterone. 
A m itrip tilline  im proved insom nia.
58M Retired
architect
P reoccup ied  w ith  com puters, “unfocussed” tinkering, d ism antled  
hom e office
57M Retired
accountant
G arden ing  fanatic , senseless paper shuffling, tinkering  on com puter, 
d ism an tled  and  collected  bikes, but unable to  reassem ble, aim less 
bike rides, d ism antled  apom orphine pum p
L ib idousness re so lved  w ith  dose reduction
53M Clerk E xcessive paper shuffling
50M Ret. carpen ter C o llects  tools, excessive D IY , unnecessarily  fe lled  tree D R T  reduction  and cypro terone for excessive libido
46M R etired  IT 
eng ineer
M eaning less and d is r iç tiv e  m anipulation  o f  g r ^ h ic s  and anim ation 
softw are
N o ted  increased  lib ido  w ith  D R T  increases
76F H ousew ife G arden ing  (im possib le  to  d istract w hen  “ on”), turns out drawCTS 
unnecessarily
58F Retired
seam stress
C onstan tly  tidy ing  (but m akes m ore m ess), repetitively  sorts buttons A fter p u nd ing  all night, w ould  occasionally  use quetiap ine 
to  abort behav iours, regu lar c lom ipram ine reduced  nocturnal 
pund ing  and im proved  sleep
57F Ret. m usician R epetitive  draw ing , constan tly  tidying Past alcohol excess, D R T  dose restric ted  after psychosis
56F Retired
m usician
C onstan tly  “ un tidying” , repetitive  hair brushing , s inging  songs w ith  
inven ted  lyrics
Q uetiap ine p rescribed  for psychotic  ep isode led to  som e 
im provem ent in punding.
54F H ousew ife C ollects and sorts nails /rubber bands, repetitive  labelling  and tidying C lom ipram ine  reduced  nocturnal d isturbance from  punding. 
A fter pund ing  all night, often took a h igh  protein  meal to  
de libera te ly  abort the behaviours
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Punders often admitted that time and money spent on their behaviours was excessive and 
inappropriate. They typically complained of difficulty in finishing their projects and usually admitted 
to creating chaos while punding. They were often irritable when distracted from their tasks (Table 
3-4). Insomnia, previously treated psychosis, and hyperlibidinous behaviour were common co­
morbidities.
Table 3-4: Other behavioural associations
Punders
(N=17)
Nonpunders
(N=33)
Collections 10 4 X=12.139;/7<0.001
Diffîculties finishing projects/ineffective 17 3 X^=38.636; /?<0.001
Creates mess pursuing hobby/pastime 17 5 X^=32.782;p<0.001
Hobby pursued overnight 15 3 X^=30.504;/K0.001
Difficult to distract from pastime/hobby 13 2 X^=26.488;/?<0.001
Interested in hobby when “on” only 11 13 X^=2.88,\p=0.09
Pattern of compulsive medication use 10 0 X^=24.265;/7<0.001
Increased gambling 1 1 X^=0.238;/?=0.626
Morbid jealousy 1 0 X^=19.81;/?=0.159
Increased libido 4 1 x'=5.239;p=0.022
Treated for past psychosis 5 4 X=2.273;/?=0.132
3.6 Discussion
The stereotyped behaviours described here are very similar to those described with high dose 
chronic psychostimulant use (Anggard et al. 1970; Ellinwood, Jr. et al. 1973; Brady et al. 1991 ; 
Scher, 1966; Schiorring, 1977; Rylander, 1972) and consistent with previous reports of punding in 
PD (Fernandez and Friedman, 1999; Friedman, 1994; Meseguer Gancedo and Garcia Ruiz, 2002). 
These behaviours were complex and repetitive and often resulted in isolation from or conflict with 
other people. Just as in previous reports, the punding behaviours that were observed often arose from 
prepotent idiosyncratic habits and pastimes and only exceptionally changed over time. The punding 
was compulsive in the sense that the person could be distracted fi'om the intrusive behaviour but 
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would become irritable if prevented from resuming. It often caused social avoidance and 
disintegration of family relationships. The majority of patients had not been treated in the past for 
psychosis (Table 3-4). In 10 of the cases, punding was associated with a pattern of compulsive 
medication ovemse satisfying the proposed Giovannoni criteria (Giovannoni et al. 2000) for DDS 
(Table 3-4).
Punding is derived from Swedish slang and literally translates into “block-head”. Under the 
influence of psychostimulants, users lose the ability to perform complex sequential acts and become 
disorganised and perseverative in thought and action. In Rylander’s original description of 154 
patients who abused Preludin (MPH), this aimless protracted continuation of an activity was found in 
40 cases (26%) (Rylander, 1972). Punding has also been reported to occur with cocaine dependence 
(Brady et a l  1991). The repetitive nature of the behaviour has led some authors to describe punding 
as “being hung-up” (Scher, 1966), “pottering” (Anggard et al. 1970) or “knick-knacking “ 
(Ellinwood, Jr. et a l  1973). The punder is aware of the inapposite obtuse nature of the behaviour but 
even self-injury resulting from the stereotypies does not abort it; e.g. one woman filed her nails until 
they bled (Ellinwood, Jr. et al. 1973), a guitarist played without stopping for three days until his 
fingers gave in (Schiorring, 1977) and another woman picked at her skin until it ulcerated (Scher, 
1966). The behaviour is reported as soothing/calming and associated with an intense curiosity. 
Punders often relate in elaborate detail how they like to examine, sort and dismantle. There is a report 
of a gang of Scandinavian motorcyclists and amphetamine abusers who drove 200 times around the 
same block of houses (Schiorring, 1977). In another account, a swindler wrote out hundreds of 
counterfeit cheques when high (Rylander, 1966). A few devote themselves excessively to some sort 
of artistic occupation, like drawing, painting, writing or playing an instrument. In another report, 
individuals were described who liked to bathe in a tub all day long, hold a note or phrase of music, or 
engage in nonejaculatory intercourse for extended periods (Ellinwood, Jr. et al. 1973).
While involved in their chosen activity, punders withdraw into themselves, become tacit and 
unresponsive and give the impression of absent-mindedness (or “snowed under” (Schiorring, 1981)). 
Hunger, thirst and the desire to defeacate are often ignored (Rylander, 1972). Invitations to take more 
drugs or fear of sanctions such as imminent arrest are more likely to abort the abnormal behaviour. 
Over time, in addition to worsening social isolation, regular psychostimulant users frequently develop
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delusions of persecution, morbid jealousy, ideas of reference, visual, auditory and olfactory 
hallucinations, disorientation, hyperactivity and aggressiveness (Ellinwood, 1969).
Punding has been reported with a L-dopa-induced state in PD (Fernandez and Friedman, 1999; 
Friedman, 1994; Meseguer Gancedo and Garcia Ruiz, 2002) (Table 3-5). Like the punding seen with 
the psychostimulant drugs, the phenomenology of punding with DRT in PD is also shaped by 
previous occupation and hobbies; an accountant engaged in the shuffling of papers (Friedman, 1994) 
and a retired carpenter in senseless home repairs (Table 3-3); a woman incessantly examined 
jewellery (Fernandez and Friedman, 1999), a seamstress became fascinated with buttons; a musician 
sang repetitively; and the IT consultant became increasingly fascinated by computer animation (Table 
3-3).
None of the punders fulfilled the core criteria for hypomania (American Psychiatric Association, 
1994) even if the link between this behavioural disorder and DRT is ignored. Hypomania and mania 
may superficially resemble punding and result in insomnia and increased goal-directed activity. In 
contrast to punding, the expansive quality of the mood in hypomania is characterised by 
indiscriminate enthusiasm for interpersonal interactions and the increase in goal-directed activity 
often involves excessive planning of, and excessive participation in, multiple activities (American 
Psychiatric Association, 1994). The manic patient’s flight of ideas precludes sustained motor activity 
of one sort for any length of time.
The stereotyped behaviours seen in punding are likely homologous to the complex stereotyped 
behaviours seen in animals with amphetamine-stereotypies (Robbins et al. 1990); cage stereotypies 
(Gamer and Mason, 2002); and isolation-induced (Lewis et al. 1990; Sahakian et al. 1975) 
stereotypies. Punding, like these other forms of stereotypy represents the culmination of a continuous 
process of psychomotor stimulation (mediated by ventral striatal structures) and behavioural 
competition (mediated by dorsal striatal stmctures) (Robbins et al. 1990; Toates, 1998; Whishaw et 
al. 1992). Lower doses of psychostimulant drugs and dopaminergic agents potentiate approach 
responses to reward, a process mediated by nucleus accumbens-related dopamine (Ikemoto and 
Panksepp, 1999). Indeed, several of the punding group showed evidence of enhanced appetitive 
behaviours: Four patients in the punding group became hyperlibidinous, two of whom required anti­
testosterone therapy (cyproterone). One patient also reported excessive gambling after treatment for 
PD (Table 3-4) and another started surreptitiously stealing food after DRT dose escalation (Table
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3-3). Lastly, the frequent concurrence of punding with compulsive DRT use suggests that punding 
might represent an important step in the eventual progression to a form of automatic behaviour in 
which voluntary control over drug use is lost (Lawrence et al. 2003).
With increasing doses, prepotent stimulus-response habits mediated by dopamine in dorsal striatal 
structures are potentiated and come to gain control over behaviour (Berridge and Aldridge, 2000a; 
Robbins et al. 1990; Whishaw et al. 1992). Stereotypies develop from prepotent habits, which are 
idiosyncratic, depending on individual life histories and, in humans include prepotent habits such as 
work-related behaviours, hobbies and past-times. Here, men tended to dismantle technical equipment 
such as radio sets, clocks, watches and car engines; the parts of which may be analysed, arranged, 
sorted, filled and catalogued but rarely put back together (Ellinwood, Jr. et al. 1973). Women, by 
contrast, repetitively sort through their handbags, tidy, continuously brush their hair (Randrup and 
Munkvad, 1972), or pohsh their nails (Rylander, 1972). Office workers and clerks stereo typically 
shuffle papers, a seamstress will stereotypically collect and arrange buttons, and so on (Table 3-3). 
Individuals become unable to control automatic response selection mechanisms; i.e. stereotypies are 
purposeless and there is a dissociation between knowledge and behaviour (Gamer and Mason, 2002; 
Toates, 1998). Patients know they are dismptive and unproductive, but continue to perform them. 
This inability to modulate automatic routines is likely due to impaired cognitive control, resulting 
from impaired frontal lobe function (Jentsch and Taylor, 1999). Large frontal lesions are associated 
with highly stereotyped behaviours, including forced coUectionism (hoarding) (Voile et al. 2002).
Punding has previously only been described in PD patients taking L-dopa. L-Dopa acts via D1 and 
D2 receptor subtypes which are both involved in the genesis of stereotypies in animals (Berridge and 
Aldridge, 2000b; Chartoff et al. 2001; Chen et al. 2001 ; Nakazato and Akiyama, 2002). In the 
present study, there was no identifiable pattern to the dopamine receptor stimulation profile of the 
medications used by the punders compared to the non-punders. Long-acting and short-acting 
dopaminergic dmgs were used by both groups; the differences in types of medication used by the 
groups likely reflect clinician’s strategies to reduce concomitant dyskinesias. However, the observed 
use of intermittent rescue medications by punders suggests that punding may represent a form of 
(psychomotor) sensitisation phenomenon similar to dyskinesias (Graybiel et al. 2000).
Patients rarely volunteer descriptions of their punding behaviour to the treating clinician although 
occasionally family members may highlight it as a problem. Dyskinesias (often disabling) were
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present in all but one of the punders and most complain of distressing motor fluctuations although this 
was not specifically examined. Disability due to social isolation in these individuals was also not 
examined but sleep disturbance due to DRT induced behavioural activation was common (Table 3-3). 
Degrees of insomnia were reported in all of the punders and some subjects reported punding all night 
(Table 3-1). The ensuing insomnia often contributes to a spiraling perception of worsening 
Parkinsonism and subsequently higher DRT requirements.
It has been argued that the ritualistic behaviours seen in obsessive-compulsive disorder (OCD) may
be homologous to stereotyped behaviours seen in animals in a hyperdopaminergic state (Graybiel and
Rauch, 2000) and that these result from hyperdopaminergia in dorsal basal gangha structures
(Graybiel and Rauch, 2000). There are reports of OCD in basal ganglia disorders, including both
Parkinson’s (Muller et al. 1997) and Huntington’s disease (De Marchi et al. 1998), encephahtis
lethargica (Cheyette and Cummings, 1995) and pallidal lesions (Laplane et al. 1989), and there is
evidence for altered dorsal basal gangha activity in OCD (Graybiel and Rauch, 2000). Punding
induced by large quantities of DRT in PD provides a clinical syndrome directly relevant for testing
the link between OCD and dorsal striatal hyperdopaminergia in humans. The current study suggests
that there are clear similarities, but also important differences between punding and OCD. Punding,
like certain ritualistic behaviours seen in OCD is purposeless, representing a dissociation between
knowledge and performance. Like punding, the phenomenology of OCD is influenced both by gender
and life history factors (Lensi et al. 1996; Roy, 1979; Dowson, 1977) and this is a further reflection
of the potentiation of personal habitual routines and species typical sequential behaviours, as in the
case of amphetamine-induced and cage stereotypies in animals (Berridge and Aldridge, 2000a;
Gamer and Mason, 2002). Also, performance of complex stereotypies produces feelings of calm and
relief, somewhat similar to OCD. By contrast with OCD, however, punding is not associated with
obsessionahty, including religious, aggressive, sexual, checking, symmetry, ordering, counting,
contamination and cleaning/washing compulsions (Rauch et al. 1998). Therefore, while certain
features of stereotyped routine behaviours might be common to both punding in PD and OCD, the
compulsive phenomena of OCD seem quite distinct from hyperdopaminergic stereotypies, including
punding. Notably, Rauch et al., (1998) in a PET imaging study found that only certain OCD
symptoms were related to striatal regional cerebral blood flow, including checking behaviours,
ordering/arranging symptoms, and repeating rituals. In the current study, the elements of the OCl that
were (mildly) enhanced in punders relative to non-punders were feelings of doubt and hoarding 
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behaviours. Therefore, OCD symptoms related to basal ganglia dysfunction, and the OC-like 
symptoms in punders (especially hoarding) may represent stereotyped behaviours resulting from the 
potentiation of psychomotor processes and habitual, routine behaviours. Hoarding contains elements 
of appetitive and routine like behaviours and is known to be sensitive to dopamine lesions in other 
mammals (Kelley and Stinus, 1985). Feelings of doubt / checking might be related to impaired basal- 
gangha mediated action-monitoring functions (Lawrence, 2000). However, there are many clear 
differences between punding and other OCD-related phenomena including a lack of response to 
selective serotonin reuptake inhibitors (Illustrative case).
In conclusion, punding in PD is much more common than has been previously described, that it can 
occur with dopamine agonist monotherapy as well as L-dopa and that the resultant social disability is 
often overlooked. Requirements for large doses of DRT, frequent rescue doses and use of rescue 
medications overnight might warrant specific enquiry into a patient’s pastimes. Patients complaining 
of sleep disturbance should also be specifically asked how they cope with the periods of sleep 
deprivation. Punding may also be suspected if the addition of further DRT at night exacerbates a 
patient’s insomnia rather than benefits it. Management of these stereotypies involves careful and 
repeated explanation of the relationship with high daily DRT dosage, limitation of rescue medications 
and enforced medication rationing (especially during the night) and management of the sleep 
disturbance.
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Table 3-5: Other reported cases o f punding in PD
1
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Daily medication 
dose:
L/C mg Punding behaviour Comorbidities H&Y Comments
,1
(Miyasaki et al. 
2007)
Mean 
disease 
duration 
8.7 years
Mean 850mg L-dopa, 
pramipexole in 3 and 
ropinirole in 1
2 computer gaming, 1 tidying, 1 building 
and dismantling objects
Dementia 2 Estimated 1.4% o f  ou^atients in 
questionnaire based survey
(Kuimner et al. 
2006)
58M 61 L-dq)a/carbidopa 
250/25 up 30/day, 
pramipexole 4 mg, 
amantadine 300 mg
Repetitive journal writing None 2
(S h ^ iro  et a l  
2006)
Two cases o f  early onset PD who 
experienced paraphilia and hypersexuality 
when selegiline was initiated, and later 
developing obsessive-compulsive and 
punding bdiaviour with the addition o f 
dopamine agonists.
(Fasano et a l  
2006)
44M 47 Pramipexole 3mg, L- 
dopa/DCI 400
Computer, excel spreadsheets None 2 Y
(Nirenberg and 
Waters, 2005)
47F pramipexole Purposeless rearrangement o f  items Binge eating
(Kurlan, 2004) 49F 53 lOOOmg/day Continual cleaning and reorganisation 
overnight when “on”
“off”  dysphoria insomnia, motor 
fluctuations
No improvement with therapy reductions Y
(Kurlan, 2004) 55F 70 l,800mg/day Continual cleaning, rearranging mainly at 
night when “on”
Insomnia, mild cognitive 
impairment, hallucinations, 
motor fluctuations
Unresponsive to SSRIs, antipsychotics, and 
sleeping tables
Y
(Kurlan, 2004) 57F 73 800mg/day,
tolcapone
Continual cleaning reordering when “on” Dementia, hallucinations No improvement with antipsychotic 
medication
Y
(Kurlan, 2004) 62M 72 1200mg Rearranging letters, financial papers when 
“on”
Euphoric, insomnia No response to dose reduction, SSRI, 
responded to clozapine
Y
(Kumar, 2005) 56F 69 1500mg, 
bromocriptine 5mg,
Rearranging dresses Peak dose dyskinesias
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selegiline lOmg
(Miwa and Kondo, 
2005)
26M 32 300mg, cabergoline 
5mg, pergolide 
1.5mg
Repetitive writing Hallucinations
(Miwa et a l  2004) 46M 54 500mg, cabergoline 
5mg, droxidopa
Checking electrical cords Psychosis Aggressive if interrupted, Punding onset 
with initiation o f quetiapine and ceased on 
reduction from 200 tolOOmg
Y
(Miwa et a l  2004) 65F 67 450mg Repeated qjening closing handbag Psychosis Symptoms appeared after initiating 
quetiapine and improved on dose reduction 
100 to 5 Omg
(Serrano-Duenas,
2002)
54F 64 2250 mg, 
bromocriptine 
37.5mg
Repetitive hair bmshing Pathological gambling, 
compulsive medication use
2 Y
(Serrano-Duenas,
2002)
40M 50 2500mg,
bromocriptine
42.5mg
Repetitive washing, eating 10 times/day 
and changing clothes
Pathological gambling, 
compulsive medication use
2 Y
(Meseguer 
Gancedo and 
Garcia Ruiz, 2002)
58M 72 N/A Collecting and manipulating paper 
figurines and paper clip on clothes
Difficult to treat motor 
fluctuations
?
(Fernandez and 
Friedman, 1999)
60F 70 1350/150mg, 
pergolide 3mg, 
oxybutynin 1.5mg
Persistent reading, purposeless gardening, 
examining jewellery, collecting and 
stacking magazines
Normal mental status 2.5 Improved after reducing levodopa to 
lOOO/lOOmg
(no change after stopping oxybutynin or 
reducing pergolide)
Y
(Fernandez and 
Friedman, 1999)
53F 67 1700/25 Omg, 
selegiline lOmg, 
pergolide 0.45mg
Picking threads from rugs, persistent 
gardening.
Normal mental status, 
dyskinesias present
3.0 Resolved after cessation o f selegiline and 
pergolide
Y
(Fernandez and 
Friedman, 1999)
53F 53 500/125mg, 
1.5mg pramipexole
Presented age 72 with 19 year history of 
repeatedly picking up objects, hoarding and 
dismantling things
Associated psychosis for 9 
months
3.0 Psychosis resolved & punding improved 
after reducing levodopa to 400/1 OOmg
Y
(Friedman, 1994) 59M 65 900/225mg, 
selegiline lOmg, 
trazadone 50mg
Singing, senseless adding of number tables, 
meaningless joking, paper shuffling.
Normal mental status 2.5 Improved after reducing levodopa to 
500/125
Y
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Chapter 4 
FACTORS INFLUENCING SUSCEPTIBILITY TO DOPAMINE 
DYSREGULATION SYNDROME
Summary
In the course of treatment, a small group of PD patients develop a harmful pattern of compulsive 
dopaminergic drug use -  DOS. Individual factors may influence susceptibility. In this study 
predisposing factors to DDS were sought in a population of PD outpatients. Clinical features, 
impulsive sensation seeking (ISS) personality traits, past experimental drug use, alcohol consumption, 
smoking behaviours and depressive symptoms in 25 DDS patients were compared to an outpatient 
sample of 100 PD patients who were not compulsively overusing dopaminergic medication. DDS 
patients had a significantly younger age of disease onset, higher dopaminergic dmg intake, greater 
past experimental drug use, more depressive symptoms, scored higher on ISS ratings and tended to 
have higher alcohol intake. Using logistic regression analysis, novelty seeking personality traits, 
depressive symptoms, alcohol intake and age of PD onset were significant predictors of DDS. These 
factors may help to identify early patients who are more vulnerable to developing a pattern of 
compulsive dopaminergic drug use and help minimise its consequences.
4.1 Introduction
PD is primarily regarded as a disorder of movement associated with progressive degeneration of 
the dopaminergic nigrostriatal pathway. The degree of putaminal dopamine loss loosely correlates 
with the severity of bradykinesia. Dopaminergic dmg therapy relieves the motor symptoms of PD, 
improves quality o f life and modestly improves survival. However, if used injudiciously and 
excessively, it may lead to damaging behavioural complications.
In susceptible individuals, sensitisation of brain dopamine systems mediating reward by 
dopaminergic dmgs is proposed to underlie the development of DDS (Lawrence et al. 2003). These 
patients demand medication increases early in the course of treatment and complain of early tolerance 
to any observed beneficial effects. They feel dysphoric and undertreated much o f the time despite the 
external appearance of adequate motor symptom control and the appearance of increasingly severe 
peak-dose dyskinesias. Compulsive dopaminergic dmg use is associated with a number of dmg- 
responsive behavioural effects (Evans et al. 2004) including punding, a form of complex behavioural
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stereotypy (Evans et al. 2004). Pathological gambling, hypersexuality and mood changes also 
frequently accompany DDS (Giovannoni et al. 2000). Most fulfill core DSM-IV diagnostic criteria 
for substance dependence due to the negative effects that their compulsive pattern of dopaminergic 
drug use has on their social, psychological and physical well-being (Beam et al. 2004).
Many longitudinal and cross-sectional studies using diverse samples and measures demonstrate a 
clear relationship between ISS personality traits and addiction proneness (Cloninger et al. 1988; 
Johnson et al. 2003; Zuckerman, 1994). Humans scoring highly on ISS personality traits demonstrate 
a wide range of responses to novel stimuli and cues predictive of reward; including positive affect 
(elation and expectation), increased energy, and enhanced psychomotor activity. ISS traits are 
considered to be mediated by the dopaminergic projections from the midbrain to accumbens-related 
circuitry, a component of the brain reward system (Pickering and Gray, 2001). Stress (Herman et al. 
1984) and previous exposure to other dmgs, such as alcohol, may enhance the effects of 
dopaminergic dmgs on brain reward systems (so called “cross-sensitisation”) (Saal et al. 2003) and 
so, in addition to ISS-traits, depression and alcohol use were predicted to be associated with DDS.
Little attention has been given to DDS despite its devastating social consequences and, apart from 
younger age PD onset (Lawrence et al. 2003), and possibly dopaminergic agonist use as opposed to 
L-dopa (Pezzella et al. 2005), no predisposing factors have been suggested. Clinical features and ISS 
traits in a group of DDS patients were compared to a representative sample of PD patients who did 
not compulsively ovemse dopaminergic medication. Smoking behaviours, alcohol consumption and 
illicit dmg use were discretely enquired about in both groups.
4.2 Patients and methods
Consecutive outpatients attending a specialist PD clinic were carefully assessed for the presence of 
DDS and were included as part of a larger questionnaire-based study of personality in PD. Proposed 
criteria (Giovannoni et al. 2000) were used to identify these patients following stmctured interviews. 
All patients were screened using the minimental state examination (MMSE) and those scoring less 
than 26 were excluded because of the requirement to complete the personality and mood rating scales. 
In the recmitment period, 167 PD patients were identified; 29 were ineligible due to their MMSE, and 
32 either didn’t consent or didn’t return the questionnaires. Eight patients were identified in this 
group as having DDS, and 6 of these completed the questionnaires. The Unified Parkinson’s Disease
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Rating Scale (UPDRS) part 2 was rated in the “on” state by the treating physician and demographic 
data including age, gender, and age of PD symptom onset was collected. Calculation of a daily L- 
dopa equivalent unit (LEU) dose for each patient was based on theoretical equivalence to L-dopa 
(Evans et al. 2004).
An additional 32 previously identified patients fulfilling elinieal criteria for DDS (Giovannoni et al.
2000) were independently approached to participate in the study. Two were uncontactable, 3 declined 
and 8 more were too cognitively impaired (MMSE<24). Of the 19 further DDS patients who agreed 
to participate, 8 had been referred by other physicians for management and 11 had been diagnosed in 
the PD clinics within University College London Hospitals Foundation Trust (UCLH), a number of 
whom were part of the original series (Giovannoni et al. 2000). Twenty-three of a total of 25 DDS 
patients had MMSE scores > 26. The other 2 (MMSE 24 & 25) were considered by the treating 
physician able to complete the required questionnaires. Clinical details were obtained during routine 
interview and by review of medical records. Dyskinesia disabihty was rated using item 33 of the 
UPDRS in the “on” state and patients provided a list of all current medications and their dosages. 
Treated psychosis was defined as the presence of hallucinations, delusions, paranoid beliefs and 
agitation that required significant reduction (i.e.>20%) in dopaminergic drug therapy or the 
introduction o f antipsychotic medications. Caregivers were independently interviewed about the 
presence of aggressive behaviour (assault or violent outbursts). Each DDS case was also individually 
matched by age (±5 years) and gender to a non-Parkinsonian control participant. Fifteen suitable 
partners or friends of participating patients attending the outpatient department and without PD or 
dementia agreed to participate and the remaining controls (N=10) were recruited at random from the 
Medical Research Council Cognition and Brain Sciences Unit healthy volunteer panel.
4.2.1 Questionnaires
Participants who provided written informed consent to protocols approved by the UCLH Trust 
local ethics committee were given a series of questionnaires to complete in their own time and return 
in a reply-paid envelope. These included measures of the ISS trait cluster; a short version of the 
sensation seeking seale (Zuckerman, 1994; Merrems and Brannigan, 1998) (SSS), novelty seeking 
(Cloninger et al. 1993) (NS) from the Temperament and Character Inventory (TCI), and the 
Behavioural Inhibition System/Behavioural Approach System (BIS/BAS) scales (Carver and White, 
1994). Sensation seeking is linked to a variety of illegal and risky behaviours such as illicit dmg use
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(Palmgreen et al. 2001), sexual risk-taking, reckless driving, smoking, and alcohol use (Zuckerman, 
1994). The TCI is a 125-item, self-administered, true-false instrument assessing 4 stable, moderately 
hereditable dimensions of temperament (Cloninger et al. 1993) and 3 of character. The NS dimension 
explores the tendency towards exhilaration or excitement in response to novelty and cues of potential 
reward, causing exploration and pursuit. Harm avoidance is the tendency toward an inhibitory 
response to signals of aversive stimuli and correlates with anxiety; reward dependence is seen as a 
bias in the maintenance or continuation of ongoing behaviour; and persistence reflects the 
perseverance of behaviour despite frustration and fatigue. Characters refer to self-concepts and 
individual differences in goals and values that are moderately influenced by socio cultural learning 
and include self-directedness, cooperativeness and self-transcendence. The BAS has 13-items 
designed to reflect variations in a behavioural activation system that underlies appetitive motivation 
and includes 3 subscales; reward responsiveness, drive and fun seeking (Carver and White, 1994). 
These measures of ISS correlate with one another (Zuckerman and Cloniger, 1996; Carver and White, 
1994). The Geriatric Depression Scale (Yesavage et al. 1982) (ODS) consists of 30 "yes" or "no" 
questions.
Data was collected on present and past cigarette smoking. Current alcohol intake was assessed with 
a food frequency questionnaire. The reproducibility and validity of assessing alcohol intake has been 
established with a similar questionnaire (Giovannucci et al. 1991). For each beverage, a commonly 
used portion size was specified and the participants were asked how often, on average, over the past 
month they had consumed that amount. The alcoholic beverages assessed included pints of low 
alcohol beer, normal strength beer, 150ml glass of wine and a standard measure of liquor. There were 
seven possible response categories ranging from “never or rarely” to “six or more times per day”. The 
alcohol content (in grams) in each serving was estimated as follows: low alcohol beer 6, beer 18, wine 
12, and liquor 14. The weekly intake in alcohol units (where a unit o f alcohol was 8 grams) was 
obtained by multiplying the estimated weekly consumption frequency of each alcohol beverage by its 
estimated alcohol content. Patients were also given the option to indicate whether they had used 
experimental drugs in the past.
4.2.2 Data analysis
Data were analyzed with SPSS Version 11, SPSS Inc., Chicago, 111. Medians/means were compared 
using Mann Whitney U test or Student’s t test where appropriate. Variables found to be predictive of
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the diagnosis of DDS were entered into a forward stepwise logistic regression model to identify those 
factors that were independently associated with DDS. Variables controlled for in the multivariable 
model were selected by considering their univariate associations with the diagnosis of DDS. The 
following possible explanatory variables were used: age, age of PD onset, disease duration, sex, 
alcohol intake, CDS, SSS, BAS sub scale scores and NS. The multivariable models were examined for 
how well they fit the data using Hosmer-Lemeshow goodness-of-fit tests.
4.3 Results
During the clinical interview, all DDS patients reported severe withdrawal dysphoria relieved by 
dopaminergic drug therapy. Clinical features of the DDS patients are given in Table 4-1.
Table 4-1: Clinical features of DDS patients
DDS group
(N = 25)
Severe “off’-period dysphoria 25
Disabling dyskinesias (UPDRS item 33 > 2) 23
Punding 22
Aggression 14
Psychosis 15
Social breakdown 16
Behavioural compulsions (sex, shopping, 
compulsive eating, gambling, stealing)
UPDRS -  Unified Parkinson’s D isease Rating Scale
16
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Table 4-2: Characteristics of patients fulfilling criteria for DDS versus PD patients recruited 
from a tertiary referral outpatient clinic. Median values are given followed by range in 
parentheses. Chi-squared test was performed if the predictive variable was categorical.
DDS
(N=25)
Healthy controls 
(N=25)
PD outpatient 
clinic controls 
(N=100“)
Age PD onset (years) 43 (17-57)tt 56 (21-76)
Disease duration 13 (4-25)t 9.5 (2-40)
Sex 19 male 19 male 59 male
UPDRS part 2 17(6-28) 14 (3-37)
MMSE 29 (23-30) 29 (26-30)
LEU dose 2000
(700-3200)tt
700
(0-1600)
Dopamine agonist therapy 20/25 61/99
Never smokers 12 6 52
Past experimental drug use 8/22*tt 2/22 5/97
CDS 19 (4-30)**tt 5 (0-28) 10 (0-23)"
Novelty Seeking 13 (5-19)*tt 9(2-15) 8 (1-16)
Harm avoidance 11 (2-19) 8 (1-20) 12 (2-20)
Reward dependence 7 (l-1 3 )t 9 (2-14) 9 (3-14)
Persistence 3(0-5) 3(0-5) 3(0-5)
Self-directedness 13 (3-22)*tt 18(3-25) 17 (1-25)
Cooperativeness 17(6-23)# 19 (9-24) 21 (2-25)
Self-transcendence 4 (0-12) 4(0-11) 5 (0-14)
BAS drive 11 (5-16)t 11 (5-16) 10 (4-16)
BAS fun seeking 12(8-16)1 12(7-15) 10 (4-16)
BAS reward responsiveness 17 (13-20)f 17 (7-20) 15 (9-20)
SSS 4(1-12) 4(0-10) 3(0-8)
Alcohol intake 9.5 (0-79.8) 16.8 (0-94.5) 3.0 (0-80.5)
U PDR S-Unified Parkinson’s Disease Rating Scale, M M SE-M inimental state examination, LEU-L-dopa equivalent unit, 
GDS-Geriatric Depression Scale, BAS-Behavioural activation scale, SSS-Sensation seeking scale, “missing data <3%, 
‘’N=94
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Table 4-2 shows the characteristics of patients fulfilling criteria for DDS compared to non­
demented PD patients recruited from a tertiary referral clinic without this complication. Compared to 
the control PD patients, DDS patients had a significantly younger age of disease onset, higher LEU 
use, greater past experimental drug use, more depressive symptoms, scored higher on ISS ratings, 
lower on reward dependence traits and tended to have higher alcohol intake (Table 4-2). DDS patients 
also had higher novelty seeking scores and depressive symptoms than a group of matched healthy 
control patients. In the patients with PD, logistic regression using these variables and clinical 
variables identified factors which were independent predictors of DDS (Table 4-3) including; age of 
PD symptom onset, NS, GDS and current alcohol intake. The final model including all of these 
variables accounted for a moderately large degree of the variance (model R^=.653). Inclusion of past 
experimental drug use or dopamine agonist therapy did not alter the structure of the model. To 
examine whether these variables may be influenced by the disease process or may relate to 
dyskinesias (a psychomotor drug sensitisation phenomenon) they were correlated with disease 
duration and dyskinesia severity. GDS correlated significantly with disease duration (^^=0.249, 
p=0.006, df=in), and dyskinesia severity (r^=0.421,p<0.001, a^ lO l). Disease duration and 
dyskinesia severity did not correlate with alcohol intake or novelty seeking.
Table 4-3: Logistic regression analysis examining the influence of personality variables, GDS, 
age of PD symptom onset, sex, disease duration and alcohol intake on the binary variable PD 
patients with DDS versus PD outpatient controls using a forward selection procedure.
Variable Model p  Value on entry to model
Novelty seeking 0.324 <0.001
GDS 0.518 <0.001
Alcohol intake 0.597 0.006
Age PD onset 0.653 0.016
GDS-Geriatric Depression Scale
Hosmer-Lemeshow goodness-of-fit statistic=10.5; 8 df,p=0.23\
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4.4 Discussion
DDS frequently leads to a constellation of behavioural and psychiatric problems which stem 
directly from excessive and inappropriate dopaminergic drug use and is frequently associated with 
severe “o ff’-period dysphoria, disabling dyskinesias, and punding. There is also a high incidence of 
hypersexuality, compulsive eating and other appetitive behavioural compulsions. As a consequence of 
motivational “spill-over” from the effects of dopaminergic drugs on brain reward systems (“cross­
sensitisation”), enhanced “Wanting” of natural rewards, such as sex (Fiorino and Phillips, 1999) and 
appetising foods (Harmer and Phillips, 1998) occurs in some individuals. DDS patients are also at 
risk of organic psychosis; characterised by paranoid delusions, auditory hallucinations, and 
hypomania. Reductions in anti-Parkinson medications usually ameliorate disabling behavioural 
compulsions (Lawrence et al. 2003) but relapses are frequent and may recur with even lower drug 
doses.
In an effort to facilitate early identification of DDS and for planning prompt therapeutic 
interventions personahty traits in DDS patients were compared with controls. PD patients with DDS 
were found to differ from control PD patients and age-matched healthy controls in personahty 
dimensions linked traits with substance dependence (i.e. high ISS traits, and low harm avoidance, 
reward dependence, selfdirectedness and cooperativeness (Cloninger, 1987b; Hosak et al. 2004; Sher 
et al. 2000)). Novelty seeking was most strongly associated with DDS compared to both healthy 
controls and control PD patients. ISS traits have a basis in animal models of compulsive drug seeking 
and, in humans, mediate biological responses to novelty (Bardo et al. 1996) and individual variability 
of drug-induced dopamine neurotransmission in the ventral striatum (Leyton et al. 2002). In 
individuals with substance dependence, ISS traits also influence craving (Zilberman et al. 2003), 
vulnerability to relapse (Meszaros et al. 1999) and social influences on drug taking (Audrain- 
McGovem et al. 2003).
In adolescence, higher ISS traits influence willingness to use alcohol and experiment with various 
drugs of abuse (Zuckerman, 1994) and portend the later development of alcohol abuse (Cloninger et 
al. 1988) and substance dependence (Sher et al. 2000). Significantly more DDS patients had a past 
history of experimental-drug use. In adults, higher ISS traits predict preference for alcoholic 
beverages (Logue and Smith, 1986) and current alcohol beverage drinking frequency (Earlywine et 
al. 1992). In general, despite the tendency of PD patients to have lower alcohol intake than healthy
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controls, alcohol intake independently predicted DDS compared to PD controls. In animal studies, 
high ethanol drinkers show heightened striatal dopaminergic responsiveness (Nestby et a l  1999).
The current data suggest that compulsive dopaminergic drug use and alcohol intake may be related 
phenomena independent of ISS score.
Age critically mediates vulnerability to addiction. Earlier age of exposure to addictive drugs 
influences subsequent development and severity of substance dependence (Chambers et a l 2003). 
Addiction proneness as well as ISS traits subsequently decline after adolescence. Although PD 
generally appears in middle age and patients typically display personahty characteristics at the lower 
pole of the ISS dimension (i.e. stoicism, industriousness, and inflexibility), younger age of exposure 
to anti-Parkinson drugs independently predicted DDS.
Depression commonly comphcates PD, and has a major impact on a patient’s quality of life (Bum, 
2002a). The comorbidity of depression with dmg abuse is well established and has important 
therapeutic and prognostic implications (Volkow, 2004). In the current study depressive symptoms 
strongly independently predicted DDS. Additionally, all DDS patients reported severe “o ff’-period 
dysphoria characterised by apathy, depression and anxiety which may resemble the negative affective 
state of withdrawal from psychostimulants in dependent individuals. Depression in patients with DDS 
may be reactive, however it is possible that compulsive dmg use arises from self-medication for an 
existing depressive state or self-medication of a dmg-generated aversive state (Koob et a l  2004). 
Further, repeated experience with end-of-dose wearing “o ff’ and co-existence of a chronic depressive 
state may enhance the incentive value of the dmg to such an extent that dopaminergic dmg seeking 
becomes the over-riding behaviour. The link that was found between depression scores and disease 
duration and dyskinesias might indicate that, in the course of the disease, neurobiological changes 
occur that may increase the risk of depression. These neural mechanisms may overlap with those that 
lead to DDS as well as the development of dyskinesias with long-term exposure to L-dopa (Guigoni 
et a l 2005).
Nearly all patients who receive a diagnosis of PD are treated with dopaminergic dmgs, yet only a 
small group develop DDS. Other potential risk factors such as impaired cognitive control, cognitive 
impulsivity, and environmental, social, genetic and pharmacological factors were not specifically 
examined. In addition, the study was cross-sectional in design. However, the regression model using 
the factors novelty seeking, alcohol use, depression and age of PD onset accounted for a moderately
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large degree of variance. Prospect!vely identifying individuals who may be vulnerable to DDS will 
hopefully reduce the devastating physical, psychiatric and social consequences which ensue. De novo 
patients could be screened for novelty seeking traits, use of alcohol, and illicit drugs in order to pick 
up potentially vulnerable individuals for watchful management in the course of the disease. 
Vulnerable individuals may be counselled early in the course of management about the potential 
small risk of compulsive use of dopaminergic drug therapy and particular efforts made to limit drug 
increases. Disabling dyskinesias and distressing “off’ period dysphoria in these individuals may 
respond to continuous dopaminergic stimulation via subcutaneous apomorphine infusion 
(Katzenschlager et al. 2005). The careful administration of low dose clozapine or quetiapine for short 
periods may also help individual cases. In others, functional neurosurgery may allow reductions of 
dopaminergic therapy (Witjas et al. 2005).
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Chapter 5 
COMPULSIVE USE OF DOPAMINERGIC DRUG THERAPY IN 
PARKINSON’S DISEASE: REWARD AND ANTI-REWARD
Summary
Background: A few Parkinson patients develop a disabling pattern of compulsive dopaminergic 
drug use (“dopamine dysregulation syndrome” - DDS). DDS patients commonly identify aversive 
dysphoric “OFF” mood-states as a primary motivation to compulsively use their drugs. We 
compared motoric, affective, non-motor symptoms and incentive arousal after overnight 
medication withdrawal and after L-dopa in DDS and control PD patients.
Methods: Twenty DDS patients were matched to 20 control PD patients for age, gender and 
disease duration and underwent a standard L-dopa challenge. Somatic symptomatology, positive 
and negative affective states, drug effects, reward responsivity, motor disability and dyskinesias 
were tested in the “OFF”-state after overnight withdrawal of medications, and then after a 
challenge with a standard dose of L-dopa, after a ftill “ON”-state was achieved.
Results: In the “OFF”-state, DDS patients reported lower positive affect, higher negative affect 
and more motor and non-motor disability. In the “ON”-state, DDS patients had higher 
expressions of drug “wanting”, reward responsivity, and dyskinesias. Positive and negative affect, 
non-motor symptomatology and motor disabihty were comparable.
Conclusion: These findings suggest that the neurobiological mechanisms associated with 
affective, motivational and motoric disturbances in PD are involved in the transition to 
compulsive drug use in individuals who inappropriately ovemse their dopaminergic medication.
5.2 Introduction
DDS individuals have higher rates of other Axis I psychopathology including depressive 
symptoms, psychosis, and a premorbid history of alcohol dependence (Evans et al. 2005). The 
association of this syndrome with a range of impulse control disorders (ICDs), e.g. pathological 
gambling, suggests a global sensitisation to dopaminergically-mediated behaviours and there are 
also overlaps with punding (Evans et al. 2004; Evans et al. 2006b). Personality and 
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physiological traits that differentially affect various stages of substance dependence in general are 
also relevant to mediating the development of DDS, especially novelty-seeking (Evans et al. 
2005).
Drug addiction is a chronically relapsing disorder that can be characterised by (a) compulsion 
to seek and take the drug, (b) loss of control in limiting intake, and (c) emergence of a negative 
emotional state during withdrawal (Koob and Le, 2008). DDS patients commonly report self- 
medicating to avoid the negative affect of a withdrawal state as well as to improve motor 
function. Their “OFF”-state dysphoria or withdrawal symptoms appear to be characterised by a 
range of aversive affective symptoms; depression, anxiety, pessimism, tiredness, restlessness, 
irritabihty, fear, and withdrawal. Somatic withdrawal symptoms including shaking, palpitations, 
tachypnoea, feelings of impending death, nausea, flushing and severe precordial oppression are 
also reported (Lawrence et al. 2003). Distressing chronic pain alone has been reported to 
powerfully motivate the compulsive self-administration of dopaminergic drugs (Stein and Read, 
1997). Seemingly, only a small number of patients justify their overuse of dopaminergic 
medication on a desire to experience positive euphoriant effects, “highs” or “buzzes” (Beam et al. 
2004). Based on clinical observations, several authors have proposed a common mechanism for 
the behavioural features of compulsive dopamine replacement therapy use and the distress related 
to non-motor symptoms (Soyka and Huppert, 1992).
The withdrawal syndrome forms part of working criteria for DDS (Giovannoni et al. 2000) 
and it was initially linked to negative reinforcement views of addiction (“Hedonistic Homeostatic 
Dysregulation”). This view suggests that addicts are motivated to take dmgs not for the initial 
pleasure that results, but by the desire to avoid unpleasant affective symptoms (Koob and Le 
Moal, 1997). Conversely, the role of the central nervous system in mediating incentive motivation 
for dopaminergic dmgs has more recently been highlighted.
The aim here was to characterise the severity and nature of non-motor symptoms that define 
the withdrawal syndrome in DDS compared to a group of PD patients with medication-response 
fluctuations without compulsive use. One prediction was that DDS patients would have greater 
affective, incentive motivational (reward responsivity) and motor responses to L-dopa and that 
depressive symptoms and personality measures might mediate these responses. Further, it was 
predicted that DDS patients would show heightened expressions of dmg “wanting” after an acute 
challenge with L-dopa.
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5.3 M eth od s
The study was carried out in accordance with the declaration of Helsinki and involved patients 
fulfilling Queen Square Brain Bank criteria for PD (Hughes et al. 1992) receiving regular 
dopaminergic drug therapy, with no significant intellectual impairment as defined by a Mini- 
Mental State Examination (MMSE) score ^24, and adequate language comprehension who 
consented to protocols approved by the Joint Ethics Committee of the National Hospital for 
Neurology and Neurosurgery and Institute of Neurology. Forty non-demented patients with PD 
experiencing motor fluctuations on treatment (32 male, 8 female) were studied. Half had harmful 
compulsive dopaminergic drug use and fulfilled working criteria for DDS (Lawrence et al. 2003) 
and half did not use drugs compulsively. The DDS group was matched for sex, disease duration, 
stage and loosely for age with control PD patients. The presence and severity of complex 
repetitive motor stereotypies (punding) was assessed according to previous guidelines (Evans et 
al. 2004) and a daily L-dopa equivalent unit (LEU) dose was calculated (Evans et al. 2004). 
Disease stage was rated with the Hoehn and Yahr score (H&Y) and depressive symptoms were 
rated with the Geriatric Depression Scale (GDS) (Yesavage et al. 1982) in an “ON”-state. 
Novelty seeking personality traits were assessed using the Temperament and Character Inventory 
(TCI) (Cloninger et al. 1993). Characteristics of the patients are given in Table 5-1.
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Table 5-1: Patient characteristics
Control PD
Mean (SD)
DDS
Mean (SD) t-test
Age 59.5 (7.9) 55.4 (7.6) ri=5.90,/?<0.001
Disease duration 13.6 (8.0) 14.0 (5.7) ^=-0.25,/) =0.806
GDS 9.0 (4.9) 17.6 (6.4) /=-4.52,/?<0.001
NS 8.4 (3.9) 12.9 (3.5) ?=-5.16,/»<0.001
Median (Range) Median (Range) Mann-Whitney Utest
Daily LEU dose 859 (150-2800) 1935 (933-4000) Z=-4.45,;?<0.001
Corrected L-dopa dose 584 (0-2800) 1425 (0-3000) Z=-2.25,p=0.025
DA LEU dose 190 (0-600) 800 (0-3600) Z=-2.47,/?=0.014
H&Y 2.5 (2 .0-3 .0) 2.5 (2 .0 -4 .0 ) Z=-1.56,/>=0.118
Punding severity 0(0 -1 ) 2 ( 1-3 ) Z=-3.89,/?<0.001
MMSE 29.1 (27 -30) 29 (24 -  30) Z=-0.466,77=0.641
H&Y -  Hoehn & Yahr scale, MMSE -  Mini-Mental State Examination, LEU -  L-dopa 
equivalent unit, DA -  dopamine agonist, GDS -  Geriatric Depression Scale, NS -  Novelty 
Seeking score
5.3.1 L-dopa challenge
Patients were examined in the morning after overnight withdrawal of anti-Parkinson 
medications and once patients were fully “switched on” after taking a suprathreshold dose of oral 
L-dopa (mean 274mg, range 200-500) plus peripheral decarboxylase inhibitor (Albanese et al.
2001). Patients were evaluated by movement disorder specialists using the UPDRS motor scale 
and patients completed questionnaires evaluating the non-motor symptoms (see next section) in 
the “OFF”-medication and “ON”-medication states. Patients’ ratings of subjective L-dopa effects 
were evaluated using a Drug Effects Questionnaire (DEQ) (de Wit et al. 1987). In the “ON’ - 
state, patients rated drug effects (Leyton et al. 2002; de Wit et al. 1987) on four VASs, with the 
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questions: “Do you feel any drug effects?”, “Do you like the effects you are feeling right now?”; 
“Are you highT\ and “Do you want more of what you consumed, right now?”. The patient’s 
reward responsivity, as measured by speeding of responses in the presence of a small monetary 
reward, was assessed using the Card Arranging Reward Responsivity Objective Test (CARROT) 
(Powell et al. 1996). Dyskinesias were assess using the Goetz rating scale (Goetz et al. 1994) 
modified by removing scoring for dystonie movements and by using a mental subtraction method.
53.2 Non-motor symptom item generation
Rating scale items were generated from a review of pubhcations identifying items reported to 
fluctuate in response to L-dopa therapy (Gunal et al. 2002; Racette et al. 2002; Riley and Lang, 
1993; Witjas et al. 2002). 31 items were selected, given a common five-point response option, 
and formatted into a questionnaire. Patients were asked to rate each item on a Likert scale 
according to the extent to which they experienced that emotion or sensation at that moment in 
time from 0 being “very little or not at all” to 4 “extremely”. As a quantitative measure for the 
severity of non-motor symptoms for each individual, if an item in the “OFF”- or “ON”-states was 
endorsed by the individual (i.e. rated >0), then it was scored as present or 1. The number of 
endorsed items by each individual was added to form a total score for the “OFF”- and “ON’ - 
states. 17 items were categorised as “Somatic” and 14 “Affective” . A version of the positive and 
negative affect schedule (PANAS) (Laurent et al. 1999) was also used which presented 15 
positive affect (PA) (e.g. “excited”) and 15 negative affect (e.g. “scared”) adjectives, which were 
endorsed by the patient on a 5 point Likert scale ranging from 1 = not at all to 5 = extremely. The 
PANAS was presented in its state version; i.e. patients were asked to rate how they felt “right 
now”.
53.3 Data analysis
Statistical analyses of clinical data were performed with SPSS version 11.0 (SPSS Inc.,
Chicago, IL, USA). The assumptions of normality and constant variance of the model residuals
were reasonably met for each of the analyses. Each measure (affect, reward responsivity, motor
and non-motor symptoms) was analyzed in separate mixed design ANOVAs with GROUP (DDS
patients or PD control) as the between-subject variable and effect of L-DOPA (two levels: OFF
medication and ON medication) as the within subjects variable. Where appropriate, post-hoc two-
tailed tests were performed to explore differences between groups and between conditions. In
each group, correlations between changes in PA and NA and individual depression and novelty
seeking scores using Pearson’s correlation coefficient were tested. In DDS patients, punding
severity was also correlated with reward responsivity. To determine whether “OFF” symptoms or 
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expressions of drug salience in “ON” were independently associated with DDS, motor UPDRS, 
PA, and NA in “OFF” and VAS scores of drug “wanting” in “ON” were entered into a forward 
stepwise logistic regression model.
5.4 Results
5.4.1 Motor scores
The significant interaction between L-DOPA effect and GROUP [F(l,38)=18.24;/?<0.001] 
(Table 5-2) indicate that the change in UPDRS from OFF to ON was greater in the DDS group 
compared to the control group. In “ON” DDS patients had comparable UPDRS scores (?=-l .15, 
p=0.255) but more disabling dyskinesias (Table 5-4).
Table 5-2: Results of mixed design 2 way ANOVAs with GROUP (DDS patients or PD 
control) and AGE as between-subject variables and effect of L-DOPA (two levels: OFF 
medication and ON medication) as the within subjects variable for UPDRS pt3, somatic and 
affective symptoms, reward responsivity (%), and positive and negative affect. Scores 
indicate mean (standard error of the mean).
L-DOPA Somatic Affective Reward Positive Negative
Group state UPDRS pt3 symptoms symptoms responsivity affect affect
“OFF” 33.1 (2.5) 5.9 (1.0) 5.8 (0.9) 3.1 (2.0) 32.7 (2.1) 22.6 (2.6)
Control PD “ON” 19.2 (2.5) 3.2 (1.0) 3.7 (0.9) -1.3 (2.0) 38.4 (2.1) 20.7 (2.6)
“OFF” 53.4 (2.5) 7.6 (1.0) 10.9 (0.9) 4.0 (2.3)* 20.9 (2.1) 32.6 (2.6)
DDS “O N ” 22.7 (2.5) 4.2 (1.0) 5.6 (0.9) 10.9 (2.0) 35.0 (2.1) 24.7 (2.6)
P-value for main effect of F(l,37)=16.6, F(l,37)=1.2, F(l,37)=10.7, F(l,35)=12.7, F(l,37)=8.7, F(l,37)=4.3,
Group P<0.001 P=0.279 P=0.002 P=0.001 P=0.006 P=0.046
f-value for main effect of L- F(l,38)=129.1, F(l,38)=15.4, F(l,38)=32.4, F(l,37)=0.4, F(l,38)=48.9, F(l,38)=8.9,
DOPA P<0.001 P<0.001 P<0.001 P=0.542 P<0.001 P=0.005
f-value for interaction F(1.38)=18.2, F(l,38)=0.2, F(l,38)=6.3, F(l,37)=6.3, F(l,38)=9.0, F(l,38)=3.3,
between Group and L-DOPA P<0.001 P=0.675 P=0.016 P=0.017 P=0.005 P=0.075
Means calculated at the average age of 57.5
*N=T5 due to patients’ inability to perform motor requirements of the task, DDS -  Dopamine Dysregulation Syndrome, 
UPDRS -  Unified Parkinson’s Disease Rating Scale
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5.4.2 Non-motor scores
The results of a paired-samples test in all 40 participants for the 31 non-motor item scores in 
off- compared to “ON”-state are given in Appendix A. The interaction between GROUP and L- 
DOPA was significant for the number of affective items endorsed [F(l,38)=6.34; /?=0.016], 
(Table 5-2). This was largely accounted for by a higher number of affective items endorsed in 
“OFF” in the DDS group (r=-4.43,p<0.0001). The number of affective items endorsed in “ON” 
was not different (^=-1.68,/?=0.101). The interaction between GROUP and L-DOPA was not 
significant for number of somatic items endorsed [F(l ,38)=0.18; /7=0.675] and there was no 
significant between GROUP effect on the number of somatic items endorsed [F(l,37)=l .21; 
p=0.279], although the main effect of L-DOPA on the number of somatic items endorsed was 
significant [F( 1,38)= 15.44;/7<0.001].
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Table 5-3: A. Paired-samples Wilcoxon signed rank test of autonomic symptoms in 40 
participants of difference between symptom ratings in “OFF” minus symptom ratings in 
“ON” and B. Paired sample nonparametric Mann Whitney tests between control PD group 
and DDS patients of the difference between the “ON”- and “OFF”-state scores.
A. Difference from “OFF” to “ON” N=40 B. Between group difference
Symptom Median Range Z P Median Range W P
Autonomic
Sweats 0.0 -4 .0 - 1.0 -2.67 0.008 0.0 -4.0 -  2.0 442.5 0.387
Feeling Hot 0.0 -4 .0 -2 .0 -1.35 0.176 0.0 -4 .0 -3 .0 397.0 0.735
Flushing of face 0.0 -3 .0 -3 .0 -1.32 0.188 0.0 -3 .0 -3 .0 431.5 0.570
Dry mouth 0.0 -4 .0 -2 .0 -2.37 0.018 0.0 -5 .0 -2 .0 447.0 0.288
Choking feeling 0.0 -3 .0 -2 .0 -2.58 0.010 0.0 -3 .0 -3 .0 446.5 0.240
Abdominal discomfort 0.0 -3 .0 -2 .0 -2.67 0.008 0.0 -3 .0 -3 .0 445.5 0.228
Cold hands/feet 0.0 -4 .0 -4 .0 -2.00 0.046 0.0 -4 .0 -4 .0 477.0 0.030
Drooling 0.0 -2 .0 -4 .0 -1.47 0.142 0.0 -3 .0 -4 .0 439.5 0.433
Need to pass urine 0.0 -4 .0 -3 .0 -2.50 0.012 0.0 -6 .0 -2 .0 418.0 0.839
Visual blurring 0.0 -4 .0 - 1.0 -2.62 0.009 0.0 -4 .0 -3 .0 452.0 0.229
Racing heart 0.0 -4 .0 - 1.0 -2.00 0.046 -1.0 -4 .0 -3 .0 410.0 1.000
Chest tightness 0.0 -1 .0 -2 .0 -2.89 0.004 0.0 -4 .0 -3 .0 420.0 0.797
Difficulty breathing 0.0 -1 .0 -2 .0 -2.85 0.004 0.0 -1 .0 -2 .0 437.0 0.375
Feverish 0.0 -4 .0 -0 .0 -1.51 0.132 0.0 -2 .0 -4 .0 394.5 0.561
Sensory
Tight feelings -1.0 -4 .0 -3 .0 -3.00 0.003 -1.0 -4 .0 -2 .0 464.0 0.148
Tingling sensations 0.0 -4 .0 -3 .0 -2.10 0.036 0.0 -4 .0 -3 .0 398.5 0.766
Pain or cramping -2.0 -4 .0 -3 .0 -2.82 0.005 -0.5 -7 .0 -3 .0 470.5 0.095
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Affective
Anxious 0.0 -3 .0 -3 .0 -3.45 0.001 0.0 -2 .0 -4 .0 471.5 0.079
Tired 1.0 -2 .0 -4 .0 -2.55 0.011 1.0 -3 .0 -4 .0 449.0 0.298
Irritable -1.0 -4 .0 -2 .0 -3.21 0.001 -1.0 -4 .0 -2 .0 505.0 0.011
Withdrawn -1.5 -4 .0 - 1.0 -4.09 <0.001 -1.0 -4 .0 -2 .0 530.0 0.001
Weary 0.0 -4 .0 -2 .0 -2.31 0.021 -1.0 -5 .0 -2 .0 469.5 0.110
Pessimism 0.0 -4 .0 -2 .0 -2.09 0.037 -1.0 -4 .0 -5 .0 471.0 0.102
Apathy 0.0 -4 .0 -2 .0 -3.00 0.003 0.0 -4 .0 -2 .0 496.5 0.020
Panicky -1.0 -4 .0 -2 .0 -3.88 <0.001 0.0 -4 .0 -2 .0 529.0 0.001
Angry 0.0 -4 .0 - 1.0 -2.05 0.040 -0.5 -4 .0 - 1.0 456.0 0.128
Cognitive
Slowness of thinking 0.0 -2 .0 -2 .0 -4.17 <0.001 -1.0 -3 .0 -2 .0 451.0 0.256
Memory problems 0.0 -4 .0 -3 .0 -3.33 0.001 -1.0 -5 .0 -2 .0 416.0 0.882
Mental emptiness 0.0 -4 .0 -2 .0 -3.85 <0.001 -0.5 -4 .0 -2 .0 515.0 0.005
Racing thoughts -1.0 -4 .0 - 1.0 -2.36 0.018 -1.0 -4 .0 -2 .0 455.5 0.121
Poor concentration -1.0 -4 .0 -2 .0 -3.97 <0.001 -0.5 -3 .0 -3 .0 469.5 0.110
Non-motor item scores were compared using the Mann Whitney U test between the DDS and 
control PD patients in the “OFF”- and “ON”-medication states. In the “OFF”-state, DDS patients 
had higher ratings of “anxious” (Z=-2.31,/?=.021), “tired” (Z=-2.20,/?=.028), “irritable” (Z=-3.01, 
/?=.002), “withdrawn” (Z=2.86,/>=.004), “weary” (Z=-2.19,/?=.029), “apathy” (Z=-2.76,/?=.006), 
“panicky” (Z=-3.23,/?=.001), “angry” (Z=-2.35,/?=.019), “slowness o f thinking” (Z=-2.25, 
/>=.024), “mental emptiness” (Z=-3.17,/>=.002), “poor concentration” (Z=-2.97,/?=.003), and 
“tight feelings” (Z=-2.95,/?=.003). In the “ON”-state, DDS patients had higher ratings of “feeling 
hot” (Z=-2.37,/?=.018), and “weary” (Z=-1.99,/?=.047) only.
5.4.2.1 Positive and Negative Affect
For PA, there was a significant interaction between L-DOPA and GROUP [F(l,38)=9.02;
;?=0.005]. For NA, there was a trend for an interaction between L-DOPA effect and GROUP 
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[F(1,38)=3.34; =0.075]. However, there was a significant main effect of L-DOPA on NA 
[F(l,38)=8.91;p=0.005] and a between-GROUP difference in ratings of NA [F(l,37)=4.26; 
/7=0.046]. The differences were largely due to reduced scores of PA (r=4.93,p<0.0001) and 
higher scores of NA (/=-2.76,/?=0.009) in the DDS group compared to controls in “OFF” (Table 
5-2). There were no between group differences in PA (^=0.95,^=0.347) or NA (r=-l .39,/?=0.172) 
in “ON”.
5.4.2.2 Reward responsivity
There was an interaction between L-DOPA effect and GROUP for reward responsivity 
[F(l,37)=6.26;/?=0.017] (Table 5-2). Means show RR went up from “OFF” to “ON” in DDS 
group but down in control group. Reward responsivity was not different between the groups in 
“OFF” (r=-0.579,p=0.566).
5.4.2.3 Drug “wanting” and Drug Effects
In “ON”, DDS patients had higher ratings of drug “wanting” but there was no difference in 
ratings of “feel” drug, “like” drug, or drug “high” compared to control PD patients (Table 5-4).
Table 5-4: Linear mixed model for dyskinesia scores, and drug effects questionnaire ratings 
in “ON” in control PD patients versus patients with Dopamine Dysregulation Syndrome 
adjusted for age.
Ratings in “ON” Control PD DDS Wald statistic; P-va
mean (SE) mean (SE)
Goetz dyskinesia score 0.9 (0.2) 2.0 (0.2) W=14.56,P<0.001
“Want” drug 7.6 (5.7) 43.6 (5.7) W=19.33,P<0.001
“Feel” drug 65.4 (6.3) 74.9 (6J) W=1.02,P=0.314
“Like” drug 65.7 (7.2) 65.9 (7.2) W=0.00, P=0.977
drug “High” 26.0 (7.1) 37.0 (7.1) W=1.22,P=0.269
* Means calculated at the average value of age
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Variables independently associated with DDS were worse UPDRS part 3 in “OFF”, increased 
expressions of drug “wanting” in “ON”, and novelty seeking and these accounted for a large 
degree of the variance (Table 5-5).
Table 5-5: Logistic regression analysis examining the influence of age, disease duration, NS, 
GDS, UPDRS part 3, PA, NA, number of affective and somatic symptoms in “OFF” and 
drug “wanting” in “ON” on the dependent binary variable: PD patients with DDS vs PD 
fluctuating controls using a forward selection procedure
Variable Model p  value on entry to model
UPDRS part 3 in “OFF” 0.579 0.001
Drug “wanting” in “ON” 0.746 0.034
Novelty seeking 0.819 0.070
Hosmer-Lemeshow goodness-o1 -fit statistic=2.9; 8 df, /? =0.942.
5.4.3 Correlations
In the DDS group, change in PA correlated with NS (r=0.461,/?=0.041, n=20) and change in 
NA with GDS (r=0.473,/?=0.035, n=20). The correlation between change in NA and GDS 
remained significant even when the severity of UPDRS in “OFF” was partialled out (r=0.456, 
/?=0.049, n-20). In DDS patients reward responsivity in “ON” correlated with punding severity 
(r=0.452,/?=0.044, n=20). In the control PD group, change in NA correlated with GDS (r=0.483, 
/7^0.031, n=20).
5.5 Discussion
Following overnight withdrawal of medications, DDS patients had more motor parkinsonism,
reduced positive affect, and reported a broader range of affective non-motor symptoms compared
to control patients. With the L-dopa challenge, DDS patients had a greater reduction in the motor
UPDRS, number of affective non-motor symptoms, and positive affect due to their relatively
lower basehne scores. They displayed generally enhanced reward responsivity and had significant
L-dopa induced increases in reward responsivity. In “ON”, DDS patients reported increased drug 
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“wanting” but did not “feel” or “like” drug effects more than controls and they had more 
disabling dyskinesias.
Treatment for the motor disability of PD may reduce depressive symptomatology (Bum,
2002b) even though dopaminergic dmgs have limited or no hedonic effects at their initiation 
(Maricle et a l 1998). With time, medication-responsive affective states may emerge and include 
anhedonia, allodynia, anxiety, fatigue, irritabihty lassitude, sadness and panic (Witjas et a l
2002). Patients with DOS, frequently complaint of disabling “OFF”-state symptomatology (Beam 
et a l 2004). In this study, a broad range of non-motor symptoms were found to fluctuate in both 
groups of PD patients in response to an acute L-dopa challenge. Affective fluctuations do not 
simply reflect a psychological reaction to worsening motor disability or changing brain 
catecholamine levels. Blinded cessation of a L-dopa infusion quickly leads to deterioration in 
affective states before any changes in motor function can be detected (Maricle et a l 1995). 
Dissociation between mood and motor states is also evident when comparing effects of 
stimulation of the subthalamic nucleus to the effects of L-dopa (Funkiewiez et a l  2003). 
Moreover some DDS patients have distressing non-motor “OFF” periods even when their motor 
symptoms are well controlled (Lawrence et a l 2003). Imaging data suggest that mood 
fluctuations result from dopaminergically mediated fimctional changes within hmbic cortices 
(Black et a l 2005).
Negative reinforcement accounts of addiction propose that escape from or avoidance of 
negative affect is the principal motive for addictive dmg use. The initially rewarding effects of 
dmgs of abuse are later followed by opposing longer-lasting emotional states during withdrawal 
as the body seeks to restore its “hedonic equilibrium”. Persistent plasticity is proposed to occur in 
the activity of neural circuits mediating two different motivational systems: recmitment of “anti­
reward” systems (i.e. brain systems that limit reward) that drive aversive states, and decreased 
function of brain reward systems driven by natural rewards (or reduction in baseline pleasure 
levels (Barr et a l  2002)). This is hypothesized to ultimately sustain compulsive dmg use.
In this study, DDS patients reported a “withdrawal” state characterised by a global reduction in 
positive affect, a trend to increased negative affect, a broader range of negative affective 
symptoms and worse motor function. The withdrawal state in DDS resembles the withdrawal 
state of psychostimulant addiction (Barr et a l 2002). Although “Somatic” withdrawal symptoms 
differ greatly between different dmgs of addiction, emotional withdrawal symptoms in particular 
seem to underpin dmg dependence (Koob and Le, 2008).
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DDS patients also had higher depression scores despite having comparable “ON” motor 
disability to the PD fluctuators group. Higher depression scores correlated with greater reductions 
of negative affect from L-dopa. In psychostimulant addiction, the severity of the withdrawal 
symptoms predict the presence of depressive symptoms (Sofuoglu et a l 2003) and greater 
severity of drug dependence. Thus, in DDS patients, negative reinforcement might not only 
represent self-medication of a drug-generated aversive state (such as withdrawal) but could also 
include self-medication of an existing aversive state (such as depressive symptoms). The latter 
proposal is in keeping with observations in untreated PD patients where depressive 
symptomatology has been found to predict greater need for symptomatic therapy (Ravina et a l 
2007). However, in treating DDS, treatment of depression alone is not effective in reducing 
compulsive drug use or its behavioral consequences (Lawrence et a l 2003).
Individual differences, either via genetic or environmental factors, at critical periods may cause 
a predisposition develop addiction disorders. In this study, greater drug-induced improvement in 
positive affect did occur in DDS patients from “OFF”- to “ON”-medication and greater change in 
PA was predicted by higher novelty-seeking personality traits. Yet, PA in “OFF” (and thus the 
change in PA) did not independently predict DDS in the regression model. In human studies of 
psychostimulants, higher novelty-seeking traits have also been found to predict greater subjective 
psychostimulant effects (Hutchison et a l 1999). Moreover, higher novelty-seeking traits are an 
independent risk factor for the development of DDS (Evans et a l 2005) and the emergence of 
impulse control disorders with dopamine agonist treatment (Voon et a l 2007).
Negative reinforcement models also propose that there is a reduction of brain reward function 
during acute withdrawal (Koob and Le Moal, 2001). The CARROT is a behavioral measure of 
responsiveness to financial incentive, in which participants sort cards under conditions of 
nonreward and reward (Powell et a l 1996). Normal subjects show a significant increase in 
sorting speed when rewarded of about 4%. In a previous study with heavy smokers, reward 
responsiveness was impaired during abstinence and restored after a single cigarette (al-Adawi and 
Powell, 1997). In contrast to the predictions of negative reinforcement models of addiction, there 
did not appear to be a “reward” deficit in the “OFF” state, in control PD patients or DDS patients 
as measured by performance on the CARROT. Others have even suggested that drug seeking in 
humans comes at the expense of natural rewards (Cardinal and Everitt, 2004) implying that 
reduced incentive processing is causally related to anhedonia (Baker et a l 2004). Instead, we 
found that DDS patients showed even greater reward responsivity with a L-dopa challenge.
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The finding that DDS patients have higher reward responsivity is relevant to clinical 
observations that link both DDS (Evans and Lees, 2004) and the dopaminergic drugs used in PD 
with a variety of impulse control disorders (Driver-Dunckley et al. 2003) and punding. 
Moreover, we observed that emotional and motivational states in “ON” and “OFF” in DDS 
patients appeared to be independent. This indicates that anhedonia may not necessarily result 
from reduced incentive processing. Heightened responsivity to nondrug (monetary) rewards in 
DDS patients may relate to a global effect of dopaminergic drugs on sensitizing incentive 
motivational systems and may share the same substrates as those mediating drug-primed craving. 
Further, these systems may also overlap with those that mediate the expression of drug-induced 
complex repetitive stereotypies (punding) due to the correlation between punding severity and 
reward responsiveness.
Appetitive motivation may also have a role in compulsive drug use in DDS. Incentive- 
motivational accounts of addiction assume that the withdrawal state enhances the incentive value 
of the drug to such an extent that drug-seeking becomes the dominant behavior (Hutcheson et al.
2001). Drug absorption, distribution, and elimination kinetics produce innumerable spikes and 
troughs in drug levels in the body over the course of drug use. The addicted individual develops 
interoceptive cues of the negative affect that occur whenever drug levels begin to fall and this 
biases a proceduralised drug motivational processing routine. Similarly, in PD, repeated 
experience with end-of-dose wearing-off and co-existence of a chronic depressive state may 
further enhance the incentive value of the dmg to such an extent that dopaminergic dmg seeking 
becomes the over-riding behavior. Many DDS patients use idiosyncratic internal symptoms to 
herald impending “OFF”-states and cue stereotyped dmg dosing schedules despite the external 
appearance of adequate parkinsonian motor control (Giovannoni et al. 2000). However, both 
groups of PD patients in this study reported at least one “withdrawal” symptom and experienced 
some hedonic impact of L-dopa. Moreover, DDS patients in “ON” did not ''like ’ the effects of 
their medications any more or experience greater 'highs ’.
Dmg-induced neuroadaptations in the dopaminergic ventral striatum (VS) and related circuitry 
may play a pivotal role in the development of DDS (Evans et al. 2006b). In “ON” DDS patients 
had comparable motor function, had comparable ratings of PA and NA and dmg “liking” but had 
greater expressions of dmg “wanting” despite more disabling dyskinesias. The VS and related 
circuitry are proposed by some authors to mediate a subcomponent of reward termed incentive 
salience (or dmg “wanting”) (Robinson and Berridge, 2000). With repeated dmg taking, brain 
reward systems mediating dmg “wanting” are proposed to become hyperresponsive (sensitized)
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to dopaminergic drugs and drug-associated stimuli. At the same time, individuals are thought to 
become tolerant to the hedonic impact of drugs (i.e. drug “liking” is reduced). Dmgs become 
compulsively “wanted” or craved even when the dmg’s pleasurable effects are diminished 
(Robinson and Berridge, 2000). L-Dopa primed craving (increased dmg “wanting” in “ON”) in 
DDS is more easily explained by these “proponent” neural processes and has been found to 
correlate with dmg-induced neuroadaptations in the nucleus-accumbens in individuals with DDS 
(Evans et al. 2006b).
We conclude that a harmful pattern of compulsive dopaminergic dmg use in PD is associated 
with an aversive medication-withdrawal state, consistent with some predictions of negative 
reinforcement models of compulsive dmg use. However, “OFF” period motor disability alone 
cannot be the only factor in the driving compulsive dmg use in these individuals. Patients in both 
groups of this study experienced some sort of aversive “OFF” symptoms and all patients had 
motor fluctuations. Moreover, the affective aspects of medication-withdrawal appeared to be less 
important than “OFF” period motor disability in predicting DDS and some aspects of motor 
function were in fact worse in the “ON” state of DDS patients. Medication-responsive affective 
states, in general, appeared to relate more to depressive symptomatology and individual 
personality traits rather than mechanisms that mediate general incentive arousal or motor 
function. Incentive leaming processes associated with repeated experience with the aversive 
“OFF” state may also contribute the development or maintenance of DDS although we did not 
specifically test whether DDS patients experienced “OFF” symptoms more frequently than 
controls. Consistent with the incentive sensitisation theory of addiction (Robinson and Berridge, 
2000), patients’ ratings of dmg “wanting” in “ON” were independently associated with DDS -  
despite DDS patients having more “ON” period motor disability due to dyskinesia.
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Chapter 6 
COMPULSIVE DRUG USE LINKED TO SENSITISED VENTRAL 
STRIATAL DOPAMINE NEUROTRANSMISSION
Summary
Objective: Sensitisation of dopamine neurotransmission is a consistently found neuroadaptation in 
animals repeatedly exposed to stimulant drugs. The aim was to evaluate L-dopa induced dopamine 
neurotransmission in the striatum of patients with DDS compared to PD controls.
Methods: A two-scan PET protocol was used to calculate the percentage change in “C-raclopride 
binding potential (BP) from a baseline withdrawal (“o ff’ drug) state to the BP after an oral dose of L- 
dopa. The subjective effects of L-Dopa were related to the effects on endogenous dopamine release of 
a pharmacological challenge with L-Dopa in 8 control PD patients and 8 patients with DDS.
Results: PD patients with DDS exhibit enhanced L-dopa induced ventral striatal-dopamine release 
compared to L-dopa treated patients with PD not compulsively taking dopaminergic drugs. The 
sensitised ventral striatal-dopamine neurotransmission produced by L-dopa in these individuals 
correlated with self-reported compulsive drug “Wanting” but not “liking” and was related to 
heightened psychomotor activation (punding).
Interpretations: This provides evidence that links sensitisation of VS-circuitry in DDS patients to 
compulsive expressions of drug “Wanting”.
6.2 Introduction
Dopaminergic drug therapy is a highly effective symptomatic treatment for the motor disability of 
PD (Hoehn, 1992). However, anti-Parkinson dopaminergic medications have the potential to be 
compulsively used (Evans and Lees, 2004; Giovannoni et al. 2000; Lawrence et al. 2003). In animal 
models, L-dopa and dopamine agonists appear to share some of the psychomotor activating properties 
of commonly abused drugs (van der Kooy et al. 1983 ; Katajamaki et al. 1998; Bardo and Bevins, 
2000). It has been posited that the addictive liability of anti-Parkinson dopaminergic medications may 
be mediated by alterations in ventral striatal dopamine neurotransmission and related neural circuitry
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(Lawrence et al. 2003) -  a system that evolved to mediate aspects of “natural” rewards such as food, 
water and sex (Wise and Bozarth, 1987; Di Chiara and Imperato, 1988).
Early experiences with high doses of L-dopa without peripheral dopa decarboxylase inhibition in 
PD and bipolar depressive disorder highlighted the frequent occurrence of neuropsychiatrie 
disturbance; including hypomania, psychosis, insomnia, aggression, impulsive behavioural 
disturbances, and intermittent “mood spells” in which patients would develop sudden feelings of 
intense exhilaration (Damasio et al. 1971 ; Murphy, 1972). More recently, it has become apparent that 
dopaminergic medications may also potentiate the appearance of drug-responsive compulsive 
behaviours (Evans and Lees, 2004; Giovannoni et al. 2000; Lawrence et al. 2003) (pathological 
gambling, hypersexuality and food bingeing (Giovannoni et al. 2000)) and the development of 
punding, a form of complex behavioural stereotypy (Evans et al. 2004). These drug-responsive 
behaviours frequently complicate DDS and may be imphcated in a common neurobiological process.
The aim of this study was to evaluate L-dopa induced dopamine neurotransmission in the ventral 
striatum of patients with DDS compared to PD controls using molecular imaging with positron 
emission tomography (PET) and the dopamine D2/3 receptor hgand "C-raclopride (RAC).
Differences in L-dopa induced endogenous dopamine release in DDS patients were correlated with 
the hedonic (i.e. pleasurable, euphoric) effects of L-dopa (drug “liking”), and a subcomponent of 
reward termed incentive salience (drug “Wanting”) (Robinson and Berridge, 1993; Robinson and 
Berridge, 2000).
6.3 Methods
Eight non-demented patients with DDS and eight non-demented control PD patients (Table 6-1) 
gave written informed consent for protocols approved by local ethics committees. Permission to 
administer RAC was obtained from the Administration of Radioactive Substances Advisory 
Committee of the UK. Patients were asked to withhold all anti-Parkinson medication for 12 hours 
prior to scanning. A two-scan protocol was used to study the effects of the pharmacological challenge 
on endogenous dopamine levels that were estimated using percentage change in RAC binding 
potential (BP) relative to a baseline withdrawal (“off’ dmg) state. Each patient received two RAC- 
PET scans on separate mornings after overnight dmg withdrawal; under baseline conditions and then 
after an oral dose of Sinemet-275 (L-dopa 250mg, carbidopa 25mg). The characteristics of the PET
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scanner are described elsewhere (Piccini et al. 1999). Dynamic emission scans were initiated at the 
beginning of administration of a slow IV bolus of a mean 183 MBq dose of RAC. Patients also had 
volumetric brain magnetic resonance imaging. Two methods of analysis were employed: 1. a Region 
of Interest (ROI) approach focusing on the ventral and dorsal striatum and 2. Statistical Parametric 
Mapping (SPM), allowing exploratory voxel-by-voxel group comparisons throughout the entire brain 
volume.
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Table 6-1: Patient characteristics
Control PD group 
mean (range)
DDS PD group 
mean (range)
Age
(years)
60.0 (45 - 70) 51.2 (42.5-61) Z= -2.10,/7=0.038
Symptom duration 
(years)
12.1 (7-17) 12.4 (5-20) NS
Mini-Mental Parkinson 
(Mahieux ft a/. 1995)
29 (27-32) 28.6 (25-31) NS
motor UPDRS 
“off’-medication
37.1 (20-64) 52.7(21-81) Z=0.71,/?=0.721
motor UPDRS 
“on”-L-dopa
27.1 (10-43) 23.1 (8 -5 9 ) Z=0.71,/?=0.721
Daily L-dopa equivalent 
unit*
848 (267-1287) 1517(700-2200) Z= -2.20,/?=0.027
UPDRS -  Unified Parkinson’s D isease Rating Scale, DDS -  dopamine dysregulation syndrome, * L-dopa equivalent unit 
was defined according to (Evans et al. 2004)
63.1 Region of interest analysis
Parametric images of RAC-BP for each patient were generated from the dynamic RAC scans using 
a BASIS function implementation of the simphfied reference region compartmental model with the 
cerebellum as the reference tissue (Gunn et al. 1997) and were anatomically co-registered 
(Studholme et al. 1997) with their respective volumetric T1 -weighted MRl. Values of BP for 
caudate, putamen, and VS were obtained by defining on the co-registered magnetic resonance images 
ROI that were subsequently applied to the parametric images similar to the method reported by 
Leyton and colleagues (Leyton et al. 2002) and averaged values of the right and left sides were 
calculated for each region. Percentage change in RAC-BP was calculated using the formula: 100 % 
[(value when “o ff’ L-dopa) - (value when “on” L-dopa)] ^ (value when “o ff’ L-dopa). Percentage 
change in motor UPDRS scores was calculated as follows: 100 jc [(value when “off’ L-dopa) - (value 
when “on” L-dopa)] (value when “o ff’ L-dopa).
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6.3.2 Statistical parametric mapping
Parametric images of RAC-BP were interrogated to localise significant differences of ligand BP at 
a voxel level using SPM99 software (Wellcome Department of Imaging Neuroscience, Institute of 
Neurology, London UK). Stereotaxic transformation of the parametric images involved spatially 
normalizing the individual RAC-BP image to an in-house RAC template in Montreal Neurological 
Institute space and subsequently spatial smoothing as previously described (Piccini et al. 2003). A 
between-group comparison localised clusters of voxels showing significant differences in mean RAC- 
BP after L-dopa between these two patient groups. An appropriately weighted contrast to localise 
significant decreases in mean voxel BP was used to derive Z scores on a voxel-wise basis using the 
general linear model. Regional brain differences were considered significant when maps of Z scores 
exceeded a threshold o f 2.33 (/?<0.01) after correction for cluster size (/?<0.05). No global BP 
normalisation was applied. Statistical analyses of data were performed with SPSS version 11.0 (SPSS 
Inc., Chicago, IL, USA).
63.3 Clinical evaluations
The positive affect and negative affect schedule (PANAS) (Watson et al. 1988) was administered 
to measure the affective state prior to scanning on both scanning days, immediately before tracer 
injection and 15 and 30 minutes after tracer injection. Change in PA and NA was determined by 
comparing baseline ratings prescan to peak PA scores and trough NA scores during both the “o ff’- 
state scan and the L-dopa scan. The percentage changes in PA and NA were calculated with the 
following formula: [(peak or trough affect scale score during the scan) - (prescan affect scores 
obtained in the “o ff’ medication state)] (prescan affect scores obtained in the “off’ medication 
state) X 100. To control for the effects of scanning on affect, a summary measure was obtained by 
subtracting the percentage change in PA and NA during the “o ff’-medication scan from the 
percentage change in PA and NA during the “on” L-dopa scan. Motor disabiUty was assessed in a 
baseline “ofF’-medication state with the Unified Parkinson’s Disease Rating Scale (Fahn et al. 1987) 
(UPDRS) and then again immediately after the “on”-drug L-dopa scan. Percentage change in motor 
UPDRS scores was calculated as follows: 100 x [(value when “o ff’ L-dopa) - (value when “on” L- 
dopa)] (value when “o ff’ L-dopa).
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6.3.4 Drug effects questionnaire
After overnight medication withdrawal, patients underwent a challenge with L-dopa in a similar 
manner to the challenge conducted on the day of PET. Patients’ ratings of subjective L-dopa effects 
(drug “Wanting” and drug “liking”) were evaluated using the DEQ (de Wit et al. 1987). In the “on” 
state, patients rated dmg effects (Leyton et al. 2002; de Wit et al. 1987) on two 100mm VAS, 
anchored at O=“not at all” and 100=“very much”, with two questions: “Do you like the effects you are 
feehng right now?”; and “Do you want more of what you consumed, right now?”. The patient’s 
reward responsivity, as measured by speeding of responses in the presence of a small monetary 
reward, was assessed using the Card Arranging Reward Responsivity Objective Test (CARROT) 
(Powell a/. 1996).
Punding behaviours were rated by the examining physician (Evans et al. 2004) and patients 
completed questionnaires assessing novelty (Cloninger et al. 1993) and BAS fun-seeking (Carver 
and White, 1994) personality traits. To minimise potentially confounding influences of stress during 
the PET scan on these assessments, DEQ, punding, the CARROT and personahty scores were rated 
during a separate L-dopa challenge prior to undergoing PET scanning.
6.4 Results
Using a priori defined dorsal- and VS-ROIs, no significant differences in “off-dmg” RAC-BP were 
found between the PD groups (ROI RAC-BP mean values ±SEM; control PD caudate 1.95 ±0.1, 
putamen 3.08 ±0.2, VS 2.01 ±0.1; DDS caudate 1.95 ±0.1, putamen 2.98 ±0.1, VS 2.07 ±0.1 p  values 
>0.72). Following L-dopa administration, both groups showed significant decreases in all regional 
striatal RAC-BPs compared to the “off-dmg” scan. L-dopa had an equal effect on percentage 
reduction in dorsal putaminal RAC-BP in control and DDS groups. In marked contrast, there was 
significantly greater percentage reduction in VS RAC-BP in response to L-dopa in the DDS group 
(Figure 6-1) indicating higher dmg-induced extracellular dopamine levels than controls. These 
findings were corroborated using voxel-based SPM analysis which confirmed the ROI findings of 
higher extracellular dopamine levels in the VS of the DDS group (Figure 6-2).
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Figure 6-1 : Effect of a single dose of L-dopa on percentage reduction in striatal RAC BP (mean 
±SEM) in control PD versus DDS patients indicating a significantly greater generation of 
dopamine in VS regions in the DDS group (putamen, controls 11.5 ±3.3, versus DDS patients 
11.6 ±2.0,p=0.88; VS, controls 3.6 ±1.5, versus DDS patients 14.4 ±2.7,p=0.003).
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Figure 6-2: Sagittal (jc=17.40), coronal (y=14), and transaxial (z= -9.85) projections of statistical 
parametric maps superimposed on a standardised MRl template. The figure shows the 
localisation of significant differences (in orange/yellow) in altered ”C-raclopride (RAC) binding 
potential after a single dose of L-dopa between control PD and DDS groups. These areas were 
identified as right and left ventral striatum using Montreal Neurological Institute coordinates 
(right x/y/z 18/12/-8,p=0.049, z=3.22; left x/y/z -14/14/-8p=0.048, z=3.38) confirming the region 
of interest findings of higher dopamine release in ventral striatum in the DDS group.
A strong representation of punding behaviour was found in the DDS group (controls 1/8 punders, 
versus, DDS patients 8/8,p=0.001). If the patients are divided along lines of punders versus 
nonpunders, the percentage reduction VS RAC-BP in punders was markedly higher (punders 14.1 
±2.4, nonpunders 0.83 ±2.1, Z= -3.23,p<0.001), however, the dorsal striatal release was no different 
between the groups.
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In the DDS group L-dopa “Wanting” was higher than in the control group and significantly 
correlated with L-dopa induced dopamine levels in the VS (Figure 6-3 A). In contrast, there was no 
significant association with L-dopa “liking” (Figure 6-3B). Self-reported drug effects were related to 
daily medication intake and a positive trend, although not significant, was found between daily 
dopaminergic drug intake and dmg “Wanting” (rs=0.621,p < 0.10, N=8) conversely “liking” was 
negatively correlated (r^= -0.771, jO=0.025, N=8). In the “o ff’-medication state, DDS patients had 
lower PA {t= -2.46,/?=0.027) and showed a trend towards a higher NA (/=1.84,/?=0.087) than 
controls. Ratings of state affect “on”-L-dopa were comparable between the groups (data not shown). 
Only a weak trend was observed for an association between L-dopa induced VS dopamine increases 
and change in PA (r^=0.690,/7=0.058, N=8) and no association with change in NA. The relationship 
between ratings of dmg “Wanting” and L-dopa induced dopamine levels in the VS was only mildly 
weakened by partialling out the effects of changes in se lf reported affect (r^=0.682,/7=0.092). DDS 
patients also showed an increased willingness to work for a small financial reward “on-L-dopa” (DDS 
patients mean “reward responsivity” on CARROT testing 12.3% SD 8.8, vs. control PD patients - 
1.9%, SD 8.8, Z= -2.94/?=0.003). Reward responsivity correlated with punding severity (^^=0.873 
/>=0.005, N=8).
UPDRS motor scores were comparable in control PD and DDS patient groups both in the “on” and 
“o ff’ L-dopa states (Table 6-1). L-dopa induced increases in dopamine neurotransmission in the 
putamen positively correlated with percentage improvement in UPDRS across the two groups 
(r5=0.59,/?=0.017, N=16) but did not correlate with L-dopa “Wanting” or “liking”. Percentage change 
in UPDRS motor scores did not correlate with the percentage reduction in VS RAC-BP.
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Figure 6-3: Rank correlation between rank percentage reductions in ventral striatal (VS) RAC 
BP induced by a single dose of L-dopa in DDS patients and: A. “Wanting” more L-dopa 
(r,=0.833,p=0.010, N=8) B. “liking drug” (r,= -0.238,p=0.570, N=8). “Wanting” and “Uking” 
ratings were obtained “on” dopa.
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DDS patients had increased novelty (Cloninger et al. 1993) and fun-seeking (Carver and White, 
1994) traits (BAS Fun seeking mean (range); controls 9.5 (7-12), DDS 12.5 (8-16), Z~ -2.34, 
p=0.021. NSl-Exploratory Excitabihty; controls 1.4 (0-3), DDS 2.6 (2-4), Z= -2.14,/?=0.050). 
Neither of these traits correlated with L-dopa induced VS dopamine release.
6.5 Discussion
Using RAC PET, an enhanced or sensitised drug-induced VS dopamine neurotransmission was 
demonstrated in PD patients compulsively using dopaminergic drug therapy despite its adverse 
consequences. Basal levels of dopamine D2 receptor availability were comparable between the 
groups. Other clinical studies have linked compulsive drug use to reductions in striatal D2 receptor 
binding. However, in those individuals, the findings may be explained by past chronic drug exposure 
or possibly represent a premorbid susceptibility factor for compulsive drug use (Voikow et al. 1993; 
Martinez et al. 2004). The control group in this study had been exposed to chronic intermittent 
dopaminergic drug schedules for a similar duration to DDS patients. Therefore, the sensitised VS 
dopamine response that was found in the DDS group would not be the result o f drug exposure per se 
but must be related to the development of a compulsive pattern of drug use.
Progressive augmentation of drug-induced VS dopamine release, measured after a period of drug 
withdrawal, is a consistently reported neuroadaptation associated with repeated psychostimulant drug 
administration in rodent microdialysis studies (Robinson and Berridge, 1993; Robinson and Berridge, 
2000; Vanderschuren and Kalivas, 2000). Basal dopamine levels, however, remain largely unaltered 
(Vanderschuren and Kalivas, 2000). Some have proposed that compulsive drug seeking results from 
neuroadaptations that lead to persistent hypersensitivity (neural sensitisation) of ventral striatal 
dopaminergic circuitry, a circuit that mediates certain aspects of reward (Robinson and Berridge, 
1993; Robinson and Berridge, 2000).
In animals, expressions of drug-induced stereotypies are influenced by drug dose (Samaha et al. 
2002; Robinson and Berridge, 2000; Robinson and Berridge, 1993) and are hypothesised to index the 
neuroadaptive changes that occur in the VS in response to compulsive drug self-administration, as the 
neural substrate that mediates drug-induced stereotypies overlaps with the neural substrate 
responsible for the rewarding effects of drugs (Robinson and Berridge, 2000; Wise and Bozarth,
1987). In PD, drug-induced complex stereotyped behaviour has been called punding. The results of
139
the current study provide further evidence that punding may be homologous to drug-induced motor 
stereotypies in laboratory animals studies (Robbins et al. 1990) as the VS dopamine levels that were 
generated after oral L-dopa ingestion was even more striking in punders than nonpunders.
DDS patients frequently demand more medication and quickly complain of tolerance to the 
beneficial effects of treatment. However, spiralling dopaminergic drug intake tends to worsen drug 
tolerance and lead to an increased frequency of distressing “off’ (medication withdrawal) periods. In 
the DDS patients enhanced L-dopa induced dopamine neurotransmission in the VS positively 
correlated with L-dopa “Wanting” but not L-dopa “liking”. Further, drug “Wanting” predicted levels 
of drug use in DDS patients. Moreover, with increasing dopamine neurotransmission there was an 
increasing dissociation between L-dopa “Wanting” and its subjective pleasurable effects (L-dopa 
“liking”) -  potentially reflecting the concurrent development of tolerance. In these individuals the 
hedonic impact of the L-dopa, as measured by dmg “liking”, was negatively related to the patients’ 
daily amount of L-dopa intake. Consequently, L-dopa “Wanting” appears to be directly related to 
compulsive use of that drug, even when its effects become less pleasant. The dopaminergic ventral 
striatum and related circuitry is proposed to mediate a specific reward process called “Wanting” or 
incentive salience (Robinson and Berridge, 1993; Robinson and Berridge, 2000). With repeated dmg 
taking, brain reward systems mediating dmg “Wanting” become hypersensitive (sensitised) to dmgs 
and dmg-associated stimuli. At the same time, individuals are thought to become tolerant to the 
hedonic impact of dmgs so dmgs become compulsively “Wanted” or craved even when the dmg’s 
pleasurable effects become diminished. These conceptualisations of compulsive dmg use (the 
Incentive Sensitisation Theory) may be directly relevant to understanding compulsive use of 
dopaminergic dmgs in PD patients with DDS. For instance, dopaminergic agonists have also been 
shown to induce the neural and behavioural phenotypes induced by psychostimulant dmgs (Capper- 
Loup et al. 2002).
Animal data investigating the behavioural effects of dmg sensitisation have found enhanced 
responding for natural reward related stimuli such as sugar, food, sex and conditioned stimuli for such 
rewards (Fiorino and Phillips, 1999; Wyvell and Berridge, 2001 ; Nocjar and Panksepp, 2002). By 
contrast, a proposed characteristic of human addiction is that responding for non-dmg reinforcement 
decreases relative to that for dmg reinforcement. It has been suggested that motivation for non-dmg 
rewards may actually be decreased in humans (Cardinal and Everitt, 2004), although there are
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anecdotal reports of hypersexuality in cocaine addicts (Robinson and Berridge, 2000) and some 
substance-dependent individuals may be hyper-responsive to money rewards (Bechara et al. 2002). 
The increased responsivity to nondrug (monetary) reward found in DDS patients is consistent with 
clinical observations that link the dopaminergic drugs used in PD and DDS (Evans and Lees, 2004) 
with other addictive behaviours such as hypersexuality and compulsive gambling (Driver-Dunckley et 
al. 2003; Dodd et al. 2005), and is relevant to the debate as to whether or not behavioural and 
chemical addictions share the same substrates. The correlation between punding severity and reward 
responsivity may reflect a relationship between the reward-enhancing and stereotypical effects of 
psychomotor stimulant drugs (Robbins, 1976) or relate to a global increase in wanting for conditioned 
rewards (Wyvell and Berridge, 2001).
A clear general relationship exists between novelty (Cloninger et al. 1993) and fun-seeking 
(Carver and White, 1994) personality traits and addiction proneness (Cloninger et al. 1988; Johnson 
et al. 2003; Zuckerman, 1994). These traits mediate biological responses to novelty (Bardo et al. 
1996) and individual variability of drug-induced dopamine neurotransmission in the VS (Leyton et al.
2002). In adolescence, high novelty seekers are more likely to experiment with drugs (Zuckerman, 
1994) and develop harmful patterns of drug (Sher et al. 2000) and alcohol use (Cloninger et al.
1988). In individuals with substance dependence, novelty-seeking traits also influence craving 
(Zilberman et al. 2003), vulnerability to relapse (Meszaros et al. 1999) and social influences on drug 
taking (Audrain-McGovem et al. 2003). Higher novelty-seeking traits independently predict the 
presence of DDS in PD (Evans et al. 2005). In this study, these trait scores did not correlate with L- 
dopa induced VS dopamine release, suggesting they may be independent predisposing risk factors for 
DDS.
These findings offer a unique insight into how exposure to a drug, even for therapeutic purposes, 
can subvert brain reward systems and lead to enduring susceptibility to compulsively use a drug. The 
findings of the present study may also be relevant to understanding the neurobiological processes that 
lead to other forms of addiction and to the development of management strategies for the disorder.
For instance, the persistence of drug-induced neuroadaptive changes in many laboratory models 
suggests that once features of DDS are present, management can be difficult and relapse of the 
disorder common. Reduction in dopaminergic drug therapies can reduce the disability caused by the 
behavioural disorders associated with DDS. However, individuals may remain sensitised to the drug’s
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rewarding effects and in time, relapse may occur with smaller drug dosages. Identifying patients 
diagnosed with PD prospectively who may be vulnerable to developing a pattern of compulsive 
dopaminergic drug use may be a critical step in preventing the physical, social and financial impact of 
DDS.
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Chapter 7 
DISCUSSION
Summary
Compulsive dopaminergic drug use, a newly described phenomenon, can have devastating 
financial, social and legal consequences in a few patients whose motor handicap has been 
successfully treated with dopaminergic therapy. Recognition, understanding, and prompt effective 
treatment are important and hopefully prediction of those at greatest risk from the dopamine 
dysregulation syndrome and impulse control disorders will become possible. Further study of these 
phenomena also has an exciting potential to yield important insights into the neurobiological process 
that are relevant to addiction in general.
7.1 Summary of work undertaken
The main aims of this work were to delineate the phenomenology associated with compulsive drug 
use in PD, understand the factors that may lead to its genesis, and examine the neurobiological 
processes that mediate its expression.
7.1.1 Study of various forms of behavioural sensitisation in early Parkinson’s disease
All the patients studied were attending Parkinson’s disease clinics at the Middlesex Hospital and 
the National Hospital for Neurology and Neurosurgery in London. The study presented in Chapter 2 
was carried out on 15 patients with newly diagnosed PD who underwent blinded L-dopa and 
methylphenidate challenges to assess their psychomotor and cardiovascular effects. With repeated 
drug dosing, individuals were predicted to develop tolerance to some drug effects whereas other drug 
effects may result from sensitisation. To assess whether this is the case, the challenges were repeated 
in all but one patient after 18 months regular treatment with dopaminergic drug therapy. A variety of 
psychomotor and dmg effects were found most notably euphoriant effects to an acute dose of 
methylphenidate and the motoric effects of L-dopa were enhanced by regular dopaminergic therapy in 
PD.
These findings indicate that the psychomotor effects, possibly mediated by striatal monoaminergic 
systems, may be sensitised by sustained intermittent dopaminergic dmg therapy a finding which may
143
be of particular importance in those individuals who are at risk of compulsively overusing their 
medication.
7.1.2 Characterisation of punding, a form of behavioural sensitisation in late Parkinson’s
disease
Animal models have provided considerable insight into the neurobiological substrate for the 
psychomotor effects of addictive drugs but translational research is generally lacking. It was posited that 
complex repetitive stereotypies, behaviours known to index the neuroadaptive changes of sensitisation in 
animal models, were demonstrable in PD outpatients and linked with DDS. Punding is a term that was 
coined originally to describe complex prolonged, purposeless and stereotyped behaviour in chronic 
amphetamine users and is homologous to the psychostimulant-induced behavioural stereotypies in animal 
models. The study presented in Chapter 3 presents the findings of a semi-structured interview of a 
selected group of 50 patients with higher dopamine replacement therapy requirements (>800LEU/day) 
from 123 unselected patients with PD. Seventeen patients (14%) exhibited punding which was associated 
with either high doses of dopaminergic drug therapy or prolonged repeated dosing. Punders also showed a 
high incidence of appetitive behavioural disorders such as hypersexuahty, and gambling. The findings 
indicate that punding is an under-reported, socially disabling phenomenon which is commonly associated 
with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive- 
compulsive disorder and mania. The frequent concurrence of punding with compulsive dopaminergic dmg 
use suggests that punding might represent an important step in the eventual progression to a form of 
automatic behaviour in which voluntary control over drug use is lost.
7.1.3 Examination of the factors which may influence the development of DDS
Personality and physiological traits differentially affect the various stages of addiction, defined 
chronologically as initiation of dmg use, regular dmg use, addiction/dependence and potential relapse.
The predictive relationship between traits characterised by impulsivity and a tendency to seek new or 
varied experiences (ISS traits) and addiction vulnerability purportedly reflect some rewarding aspect of 
experiencing novelty and suggests that novelty-elicited exploration and dmg stimuli may interact in 
biologically and behaviourally meaningful ways. Other factors such as exposure to dmgs capable of cross- 
sensitising brain reward systems to the effects of dopaminergic dmgs and stress and genes may also be 
relevant.
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In the study presented in Chapter 4, predisposing factors to DDS were sought in a population of PD 
outpatients. Clinical features, ISS personahty traits, past experimental drug use, alcohol consumption, 
smoking behaviours and depressive symptoms in 25 DDS patients were compared to an outpatient sample 
of 100 PD patients who were not compulsively overusing dopaminergic medication. DDS patients had a 
significantly younger age of disease onset, higher dopaminergic drug intake, greater past experimental 
dmg use, more depressive symptoms, scored higher on ISS ratings and tended to have higher alcohol 
intake. Using logistic regression analysis, novelty seeking personahty traits, depressive symptoms, alcohol 
intake and age of PD onset were significant predictors of DDS. These factors may help to identify early 
patients who are more vulnerable to developing a pattern of compulsive dopaminergic dmg use and help 
minimise its consequences.
7.1.4 Characterisation of an aversive withdrawal state in DDS
PD patients with DDS commonly identify dysphoric “o ff’ mood-states as the primary motivation to 
compulsively use their dmgs. Several notions of addiction claim that the motivational force for 
compulsive dmg-taking arises from the need to alleviate the negative emotional state of dmg abstinence.
In the study presented in Chapter 5, affective state, motor function and incentive motivational state was 
assessed after withdrawal and then in response to L-dopa in 20 patients with DDS and 20 control PD 
patients. The effect of depressive symptoms and personality traits on the response to L-dopa was assessed. 
In the “o ff’-state, DDS patients reported lower PA, higher NA and more motor and non-motor disabihty 
in the “off’-state. However, reward responsivity (implicit reward processes) was not different between the 
groups in withdrawal. In “on”, DDS patients had higher expressions of dmg “Wanting”, reward 
responsivity, and dyskinesias. Positive and negative affect, non-motor symptomatology and motor 
disability were comparable in both groups in the “on”-state.
These data suggest that the same neurobiological mechanisms that mediate the transition to compulsive 
dmg use in individuals with DDS are imphcated in the development of a broad range of affective, 
motivational and cognitive disorders.
7.1.5 “C-Raclopride study of neuroplastic changes in dopaminergic brain reward systems 
induced by compulsive dopaminergic drug use
A major theme underlying the development of addictions is the neuronal and behavioural plasticity 
induced by addictive dmgs. In humans, the neurobiological substrate that is responsible for the transition
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from drug use to drug addiction is poorly understood and little is known about why some individuals are 
more susceptible to this transition than others. This novel clinical paradigm of drug dependence in 
patients with PD was studied in Chapter 6. The effects of a pharmacological challenge on ' ’C-Raclopride 
binding potential in 8 individuals with DDS were compared to a control group of PD patients who had 
been exposed to chronic intermittent dopaminergic drug regimens for a similar duration to DDS patients 
but were not using them compulsively. PD patients with DDS exhibit enhanced L-dopa induced VS- 
dopamine release compared to L-dopa treated patients with PD not compulsively taking dopaminergic 
drugs. This finding would not be the result of drug exposure per se but must be related to the development 
of a compulsive pattern of drug use. The sensitised VS-dopamine neurotransmission produced by L-dopa 
in these individuals correlated with self-reported compulsive drug “Wanting” but not “liking” and was 
related to heightened psychomotor activation (punding). Therefore drug-induced sensitisation of VS- 
circuitry, mediating compulsive drug “Wanting”, is sufficient for the development of substance 
dependence in humans. These findings are relevant to a broad range of compulsive disorders.
7.2 Conclusion
The dopamine dysregulation syndrome is characterised by a disabling cluster of psychomotor, 
associative, cognitive, and emotional symptoms. The similarity of the symptomatology of DDS with that 
seen in psychostimulant abuse also provides support for a role of dopamine in these addictions. Nearly all 
patients diagnosed with PD are treated with dopaminergic drugs, but only a minority compulsively use 
them. Abuse of other anti-Parkinsonian drugs in PD has been rarely, if ever, described. Thus, extrinsic 
factors influencing addictive susceptibility may be less influential in predicting vulnerability to 
compulsive dopaminergic drug use in PD patients. These patients therefore represent an opportunity to 
understand individual factors that may predispose to addiction.
The brain region found to be involved in mediating the transition to compulsive drug use was the 
mesolimbic dopaminergic projections and the nucleus accumbens. Neuroadaptive changes within the 
nucleus accumbens were linked to a subcomponent of reward, drug “Wanting”, or incentive sahence. 
These findings provide support for Robinson and Berridge’s 1ST of addiction. 1ST assumes that over the 
course of iterative drug use, there are progressive and persistent neuroadaptations induced in dopamine 
projections to the nucleus accumbens-related circuitry. These critical neuroadaptations are proposed to 
sensitise neural systems that mediate the incentive motivational or rewarding effects of drugs. The 
transition to compulsive drug use is posited to involve excessive salience attribution to drugs activating 
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this circuitry making them pathologically “Wanted” or craved. In these accounts, the process of incentive 
salience attribution is thought to be dissociated from neural systems mediating the hedonic impact of 
drugs.
Similar neuroadaptive changes were also linked to punding and heightened reward responsivity in DDS 
patients. The latter is thought to represent a form of motivational spillover in which sensitisation of brain 
systems of drug-reward can also involve brain systems mediating nondrug reward. This is consistent with 
observations described in Chapter 3 in which a link was found between punding and a variety of impulse 
control disorders (hypersexuality, pathological gambling, binge eating and so on). In the 5th Chapter, 
these behavioural expressions o f sensitisation were further linked to the development of an aversive 
withdrawal state “ofF’-medication. This has relevance to theories of addiction that emphasise the role of 
the withdrawal syndrome as a critical motivator in compulsive expressions of drug use. These data 
suggest that the withdrawal syndrome and possibly depressive symptoms in general, represent another 
form of behavioural sensitisation phenomenon.
7.3 Future work
7.3.1 Validation of factors that predict DDS
Why exposure to dopaminergic drugs affects only a minority of individuals remains unresolved. The 
results presented in Chapter 4 should form the foundation for ongoing research project to follow a cohort 
of recently diagnosed PD patients throughout the progression of their disease. This may provide useful 
information about the prognostic implications attached to the syndrome, which in turn may influence 
clinical decisions taken by those managing PD patients.
7.3.2 Dopamine dysregulation syndrome and Impulse control disorders -  part of the same 
spectrum or mediated by separate but overlapping neurobiological systems?
There is considerable overlap between individual vulnerability factors for DDS and ICDs in PD and
similarities with susceptibility factors for PG in the general population. As in the general population PG in
PD is linked to being male, having comorbid psychiatric,(Gallagher et al. 2007) or alcohol use disorders,
and having higher ISS traits (Voon et al. 2007). However, there are important differences. Depressive
symptomatology may not be a strong factor for PG (Voon et al. 2007). A number of patients with PG
have been specifically reported not to have DDS and, conversely, not all patients with DDS have PG or
another ICD as part of the syndrome. Pathological gambling and DDS, but not hypersexuality, have been 
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associated with alcohol use. Moreover, DDS is associated with high doses of L-dopa and higher total 
daily L-dopa equivalent doses compared to ICDs that appear to be highly influenced by agonist dose 
(Gallagher ef a/. 2007).
73.3 Identification of criteria for impulse control disorders in Parkinson’s disease
An association between PD and impulse control disorders (ICDs) and DDS and ICDs is likely linked to 
the pathophysiology of PD, and interventions used to treat PD. Many studies have noted onset of ICD 
behaviours particularly with dopamine agonist onset or dose increase and a remission or reduction in ICD 
behaviours with reductions or cessations of dopaminergic therapies (Gallagher et al. 2007). This raises 
the possibihty that different dopaminergic dmgs may sensitise different aspects of brain dopamine 
function. Research gaps therefore exist in the definition, knowledge of prevention and treatment strategies 
related to impulse control disorders in PD and the relationship with dopaminergic dmgs.
7.3.4 Determination of why dopaminergic agonists preferentially sensitise behaviours 
mediated by ventral striatal systems and L-dopa preferentially sensitises behaviours mediated by 
dorsal striatal systems
There is a strong and dose-dependent association between DA therapy and ICDs (Courty et al. 1997; 
YAosetal. 2005; Nirenberg and Waters, 2005; Uitti ût/. 1989; Voon a/. 2006a); and daily L-dopa 
equivalent dose and DDS. However, PG differs from DDS in that DA use is almost invariably associated 
(98.3%), whereas DDS is associated with high doses of L-dopa and higher total daily L-dopa equivalent 
doses (Gallagher et al. 2007).
Disabling punding has also been linked to higher daily requirements of dopaminergic dmgs (Evans et 
al. 2004) and punding-like behaviour has been linked to concomitant daily medication dosage from 
dopamine receptor agonists (Lawrence et al. 2007). Cases series also highhght improvement in punding 
behaviour after reduction or cessation of DA therapy (Kimber et al. 2008; Miyasaki et al. 2007).
In contrast, L-dopa is associated with the earlier appearance of motor fluctuations and dyskinesias 
(Hubble, 2002), proposed to reflect sensitisation phenomena of the dorsal striatal system (Pavese et al. 
2006).
It is interesting to speculate why the uncontrolled effects of dopaminergic agonism via oral dopamine 
agonists might be linked to enhanced gambling behaviour, hypersexuahty, and punding. Dopamine D3 
receptors are localised to limbic regions. Additionally, orbitofrontal cortex dysfunction has been 
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implicated in ICDs from imaging studies (Reuter et al. 2005). Subsequently, D3 preferring dopaminergic 
agents have been demonstrated to have an inhibitory influence on orbitofrontal cortex function -  
potentially contributing to aspects of behavioural disinhibition (Black et al. 2002). However, receptor 
activation profile alone is not enough to explain the dissociated effects of agonists and L-dopa as the 
association between PG and agonists appears to be a class effect (Gallagher et al. 2007) and some 
agonists have relative little D3 activation.
7.3.5 Histopathological correlates
Behavioural sensitisation following repeated intermittent psychostimulant administration in animals 
involves alterations in neural activity within the accumbens and caudate brain regions. In humans, Fos 
immunohistochemistry, c-fos in situ hybridisation and morphological examination of striatal medium 
spiny neurons might be used to assess changes in dopaminergic drug-induced neural activity following 
compulsive dopaminergic drug use in behaviourally sensitised individuals.
73.6 Longitudinal treatment studies
Some of the manifestations of behavioural sensitisation with dopaminergic drugs (i.e. dyskinesias) have 
been demonstrated to reverse through therapies that involve continuous dopaminergic stimulation (such as 
with continuous subcutaneous apomorphine infusions) and surgical therapies. However, there is little data 
on what effect these therapies might have on individuals with DDS. Moreover, other features of 
behavioural sensitisation have not been examined in the context of these therapies.
73.7 Clinicogenetic studies
A specific predisposition to the addictive effects of dopaminergic therapy is probably present in 
affected patients. They may be genetically predisposed to addiction and efforts to characterise their unique 
genetic constitutions may provide an important insight into the neurobiological basis of addiction in 
general. These patients may represent a natural experiment in which a pharmacological probe has 
disclosed a unique genetic predisposition that can be identified with results that may be generalisable to 
other addiction disorders.
73.8 Cognitive and behavioural correlates
The behavioural profile of DDS patients is similar to that seen with substance dependence in 
individuals without PD. Cognitive studies might explore the nature of the decision-making impairments in
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PD that may either predispose to developing DDS in the course of treatment (i.e. certain cognitive profiles 
in early disease may predispose to the genesis of the disorder) or arise from DDS and lead to further loss 
of inhibitory control on drug taking. Further study of these individuals may provide insight into other 
neuropsychiatrie features of DDS including depression, psychosis, mania, hallucinations, gambling 
disorders, sexual deviations, and aggression. Longitudinal studies of the nature of the study in Chapter 2 
could be particularly relevant in studying the various changes in drug effects that occur after initiation of 
sustained dmg therapy for motor symptom control.
7.3.9 Neuroimaging studies
fMRI of DDS patients in dopaminergic withdrawal and in response to a drug challenge may yield 
significant findings about the underlying neural correlates of changes in motivation for natural and drug 
rewards, and neural circuitry mediating aversive “off’-symptoms in these individuals. This type of study 
is likely to reveal the role o f non-ffontostiiatal circuitry, such as the cerebellum, in these processes. 
However, this can be problematic as DDS patients can be intolerant of prolonged drug withdrawal.
This research also provided a hint that compulsive dopaminergic drug use in DDS patients may 
contribute to a further worsening of frontal cognitive functions. Further dynamic studies using raclopride 
to explore the release of dopamine during cognitive tasks might form the basis of a future study to directly 
determine the role that dysregulation of dopaminergic systems play in the cognitive impairment observed 
in DDS. Additionally, DDS patients would be predicted to show changes in brain glucose metabolism in 
withdrawal that may relate to aversive “o ff’-symptoms and fi'ontal cognitive deficits.
7.4 Summary
PD is a progressive condition that often requires specialist care for a variety of motor and non-motor 
symptoms due to the disease process and also the medications used to manage the disease. Dopaminergic 
drugs used to treat Parkinson’s disease improve quahty of life, reduce motor handicap and prolong 
survival (Hoehn, 1992). In addition to commonly reported motor drug side-effects, a small group of 
patients appear to compulsively use dopaminergic medications well beyond the dose needed to optimally 
control their motor disability. This destructive behaviour occurs in the face of a mounting number of 
resulting harmful physical, psychiatric and social sequelae. Hedonistic homeostatic dysregulation was first 
used to describe this uncommon complication but the term dopamine dysregulation syndrome is now 
preferred.
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Although compulsive dopaminergic drug use is a relatively uncommon side-effect of dmg management 
in PD, many of the behavioural associations of the disorder such as punding, and ICDs such as gambling 
and hypersexuahty have been linked to dopamine agonist use in particular, in the absence of compulsive 
dopaminergic dmg use. This suggests two things; firstly, dopamine has a pivotal role in behavioural 
addictions, dmg-induced stereotypies and dmg addiction; and secondly, the brain systems that mediate the 
transition from dmg-use to compulsive dmg-taking and craving would be expected to overlap with those 
systems that mediate behavioural addictions and the development of dmg-induced stereotypies.
Consistent with this, chronic treatment with dopaminergic dmgs in PD was able cross-sensitisation to the 
euphoriant effects of methylphenidate and L-dopa as well as generally enhance reward responsivity. 
Moreover, regular dopaminergic dmg therapy led to sensitisation to the motor effects of L-dopa.
Psychostimulant dmgs and dopaminergic agonists induce complex motor stereotyped behaviour in 
animals. A study to identify similar behaviours in patients with PD was carried out and identified a group 
of patients with complex stereotyped motor behaviours similar to those previously described in 
amphetamine and cocaine addicts (punding).These were often socially disabling and the chosen activity 
tended to reflect the premorbid interests of the patient. They were more common in patients exhibiting 
other core features of the DDS.
This research was driven by the need for more accurate patient characterisation and it proposes 
mechanisms by which patients with the syndrome may be identified early. This disorder and the 
accompanying phenomenology can lead to potentially devastating consequences. This increases the need 
for further improvements in understanding the aetiology of the syndrome and finding tailored approaches 
to its management. The relative rarity of DDS provides testament to the low addictive liabiUty of 
dopaminergic drugs used to treat PD but also suggests that it should be possible to identify which 
individuals about to start dopaminergic therapy are vulnerable to becoming addicted to it. Since nearly all 
Parkinson’s patients are exposed to dopaminergic drugs in the course of management of their symptoms, 
individual susceptibility factors are less likely to be subject to the confounding effects of environment, 
and social influences. Impulsive sensation seeking personality traits relevant to epidemiological studies of 
substance dependence and other substance use were found to be highly predictive in the DDS patients as 
well as an independent association of depressive mood symptoms. Impulsive sensation seeking traits have 
subsequently been demonstrated to be relevant to individual susceptibihty to the emergence of ICDs with 
treatment with dopamine agonists.
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DDS patients report and were found to display an aversive drug withdrawal state akin to the withdrawal 
state with drugs of addiction. The nature of the medication-withdrawal state was characterised in a group 
of DDS patients after drug withdrawal after an overnight fast. Following overnight withdrawal of 
medications, DDS patients had more motor Parkinsonism, reduced positive affect, and reported a broader 
range of affective non-motor symptoms compared to control patients. With the L-dopa challenge, DDS 
patients had a greater reduction in the motor UPDRS, number of affective non-motor symptoms, and a 
greater increase in reward responsivity and positive affect. In “ON”, DDS patients reported increased drug 
“wanting” but did not “feel” or “like” drug effects more than controls. They had more disabling 
dyskinesias and showed enhanced reward responsivity.
A novel clinical paradigm of drug dependence was investigated using a two-scan ‘'C-Raclopride 
protocol. The results of this study have provided the first human evidence that drug-induced sensitisation 
of ventral striatal-circuitry mediates compulsive drug “wanting” and is sufficient for the development of 
substance dependence in humans. These findings are relevant to a broad range of compulsive disorders in 
general.
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Appendix A 
PUNDING QUESTIONNAIRE
Appendix A: Questionnaire
Do you have any hobbies or pastimes?
If yes, when did you become interested in your hobby (years)?
How do you feel when you are engaged with your hobby and why do you do it? (i.e. do you find it 
soothing? calm? fascinating? or are you driven to it in response to obsession? fear? anxiety?).
How many hours per day do you spend on the hobby?
Do you sometimes spend excessive amounts of time on your hobby?
Do you ever do it if you can’t sleep at night (e.g. between midnight and 5:30?)?
If yes, have you ever missed a whole night’s sleep because of it?
Are you easily distracted when you are engaged with your hobby?
How do you feel when you are mtermpted when you are engaged with your hobby? i.e. do you ever get 
angry or upset? Do you go “o ff’?
Are you interested in your hobby only when “on” or when you are “on” and “o ff’?
Do you make much of a mess when you are pursuing your pastimes or hobbies?
Do you have difficulties in finishing projects?
How many hours per day do you spend on the following?
> Cleaning/tidying
> Do-it-yourself
> Gardening
> Collecting things
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> Repairing/dismantling -  computers, television, radios, apomorphine pump (If yes, were you able 
to put them back together)
> Sorting -  papers, through drawers/handbag?
> On the computer?
What is your past occupation? When did you retire and why?
Do you use rescue medications? If yes, how often per day and do you ever use them after 11pm or before 
6am?
Other questions;
Insomnia -  How many hours do you sleep per night on average? If you cannot sleep, do you ever 
get up and continue with your pastime or hobby?
Spending excessive amounts of money or money on unnecessary things for your hobby or 
pastime?
Do you gamble? Have you ever gambled and lost too much money?
Has your libido changed with the introduction of medications for Parkinson’s disease?
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